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Abstract 
 
 The ability to flexibly react to our dynamic environment is a cardinal 
component of cognition and our human identity. Millions across the globe are 
affected by disorders of cognition, affecting their ability to live independently. The 
prefrontal cortex is required for optimal cognitive functioning, but its circuitry is 
often disrupted in conditions of impaired cognition. In addition, the cholinergic 
system is vital to optimal executive function, but this is disrupted in a number of 
conditions, including Alzheimer’s disease and schizophrenia. The actions of 
cholinergic receptors were explored in this project with local application of 
cholinergic compounds onto prefrontal neurons as rhesus monkeys performed a 
rule-based saccadic task that requires working memory maintenance. The 
antisaccade task is a useful probe of prefrontal cortex function that elicits errors 
in neuropsychiatric conditions. Some prefrontal neurons respond to different task 
aspects of the antisaccade task, e.g., discharging preferentially for one task rule 
over the other (pro- or antisaccades), and are thought to be involved in the 
circuitry for correct behavioural responses. Chapter 2 explored the effect of 
general stimulation of cholinergic receptors on rhesus PFC neuronal activity 
during antisaccade performance. In Chapter 3, newly developed cholinergic 
receptor subtype-specific compounds were utilized to examine the actions of 
muscarinic M1 receptor stimulation on prefrontal activity. Cortical oscillations are 
emerging as an important aspect of cognitive circuitry, such as during working 
memory maintenance. Chapter 4 examined the influence of local cholinergic 
receptor stimulation and blockade on the power of local field potential in different 
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frequency bands. This project characterized the role of cholinergic receptors in 
prefrontal cortical neurons that were actively involved in cognitive circuitry. This 
and future work on the cholinergic influence on prefrontal cortex will provide 
insights into the altered cognitive functioning in Alzheimer’s disease and 
schizophrenia, which are also affected by disrupted cholinergic systems. 
 
Keywords 
Cholinergic, muscarinic, acetylcholine, prefrontal cortex, dorsolateral prefrontal 
cortex, working memory, antisaccade, iontophoresis, local field potential, single 
neuron electrophysiology, macaque, rule 
  
	  	   iv 
Co-Authorship 
 
Alex J. Major, Susheel Vijayraghavan, Liya Ma, Kevin Johnston, and Stefan 
Everling 
 
As primary author of this thesis, Alex J. Major was responsible for designing the 
experiments, data collection, analysis, interpretation of results, and manuscript 
composition. Susheel Vijayraghavan assisted in aspects mentioned above in all 
three projects. Liya Ma assisted in analysis, interpretations, and writing of 
Chapter 4. Kevin Johnston provided invaluable support in all aspects and 
performed surgical procedures. Stefan Everling was the principal investigator, 
and oversaw design, analysis, interpretations, writing, and surgical procedures. 
 
 
   
	  	   v 
Dedication 
 
To my parents, for their endless encouragement and support, and for teaching 
me the value of hard work. 
  
	  	   vi 
Acknowledgements 
 
 I would like to thank Dr. Stefan Everling for welcoming me into his 
pioneering neuroscience lab and for his advice and encouragement over the past 
several years. His mentorship guided me through the many challenges I faced 
during my PhD experience. One day, I hope that I may inspire others with similar 
aptitude and excitement. 
 I am indebted to Dr. Susheel Vijayraghavan for his expert guidance in 
neurophysiology and for teaching me the art of extracellular recordings combined 
with iontophoresis. His enthusiasm and encyclopedic knowledge spurred 
countless discussions on neuroscience and world events, for which I am grateful. 
  Thank you to Dr. Kevin Johnston, who was a constant source of expertise, 
reassurance, and conversation during my six years in the lab. His sense of 
humour and his advice on both research and my career were greatly appreciated 
and invaluable to my success. 
 Thank you to Dr. Liya Ma for her thorough knowledge and advice on local 
field potential analysis. I learned a great deal through her methodical analysis, 
statistical prowess, and careful interpretations. 
 Thank you to my advisers, both formal and informal, including Dr. Brian 
Corneil, Dr. Andrew Pruszynski, Dr. Julio Martinez-Trujillo, Dr. Susanne Schmid, 
Dr. Arthur Brown, and Dr. Marco Prado. Their advice and healthy skepticism 
made tangible improvements to my analysis, interpretations, and skill as a 
science communicator. 
	  	   vii 
 I’d like to thank Susan Simpson for being a constant source of support, 
professionalism, and laughter throughout my PhD. 
 Finally, a special thank you to my friends in the lab community, including 
Ramina, Sebastian, Sahand, Darren, Maryam, Lauren, David, Becca, Nicole, 
Ashley, Cheryl, Whitney, Janahan, Justine, Yuki, Jason, Brandon, and Nikoo. 
They helped make Robarts a fun place to work everyday, filled with laughter and 
engaging scientific discussion. 
  
	  	   viii 
Table of Contents 
Abstract ................................................................................................................. ii 
Co-Authorship Statement ................................................................................... iv 
Dedication ............................................................................................................. v 
Acknowledgements ............................................................................................. vi 
Table of Contents .............................................................................................. viii 
List of Tables ....................................................................................................... xi 
List of Figures ..................................................................................................... xii 
List of Abbreviations ......................................................................................... xiv 
 
CHAPTER 1 
Introduction .......................................................................................................... 1 
1.1 Disorders of Cognition ........................................................................... 1 
1.1.1  Alzheimer’s disease ............................................................... 1 
1.1.2  Schizophrenia ........................................................................ 4 
1.2 Prefrontal Cortex (PFC) ......................................................................... 6 
1.2.1  Lesions of PFC ...................................................................... 7 
1.2.2  Anatomical connections of PFC ........................................... 10 
1.2.3  Delay activity ........................................................................ 13 
1.2.4  Dorsolateral PFC cytoarchitecture and microcircuits ........... 17 
1.3 Cholinergic System .............................................................................. 30 
1.3.1  Cholinergic innervation  ....................................................... 36 
1.3.2  Wired vs. volume transmission ............................................ 40 
1.3.3  Muscarinic receptors  ........................................................... 45 
1.3.4  Nicotinic receptors  .............................................................. 49 
1.4 Antisaccade task ................................................................................. 51 
1.5 Iontophoresis ....................................................................................... 56 
1.6 Objectives ............................................................................................ 60 
1.6.1  Examine the effects of local cholinergic stimulation using 
general agonist carbachol  ................................................... 60 
1.6.2  Examine the effects of selective stimulation and blockade of 
muscarinic M1 receptors using VU0357017 and pirenzepine 
 ............................................................................................. 61 
1.6.3  Examine the influence local cholinergic receptor perturbation 
on prefrontal LFP power  ..................................................... 62 
1.7 References .......................................................................................... 64 
 
CHAPTER 2 
Cholinergic overstimulation attenuates rule selectivity in macaque 
prefrontal cortex  ................................................................................................ 90 
2.1 Introduction .......................................................................................... 90 
2.2 Materials and Methods ........................................................................ 88 
2.2.1  Behavioural Task ................................................................. 89 
 
 
	  	   ix 
2.2.2  Neuronal Recordings and Pharmacology ............................ 96 
2.2.3  Data Analysis ....................................................................... 97 
2.3 Results ............................................................................................... 102 
2.3.1  Effect of carbachol on discharge rates ............................... 102 
2.3.2  Effect of carbachol on task-selective neurons ................... 106 
2.3.3  Effects of carbachol on putative pyramidal and nonpyramidal 
neurons .............................................................................. 116 
2.4 Discussion ......................................................................................... 123 
2.4.1  Effect of carbachol on neuronal discharge rate in DLPFC . 124 
2.4.2  Effects of carbachol on task selectivity of DLPFC neurons
 ...................................................................................................... 125 
2.5 References ........................................................................................ 130 
 
CHAPTER 3 
 Muscarinic M1 receptor overstimulation disrupts working memory activity 
for rules in primate prefrontal cortex  ............................................................ 136 
3.1 Introduction ........................................................................................ 136 
3.2 Methods ............................................................................................. 139 
3.2.1  Experimental Model and Subject Details ........................... 139 
3.2.2  Behavioural Paradigm ........................................................ 142 
3.2.3  Neuronal Recordings with Microiontophoresis and Pneumatic 
Injections ............................................................................ 143 
3.2.4  Data Analysis ..................................................................... 146 
3.3 Results ............................................................................................... 153 
3.3.1  Effects of M1R Agents on DLPFC Neuronal Physiology ... 154 
3.3.2  Effects of M1R Agents on Task Selectivity of DLPFC 
Neuronal Activity ................................................................ 162 
3.3.3  Trial Rule Selectivity .......................................................... 165 
3.3.4  Saccade Direction Selectivity ............................................. 173 
3.4 Discussion ......................................................................................... 174 
3.4.1  M1R Modulation of Neuronal Excitability in DLPFC ........... 175 
3.4.2  M1R Modulation of Behavioural Task Representation in PFC 
Activity ................................................................................ 179 
3.5 Supplemental Results ........................................................................ 184 
3.6 References ........................................................................................ 190 
 
CHAPTER 4 
Cholinergic receptors in macaque prefrontal cortex influence cortical 
oscillations in a rule-based saccade task ...................................................... 196 
4.1 Introduction ........................................................................................ 196 
4.2 Materials and Methods ...................................................................... 199 
4.2.1 Animals .............................................................................. 199 
4.2.2 Behavioural Task ............................................................... 199 
4.2.3 Recording and Drug Administration ................................... 202 
 
 
	  	   x 
4.2.4 Data Analysis ..................................................................... 202 
4.3 Results ............................................................................................... 205 
4.3.1 Effect of cholinergic receptor perturbation on LFP power .. 206 
4.3.2 Cholinergics receptors modulate delay-related beta power 
 ...................................................................................................... 209 
4.3.3 Effect of cholinergic receptor perturbation on rule preference 
of LFP power  ............................................................................... 213 
4.4 Discussion ......................................................................................... 216 
4.4.1 Beta power was enhanced by both scopolamine and 
carbachol  ..................................................................................... 217 
4.4.2 Cholinergic stimulation enhanced theta power  ................. 220 
4.4.3 Muscarinic antagonism disrupted task rule preference of 
cortical oscillations ........................................................................ 223 
4.5 References ........................................................................................ 225 
 
CHAPTER 5 
General Discussion  ......................................................................................... 234 
5.1 Summary of Main Findings ................................................................ 234 
5.1.1  Local cholinergic stimulation had mixed effects on prefrontal 
activity and decreased task-related rule preference  ......... 234 
5.1.2  Stimulation of muscarinic M1 receptors was inhibitory to 
prefrontal discharge rate and attenuated rule preference .. 236 
5.1.3  Cholinergic receptor perturbation primarily affects oscillatory 
power in the beta frequency band  ..................................... 238 
5.2 Caveats and Limitations .................................................................... 240 
5.3 Future Directions ............................................................................... 243 
5.4 Concluding Remarks ......................................................................... 245 
5.5 References ........................................................................................ 247 
Appendix A: Ethics Approval  ......................................................................... 252 
Curriculum Vitae  .............................................................................................. 253 
 
 
 
 
  
	  	   xi 
List of Tables 
Table 2.1 Summary of multiple linear regression analysis for rule-selective 
neurons ......................................................................................... 113 
Table 2.2 Summary of multiple linear regression analysis for broad-spiking 
saccade-direction-selective neurons ............................................ 122 
Table 3.1 Statistics of Task-Selective Neurons Identified by ANOVA .......... 164 
Table 3.S1 Trial count statistics and individual statistics of neuronal recovery 
from drug effects  .......................................................................... 184 
 
 
  
	  	   xii 
List of Figures 
Figure 1.1 Intrinsic and extrinsic connections of the prefrontal cortex  ............ 11 
Figure 1.2 The memory-guided saccade task and delay cells  ........................ 15 
Figure 1.3 Human and rhesus macaque prefrontal cortices  ........................... 18 
Figure 1.4 Laminar distribution of GABAergic interneurons in macaque area 46
 ........................................................................................................ 21 
Figure 1.5 Goldman-Rakic model of the prefrontal working memory circuit. ... 24 
Figure 1.6 Diagram of pyramidal neurons and interneurons in proposed 
microcircuit of working memory  ..................................................... 26 
Figure 1.7 Proposed canonical microcircuit of feedforward and feedback 
cortical connections  ....................................................................... 29 
Figure 1.8 Cholinergic nuclei of the human brain ............................................ 31 
Figure 1.9 Density of cholinergic axons in primary visual cortex of six different 
species ............................................................................................ 39 
Figure 1.10 Transient release of choline in rat medial prefrontal cortex ............ 43 
Figure 1.11 The antisaccade circuit ................................................................... 54 
Figure 1.12 Iontophoretic electrode and drug ejection. ...................................... 57 
Figure 2.1 Experimental paradigm and single neuron recording with concurrent 
iontophoresis .................................................................................. 95 
Figure 2.2 Effects of carbachol on prefrontal neuron discharge rate ............. 104 
Figure 2.3 Effect of carbachol application on two representative rule-selective 
prefrontal neurons ......................................................................... 108 
Figure 2.4 Effects of carbachol on population rule selectivity ........................ 111 
Figure 2.5 Effects of carbachol on putative pyramidal and nonpyramidal 
neurons. ........................................................................................ 117 
Figure 2.6 Effect of carbachol on saccade direction selectivity of broad-spiking, 
putative pyramidal neurons. .......................................................... 120 
Figure 3.1 Recording Locus, Iontophoretic Electrophysiology, and Behavioural 
Task .............................................................................................. 141 
Figure 3.2 M1R Stimulation Dose-Dependently Suppresses Population Activity 
of PFC Neurons ............................................................................ 155 
Figure 3.3 M1R Blockade Dose-Dependently Suppresses Population Activity 
of PFC Neurons ............................................................................ 159 
Figure 3.4 Classification of DLPFC Neurons Based on Waveform Shape .... 161 
Figure 3.5 Both M1R Stimulation and Blockade Inhibit Activity and Disrupt 
Rule Selectivity of Individual PFC Neurons .................................. 167 
Figure 3.6 M1R Stimulation Dose-Dependently Disrupts the Population Rule 
Selectivity of PFC Rule-Selective Neurons ................................... 170 
Figure 3.7 M1R Blockade Has No Effect on the Population Rule Selectivity of 
PFC Rule-Selective Neurons ........................................................ 172 
Figure 3.S1 Inhibition of PFC neurons by pneumatic pressure ejection of M1R 
agonist VU0357017 ...................................................................... 185 
Figure 3.S2 Effects of M1R-preferring agonist McN-A-343 on PFC neurons ... 186 
Figure 3.S3 Effects of M1R agonist VU0357017 and M1R antagonist 
pirenzepine application over the course of the trial ...................... 187 
	  	   xiii 
Figure 3.S4 Examples of excitation of DLPFC rule selective neuron and 
enhancement of DLPFC neuronal rule selectivity by iontophoretic 
M1R stimulation and reduction in rule selectivity due to M1R agonist 
pressure ejection .......................................................................... 188 
Figure 3.S5 M1R blockade disrupts population postsaccadic selectivity for the 
contralateral saccade PFC saccade-selective neurons ................ 189 
Figure 4.1 Experimental paradigm and recording with concurrent iontophoresis
 ...................................................................................................... 201 
Figure 4.2 Effect of local muscarinic blockade and cholinergic stimulation on 
raw local field potential (LFP) power ............................................. 208 
Figure 4.3 Delay-related effects of scopolamine and carbachol on delay period 
LFP power .................................................................................... 210 
Figure 4.4 Rule preference of normalized LFP power before and after drug 
application ..................................................................................... 215 
  
	  	   xiv 
List of Abbreviations 
 
ACC  anterior cingulate cortex 
ACh  acetylcholine 
AD  Alzheimer’s disease 
AUROC area under the receiver operating characteristic 
BACE1 beta-secretase 1 
BG  basal ganglia 
cAMP  cyclic adenosine monophosphate 
CB  calbindin 
CCK  cholecystokinin 
CR  calretinin 
DAG  diacylglycerol 
DBS  deep brain stimulation 
DLPFC dorsolateral prefrontal cortex 
EEG  electroencephalogram 
FEF  frontal eye field 
FR  firing rate 
GABA  gamma-aminobutyric acid 
GPCR  G protein-coupled receptor 
IP3  inositol triphosphate 
KCNQ  KQT-related voltage-gated delayed rectifier potassium channel 
LFP  local field potential 
M1R  muscarinic M1 receptor 
M2R  muscarinic M2 receptor 
	  	   xv 
MAPK  mitogen-activated protein kinases 
MD  medial dorsal nucleus of the thalamus 
MGS  memory-guided saccade 
MRI  magnetic resonance imaging 
MT  middle temporal area 
NHP  nonhuman primate 
NMDA N-methyl-D-aspartate 
NPY  neuropeptide Y 
PFC  prefrontal cortex 
PKC  protein kinase C  
PLC  phospholipase C 
PV  parvalbumin 
REM  rapid eye movement 
SC  superior colliculus 
SOM  somatostatin 
SZ  schizophrenia 
V1  primary visual area 
VIP  vasoactive intestinal polypeptide 
WM  working memory
	  	  
1 
CHAPTER 1 – INTRODUCTION 
 
1.1 Disorders of Cognition  
1.1.1 Alzheimer’s disease 
  Dementia is a neurodegenerative condition that affects over 500,000 
Canadians as of 2019 (~1.3% of population; approx. 2/3 women and 1/3 men). 
This number is expected to rise to over 1.1 million by 2038 (Alzheimer Society of 
Canada, 2010). Alzheimer’s disease (AD) is the most common type of dementia 
and is progressive, degenerative, and often leads to death within seven to 10 
years of diagnosis. It often has an insidious onset characterized by behavioural 
and mood changes, loss of memory, decreased ability to communicate, and 
cognitive decline. 
  The Alzheimer Society of Canada quantifies the total economic burden of 
dementia by summing direct costs (medication, staff, administration, physicians), 
unpaid caregiver opportunity cost (i.e., unpaid time spent by family members 
caring for their loved ones), and indirect costs (loss of wages and reduced 
productivity). In the landmark report, Rising Tide: The Impact of Dementia on 
Canadian Society (Alzheimer Society of Canada, 2010), the total annual 
economic burden of dementia was estimated to be over $36 billion in 2018 and 
expected to rise to over $152 billion by 2038. Thus for many reasons, there is 
rising urgency to reduce the incidence of this disease and improve care as the 
years progress. 
 Physiologically, AD is characterized by degeneration of neurons and 
synapses in many areas of the brain, causing widespread atrophy. Acetylcholine-
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producing neurons in the brain are among the affected targets. Acetylcholine 
(ACh) is one of the primary neurotransmitters in the brain, as well as in the 
periphery. The cholinergic hypothesis of AD (Bartus et al., 1982), posits the 
disease is caused by a deficient cholinergic system (Whitehouse et al., 1982). 
This includes decreased choline acetyltransferase (Bowen et al., 1976; Davies 
and Maloney, 1976), reduced choline uptake (Rylett et al., 1983), ACh release 
(Nilsson et al., 1986), and loss of cholinergic neurons in the nucleus basalis of 
Meynert (Whitehouse et al., 1982). Although a deficient cholinergic system does 
not fully explain the disease (Francis et al., 1999), cholinergic receptors are 
surely involved. Aptly, one of the primary treatments for AD is the use of 
acetylcholinesterase inhibitors, which slow the metabolism of ACh in synapses 
(the other mainstay treatment is memantine, an NMDA receptor antagonist). 
However, the magnitude of effect of these drugs is small and has been criticized 
as a temporary, symptomatic approach (Fisher, 2012; Birks and Harvey, 2018). 
 Over the past couple decades the amyloid hypothesis of AD has likely 
been the most popular. This theory suggests the neurodegeneration observed in 
AD is caused by aggregation of amyloid beta proteins (Glenner and Wong, 1984; 
Selkoe and Hardy, 2016). Indeed early-onset familial AD (3.5% of cases, Harvey 
et al., 2003) is a devastating variant of AD that is caused by dominant genetic 
mutations that alter the processing of amyloid precursor protein, resulting in a 
greater proportion of toxic amyloid beta. In general, amyloid beta is found 
extracellularly in both soluble and insoluble forms and is thought to aggregate in 
plaques or oligomers to degenerate cells via contested mechanisms (Masters et 
al., 1985; Lue et al., 1999; Zhao et al., 2012). Many investigators have attempted 
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to treat AD by reducing amyloid beta load by inhibiting production, increasing 
clearance, and preventing deposition (Panza et al., 2019) and although many of 
these trials are still underway, clinical trials to treat AD have been anything but 
fruitful in recent years. In fact, no new drugs for AD have emerged from clinical 
trials in the past 15 years (Panza et al., 2019). This paucity of clinical progress 
ultimately led the pharmaceutical giant Pfizer to announce its exit from AD 
research in January of 2018 (Hawkes, 2018). In March of 2019 Biogen 
announced the halt of phase 3 clinical trials for aducanumab, a promising amyloid 
beta antibody and potential AD treatment, due to lack of efficacy. 
 There are many other proposed contributors to AD pathophysiology that 
are regrettably outside the scope of this thesis, including toxic accumulation of 
tau protein (Ballatore et al., 2007), dysfunction of the blood-brain barrier (Hawkins 
and Davis, 2005), oxidative stress (Lin and Beal, 2006), air pollution (Moulton and 
Yang, 2012), gum disease (Dominy et al., 2019), low sleep quality (Minakawa et 
al., 2019) and of course a lack of proper diet (Liu, 2003; Morris et al., 2003; Sofi 
et al., 2008) and exercise (Laurin et al., 2001; Lautenschlager et al., 2008). 
Iaccarino et al. (2016) recently suggested an unusual treatment strategy: flashing 
light and pulsing audio stimuli at 40 Hz, which reduced amyloid plaque deposition 
in a mouse model of AD. 
 Despite decades of research, an optimal treatment strategy for AD 
remains elusive. This project will attempt to contribute to this work by observing 
neuronal activity during cognitive behaviour and characterizing the involvement of 
cholinergic receptors, which appear to be associated with some AD 
symptomology. 
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1.1.2 Schizophrenia 
 Schizophrenia (SZ) is a mental condition that affects approximately 1% 
Canadians. Although there are sex differences in age of incidence (e.g., men are 
often diagnosed earlier than women), no difference in prevalence between sexes 
has been reported (McGrath et al., 2008). People with SZ display a wide range of 
behavioural symptoms, broadly categorized into three groups: positive, negative, 
and cognitive (Kay et al., 1987). Positive symptoms include hallucinations, 
delusions, disorganized thoughts, difficulty concentrating, and catatonic 
movements. Negative symptoms include anhedonia, difficulty communicating, 
blunted emotions, avolition, and social withdrawal. Cognitive symptoms include 
deficits in decision making, response inhibition, and working memory (WM). 
According to Bowen et al. (1994) it is the cognitive deficits of SZ, such as WM 
impairment, that lead to poor social and occupational functioning. For example, if 
an effective treatment for these cognitive symptoms could be addressed, people 
with SZ may be able to lead happier, more fulfilling lives. SZ is often comorbid 
with other conditions such as substance abuse. Treatment of SZ has limited 
efficacy and involves the use of antipsychotics, in addition to behavioural therapy 
and social support networks. Antipsychotics are typically suitable for suppressing 
the positive symptoms of SZ, but are less effective at addressing negative and 
cognitive symptoms (Carbon and Correll, 2014). 
 Although the causes of SZ remain unclear, it is thought to involve both 
genetics and the environment. There are some notable differences in the SZ 
physiology that may provide clues towards more effective future treatments. 
	  	  
5 
Revealed by postmortem studies, such brain changes include: enlarged 
ventricles, smaller grey matter and whole brain volume, smaller medial temporal 
lobe and thalamic volume, and smaller cortical pyramidal neurons (Harrison, 
2000). Importantly, there are no signs of gliosis or AD neurodegeneration (such 
as amyloid plaques, neurofibrillary tangles) in postmortem SZ brain histology 
(Arnold et al., 1998), suggesting these conditions arise from very different 
mechanisms. For example, many have postulated SZ is a type of developmental 
disorder, with changes occurring during neural development in the fetus. Indeed, 
researchers have found several aberrations in SZ cytoarchitecture including 
abnormal neuronal organization in entorhinal cortex, hippocampus, and white 
matter (Kovelman and Scheibel, 1984; Jakob and Beckmann, 1986; Akbarian et 
al., 1993). 
 The dopamine hypothesis is another popular theory of SZ. SZ postmortem 
studies have found increased dopamine D2 receptors and decreased cortical 
dopamine innervation (Seeman and Niznik, 1990; Akil et al., 1999). In addition, 
although psychosis and SZ are not synonymous, dopaminergic compounds 
produce psychosis. And of course antipsychotics, the mainstay of SZ treatment, 
are all dopamine D2 receptor antagonists. 
 Although the aforementioned are important clues towards etiology and 
future treatment strategies, there are many other neurotransmitter systems that 
are disrupted in SZ, including the glutamatergic system (i.e., the glutamate 
hypothesis of schizophrenia and NMDA blockade model of schizophrenia; Javitt, 
1987; Coyle, 1996; Gil-da-Costa et al., 2013; Ma et al., 2018), the serotoninergic 
system, and the GABAergic system (Harrison, 1999). The cholinergic system, 
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despite not receiving as much attention in SZ as other neurotransmitters, is also 
disrupted in SZ. For example, expression of muscarinic M1 receptors is 
decreased in SZ (Dean et al., 2002). People with SZ are 5x more likely to be 
smokers (de Leon and Diaz, 2005; McClave et al., 2010). Although it is difficult to 
pin causality on SZ, especially considering the number of comorbid and lifestyle 
situations of people with SZ, some have posited smoking may be a form of self-
treatment (the self-medication hypothesis; Kumari and Postma, 2005). For 
example, stimulation of nicotinic receptors (nicotine is the main psychoactive 
compound in cigarettes) is known to improve performance in a number of 
cognitive tasks (Levin et al., 2006). However, a recent meta-analysis found that 
smokers with SZ did not have a distinct cognitive advantage over nonsmokers 
with SZ, and the effect of smoking likely differs based on the cognitive domain 
tested (Wang et al., 2019). 
 SZ, similar to AD, is associated with both impaired cognition and altered 
cholinergic system. Although many models of schizophrenia have been 
proposed, there is a gap in knowledge to be addressed regarding how 
acetylcholine modulates both normal and abnormal cognitive circuitry. The 
prefrontal cortex, which receives dense cholinergic innervation, has been a 
prominent focus of cognitive neuroscience. This investigation will explore the role 
of cholinergic receptors in prefrontal activity, attempting to provide insights into 
the cholinergic pathology in conditions of impaired cognition such as AD and SZ. 
 
1.2 Prefrontal Cortex 
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The primate lateral prefrontal cortex (PFC) contributes to a range of higher 
order cognitive functions (Miller and Cohen, 2001), including attention, response 
inhibition, WM maintenance and manipulation, and context-dependent or goal-
directed behaviour.  PFC is particularly sensitive to atrophy in AD 
(Giannakopoulos et al., 1997). Total PFC grey matter is reduced in AD compared 
to age-matched controls (Salat et al., 2001) and both presynaptic terminals and 
synapses are also reduced (Brion et al., 1991; Masliah et al., 1991). Young et al. 
(2014) reported that in AD, pyramidal dendritic spines in PFC degrade faster than 
V1 spines. This degeneration likely contributes to cognitive symptoms. Serra et 
al. (2010) found cingulate and right middle frontal gyri grey matter volume 
inversely correlated with disinhibition scores of AD patients. PFC is also 
abnormal in SZ: pyramidal spine density is decreased (Glantz and Lewis, 2000), 
parvalbumin expression in interneurons is decreased (Hashimoto et al., 2003), 
inflammatory markers are increased (Fillman et al., 2013), and regulation of 
presynaptic gene expression is reduced (Mirnics et al., 2000). Individuals with SZ 
show abnormal activation of PFC during performance of executive tasks (Barch 
et al., 2001), and task performance is correlated with degree of altered prefrontal 
activation (Weinberger et al., 1986; Perlstein et al., 2001). Thus, there is 
evidence for a role of PFC in the cognitive deficits observed in AD and SZ. The 
necessity of PFC in executive function can be experimentally determined by 
observing the effects of prefrontal lesions. The next section will overview previous 
reports examining PFC lesions and resultant effects on cognition.   
 
1.2.1 Lesions of PFC 
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 Studies examining the effects of brain lesions have been used for decades 
and have provided many insights into the functions of different brain regions. For 
example, topographical mapping of the visual field onto area V1 was aided by 
observing how V1 scotomas affected vision in different portions of the visual field 
(Lister and Holmes, 1916). There are numerous investigations reporting the 
effects of frontal lobe lesions in humans. For example, Milner, 1963 had epileptic 
patients perform the Wisconsin Card Sorting Test (WCST) before and after 
unilateral cortical excisions to relieve seizures. Dorsolateral frontal lesions 
resulted in marked reductions in WCST performance:  number of errors was 
increased and number of categories achieved was decreased. The increase in 
errors was largely perseverative errors, e.g., patients would be told their choice of 
card was wrong but they would not correct this behaviour in future actions. Milner 
suspected there was a disconnect between observation of an error and change to 
the appropriate action. Deficits in planning and WM were also found by Owen et 
al. (1990), which tested patients with frontal lobe lesions. 
 Of course, the extent of frontal lesions in humans is highly variable, 
depending on the reason for excision (e.g., epilepsy, aneurysm, cancer). This can 
make interpretations on the functions of individual brain regions difficult, since 
surgical excisions do not adhere to cytoarchitecturally-defined brain areas. The 
use of nonhuman primates (NHPs) is extremely useful for this reason, since 
experimental ablations can be confined to a particular region (e.g., principal 
sulcus) and consistent across subjects. The use of NHPs is invaluable in 
research towards treating conditions of disrupted cognition such as AD and SZ, in 
which PFC function is altered. Although the use of rodent models is pivotal for 
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many areas of neuroscience research, rats do not have a granular PFC 
analogous to that of humans (Preuss, 1995). 
 Several investigators have explored the effects of ablation to principal 
sulcus and surrounding area on WM (Gross and Weiskrantz, 1962; Butters and 
Pandya, 1969; Mishkin and Manning, 1978; Passingham, 1985; Funahashi et al., 
1993a). These findings support a vital role of dorsolateral PFC (DLPFC), and 
especially principal sulcus, in successful performance in spatial WM tasks. 
Funahashi et al. (1993a) found unilateral principal sulcus lesions disrupted 
performance of memory-guided saccades in the contralateral visual field. These 
deficits were exaggerated with increased delay length, suggesting optimal 
DLPFC function is required even more during greater WM load. Deactivation of 
DLPFC can also be examined using local injections of muscimol, a GABAA 
receptor agonist. Similar to ablation, muscimol injections caused increased errors 
and saccadic dispersion to the contralateral targets during memory-guided 
saccades (Sawaguchi and Iba, 2001). 
 Gregoriou et al. (2014) lesioned right PFC (including FEF), corpus 
callosum, and anterior commissure and recorded from both right (no prefrontal 
input) and left (control) visual area V4 in two rhesus macaques. Compared to the 
control hemisphere, right V4 then experienced diminished effects of attention and 
reduced spiking coherence with cortical oscillations. 
 Experiments using lesions have thus illuminated the role of PFC in 
executive function, including WM and attention. As discussed in the following 
section, due to the interregional connections of PFC, it is well suited to 
accumulate sensory inputs and coordinate goal-directed behaviour, such as 
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during WM tasks. 
 
1.2.2 Anatomical connections of PFC 
 The PFC is interconnected with many of cortical and subcortical regions, 
making it well positioned to receive sensory information, communicate between 
regions, and execute appropriate actions (Fig. 1.1; Miller and Cohen, 2001). 
Taking context into account and flexibly choosing the appropriate action is 
believed to be a cardinal function of PFC. The expansion of association cortices 
such as PFC has accelerated over the course of evolution at a faster rate than in 
our relative species (Rilling and Insel, 1999). The cognitive specializations of PFC 
are likely involved in development of human intelligence and our identity as a 
species (Roth and Dicke, 2005). Human PFC has a disproportionately high 
degree of connectivity, measured by white matter volume (Schoenemann et al., 
2005).  
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Figure 1.1 
Intrinsic and extrinsic connections of the prefrontal cortex. 
Regions of prefrontal cortex is heavily connected with other prefrontal regions, 
and distant brain areas such as sensory cortices, motor regions, basal ganglia, 
temporal cortex, and thalamus. Through these extensive connections, prefrontal 
cortex is well suited to flexibly coordinate cognitive control. Solid lines represent 
bidirectional connections; arrows indicate unidirectional connections. Reprinted 
with permission from: Miller and Cohen. (2001) An integrative theory of prefrontal 
cortex function. Annual Review of Neurosciscience. 24:167–202.  
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 Lateral PFC receives input from a wide range of regions, including 
occipital, temporal, and parietal cortices. In particular, DLPFC is thought to 
converge multisensory information, with inputs from visual, auditory, and 
somatosensory cortices, and also regions that are themselves multimodal (Bruce 
et al., 1981; Goldman-Rakic and Schwartz, 1982; Barbas and Pandya, 1989; 
Pandya and Yeterian, 1990). 
 DLPFC is proposed to maintain goals during delayed responses and 
influence output motor regions via direct connections. Although DLPFC does not 
terminate on M1 directly, it has afferents in supplementary motor area, pre- 
supplementary motor area, and premotor cortex, where it is thought to promote 
actions related to premeditated goals (Bates and Goldman-Rakic, 1993; Lu et al., 
1994). DLPFC also influences saccadic behaviour directly with connections to 
superior colliculus (Goldman and Nauta, 1976; Johnston and Everling, 2009), and 
indirectly via the frontal eye fields (FEF) and basal ganglia (Stanton et al., 1993). 
Prefrontal influence on SC was historically thought to be inhibitory, thereby 
suppressing inappropriate saccades during tasks such as the antisaccade task 
(Guitton et al., 1985; Pierrot-Deseilligny et al., 1991). However, recent work 
involving cortical cooling of rhesus DLPFC and concurrent SC recordings suggest 
that PFC instead has an excitatory influence on SC, promoting saccades towards 
goal-directed targets (Koval et al., 2011; Everling and Johnston, 2013; Johnston 
et al., 2014). 
 There are also dense connections from PFC to basal ganglia (BG), and 
back from BG to PFC (via the thalamus). The BG is involved in several cortical-
subcortical-thalamic loops (Alexander et al., 1986), and is known for its role in 
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facilitating or inhibiting movement. Degeneration of these cortical-BG loops may 
elicit the cognitive deficits in Parkinson’s disease and Huntington disease 
(Stocchi and Brusa, 2000). 
 PFC is also interconnected with hippocampus (Goldman-Rakic et al., 
1984) and the two areas oscillate synchronously during WM tasks (O'Neill et al., 
2013; Tamura et al., 2017), suggesting flow of information. These connections 
may mediate reflection of past experiences to gauge current context 
(Eichenbaum, 2017). Finally, PFC is also connected with the amygdala (Porrino 
et al., 1981; Amaral and Price, 1984; Barbas and De Olmos, 1990) and the 
hypothalamus (Rempel-Clower and Barbas, 1998). Through these 
communication channels, PFC is thought to process emotional and internal 
states (Miller and Cohen, 2001). 
  Thus, the PFC is densely interconnected with many brain regions and is 
well suited to intake and process sensory information, maintain this 
representation in WM, and output and appropriate response. This begets the next 
question: how is maintenance of a short-term memory represented in the brain? 
Many investigators have explored this question using NHP electrophysiology. 
 
1.2.3 Delay Activity 
 For decades, in vivo NHP electrophysiology has been a powerful tool for 
exploring cortical representations of WM. This technique allows observation of 
neuronal activity from a primate with a granular PFC similar to that of humans 
(Petrides and Pandya, 1999; Croxson et al., 2005), concurrent with performance 
of executive tasks. One fascination of electrophysiologists was the ability of some 
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neurons in lateral PFC to discharge persistently during a delay period of WM 
tasks, i.e., after a cue directing a later action and in the absence of sensory 
stimuli. For example, Kubota and Niki (1971) found neurons around the macaque 
principal sulcus that would preferentially discharge during the 5 s delay period of 
a delayed alternation task. These delay cells have been found by many other 
investigators (Fuster and Alexander, 1971; Fuster, 1973; Niki, 1974a; Niki, 
1974b; Niki, 1974c; Niki and Watanabe, 1976; Fuster et al., 1982; Kojima and 
Goldman-Rakic, 1982; Kojima and Goldman-Rakic, 1984; Batuev et al., 1985). 
 A very common task in NHP electrophysiology is the oculomotor delayed-
response task, also known as memory-guided saccades (Fig. 1.2A). In this 
experimental task, monkeys are head-fixed in front of a monitor and trained to 
fixate on a central dot. Next, a cue is flashed in the periphery at one of eight 
locations and the monkey must maintain central fixation over a delay period 
(typically 1–3 s). Finally, the central fixation dot disappears and the monkey must 
saccade to the previously cued location. When prefrontal neurons are recorded 
during performance of this task, especially around the principal sulcus, 
approximately approx. 25–33% of neurons discharge preferentially during this 
delay period (Fig. 1.2B; Funahashi et al., 1989). This persistent firing after the 
removal of visual stimulation, and despite the presence of distractors (Jacob and 
Nieder, 2014), led many to suspect this activity could be the neurophysiological 
basis of WM maintenance (Funahashi et al., 1989; Goldman-Rakic, 1995). Other 
cortical regions are much more susceptible to respond to distractors (Suzuki and 
Gottlieb, 2013). Prefrontal delay cells also show directional selectivity, with many 
firing only for cues in certain receptive fields (or “memory fields”).  
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Figure 1.2 
The memory-guided saccade task and delay cells. 
A, This task begins with central fixation (FP) and a flashed cue in one of eight 
peripheral locations. The subject must maintain fixation through this briefly 
flashed cue (C) and the following delay epoch (D), which can vary from 1–3 s. 
After the delay epoch comes the response epoch (R), when the central fixation 
dot is extinguished and the subject must saccade to the location of the previous 
peripheral cue. Rasters and spike histograms are shown for a single dorsolateral 
prefrontal cortex neuron during eight different trial types, each with a different 
peripheral cue location. This example neuron selectively discharges during the 
delay epoch for the 270° visual angle. Modified with permission from Funahashi 
et al. (1989) Mnemonic coding of visual space in the monkey's dorsolateral 
prefrontal cortex. J Neurophysiol. 61(2):331–49. B, Shown are three of the cell 
types observed in prefrontal cortex during performance of memory-guided 
saccades: cue-, delay-, and response-selective cells. Delay cells discharge in the 
absence of visual stimuli, often only for certain visual locations in memory. 
Modified with permission from Goldman-Rakic. (1995) Cellular basis of working 
memory. Neuron. 14(3):477–85.  
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 Based on these results, Goldman-Rakic (1995) popularized a theory of 
WM maintenance, in which layer III of lateral PFC held information in WM by 
recurrent excitation between reciprocally connected pyramidal neurons. As 
discussed in the next subsection, the DLPFC indeed has suitable 
cytoarchitecture for recurrent activation, with most layer III pyramidal neurons 
synapsing onto other layer III pyramidal neurons (Melchitzky et al., 1998). 
 However, this model of WM involving delay cells and persistent activity 
within PFC has recently come under criticism. Firstly, delay cells are found in a 
wide variety of brain regions other than PFC, which appears to weaken the 
necessity of prefrontal delay activity in WM (we know from lesion studies that WM 
is reliant on PFC). Other regions with delay activity include parietal cortex (Qi et 
al., 2010; Katsuki and Constantinidis, 2013), inferotemporal cortex (Fuster, 1990; 
Freedman et al., 2003), visual cortices (Hayden and Gallant, 2013; van Kerkoerle 
et al., 2017), somatosensory cortices (Zhou and Fuster, 1996), and thalamus 
(Watanabe and Funahashi, 2004), albeit to varying degrees (Levitt et al., 1993). 
  The Miller lab has suggested that this persistent activity observed during 
delay periods is not very prevalent in most prefrontal neurons, and their 
appearance in single-unit and population spike density functions is the result of 
averaging across trials and neurons. Several reports have shown spiking is in 
fact sparse during individual trials (Lundqvist et al., 2016) and true delay cells are 
overrepresented in publications due to the use of idealistic (instead of 
representative) example neurons in figures. Delay activity could be related to 
motor preparation instead of memory retention (Shafi et al., 2007). Indeed many 
neurons show “ramp-up” activity that peaks upon motor or oculomotor response. 
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The Miller lab believes transient discharges are sufficient for WM maintenance, in 
which asynchronously active neurons take turns firing to maintain WM 
information (Lundqvist et al., 2010). Transient gamma bursts are also observed 
during memory-guided saccade WM maintenance (Lundqvist et al., 2016), can 
show task-related tuning during WM tasks (Pesaran et al., 2002), and can predict 
upcoming errors with higher accuracy than spiking alone (Lundqvist et al., 2018). 
The Miller lab further proposes that instead of persistent spiking, short-term 
information can be maintained via synaptic facilitation, augmentation, and 
potentiation (Wang et al., 2006). Such non-spiking maintenance is less 
metabolically expensive and possibly less prone to interruption from distractor 
sensory input. 
 
1.2.4 Dorsolateral PFC cytoarchitecture and microcircuits 
  Brodmann (1905) labelled the dorsolateral region of PFC as area 9. This 
region of cortex was later split into two, adding area 46 (Walker, 1940) because 
of area 46’s characteristic thick granular layer IV. Walker’s area 46 was ultimately 
split again, adding new area 9/46 (Fig. 1.3) due to the large pyramidal neurons in 
deep layer III of area 9/46 (Petrides and Pandya, 1999). 
  
	  	  
18 
Figure 1.3 
Human and rhesus macaque prefrontal cortices. 
Lateral views of human (A) and rhesus macaque (B) left prefrontal cortices. 
Homologous prefrontal regions are shown. Recordings during this project were 
performed in dorsal area 9/46. This area, medial to the posterior principal sulcus 
corresponds to the human middle frontal gyrus. Modified with permission from 
Petrides and Pandya. (1999) Dorsolateral prefrontal cortex: comparative 
cytoarchitectonic analysis in the human and the macaque brain and 
corticocortical connection patterns. Eur J Neurosci. 11(3):1011–36.  
A B
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 One of the reasons DLPFC has been the subject of WM conversations is 
because of its extensive local interconnections, which may support recurrent 
activity during WM maintenance. Histological studies have indeed shown that 
layer III pyramidal neurons of DLPFC have bidirectional connections with layer III 
of nearby cortical columns (Levitt et al., 1993; Kritzer and Goldman-Rakic, 1995; 
Pucak et al., 1996). DLPFC also has bidirectional connections with distant brain 
regions such as parietal cortex (Leichnetz, 1980; Goldman-Rakic and Schwartz, 
1982; Schwartz and Goldman-Rakic, 1984). As discussed previously, if delay 
activity (or persistent activity) is indeed a component of WM maintenance, these 
dense recurrent connections may support such activity. Melchitzky et al. (1998) 
provided a convincing example of these recurrent connections in macaque PFC: 
over 95% of layer III pyramidal neuron terminations were onto other layer III 
pyramidal neurons in PFC. These pyramidal-to-spine terminals appear to be 
especially prevalent when synapsing onto a different prefrontal column or 
terminating in another PFC area (Melchitzky et al., 2001). 
 Dendrites of pyramidal neurons have a unique profile in human PFC, with 
a high number of spines and branches. Human PFC has many more spines than 
neurons in other areas such as V1 (Jacobs et al., 2001; Elston, 2003) and has 
23x more layer III dendritic spines than rhesus macaque PFC (Elston, 2001). This 
dendritic labyrinth is interpreted as allowing for greater information processing 
capacity in human PFC and may contribute to the advanced cognitive flexibility of 
humans (Roth and Dicke, 2005). Prefrontal spines express a variety of 
neuromodulatory receptors and are actively being investigated as 
pharmacological targets (Arnsten et al., 2012). Intriguingly, all three of the 
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following conditions with deficient cognition—AD, SZ, and normal aging—involve 
reduction of PFC layer III spines (Peters et al., 2008; Boros et al., 2017; Hoftman 
et al., 2017). Prefrontal spine density correlates with indicators of cognitive 
function during aging (Dumitriu et al., 2010), and in AD prefrontal spines degrade 
faster than spines in V1 (Young et al., 2014). 
 Interneurons (approx. 20–30% of cortical neurons) also play a prominent 
role in prefrontal circuits. Compared to pyramidal neurons, cortical interneurons 
are diverse in morphology, physiological properties, and function. There are 
different methods of classifying interneurons, including based on molecular 
markers, morphology (including synapse morphology), and electrical properties. 
For example, calcium-binding proteins parvalbumin (PV), calretinin (CR), and 
calbindin (CB) are commonly used to aid in interneuron identification 
(Demeulemeester et al., Neurosci LEtt, 1989; Rogers and Resibois, 
Neuroscience, 1992; Kubota et al., 1994). Neuropeptides such as somatostatin 
(SOM), vasoactive intestinal polypeptide (VIP), cholecystokinin (CCK), and 
neuropeptide Y (NPY) can also aid in identification (Hendry et al., 1984). 
However, distinction using molecular markers are cannot accurately identify 
interneuron type unless multiple markers are used in conjunction (Markram et al., 
2004). Rudy et al., (2011) have proposed that distinction using PV, SOM, and 
serotonin receptor 3a can account for nearly all GABAergic neurons. Conde et al. 
(1994) used immunohistochemistry to find the laminar distribution of interneurons 
in rhesus macaque area 46. They found the highest density of interneurons in 
superficial layers, although PV neurons were also present in granular and 
infragranular layers (see Fig. 1.4).  
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Figure 1.4 
Laminar distribution of GABAergic interneurons in macaque area 46. 
Laminar distributions of calretinin (CR), calbindin (CB), and parvalbumin (PV) 
immunoreactive structures are shown in macaque area 46. CR and CB neurons 
were most prominent in supragranular layers, and PV neurons were mostly in 
layer IV, followed by layer III. Modified with permission from Condé et al. (1994) 
Local circuit neurons immunoreactive for calretinin, calbindin D-28k or 
parvalbumin in monkey prefrontal cortex: distribution and morphology. J Comp 
Neurol. 341(1):95–116. 
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 During extracellular electrophysiological recordings in vivo, neurons can 
only be putatively classified based on waveform shape (other properties such as 
discharge rate can also be useful in classification; Connors and Gutnick, 1990; 
Kawaguchi, 1993; Gonzalez-Burgos et al., 2005). Neurons with broad waveforms 
(longer trough-to-peak duration) are putatively labelled as pyramidal and neurons 
with narrow waveforms (shorter trough-to-peak duration) can be labelled as 
nonpyramidal. Specifically, narrow-spiking neurons are thought to often be PV 
interneurons. Other types of interneurons do not exhibit this narrow waveform, 
e.g., VIP interneurons often have broad spike waveforms similar to that of 
pyramidal neurons (Mesik et al., 2015). SOM interneurons can have either 
narrow or broad waveforms, depending on the subtype (Kim et al., 2016). Indeed, 
this classification scheme is not perfect, pyramidal tract neurons with narrow 
waveforms have been identified in macaque motor areas (Vigneswaran et al., 
2011). 
 Rao et al. (1999) simultaneously recorded putative pyramidal and 
nonpyramidal neurons during macaque performance of memory-guided 
saccades. They found similar directional tuning between adjacent pairs, whereas 
pairs that were further away from each other displayed opposite directional 
preference (Wilson et al., 1994). These findings, combined with anatomy showing 
recurrent connectivity within PFC, led to a proposed role of interneurons in 
directional tuning during memory-guided saccades. As pyramidal neurons 
propagate activity to similarly-tuned cortical columns, they also activate 
GABAergic interneurons within their own cortical column, which go on to 
suppress activity in other, dissimilarly-tuned cortical columns (e.g., containing 
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pyramidal neurons that preferentially fire for a different stimulus direction or 
“memory field”; see Fig. 1.5). This GABAergic control of neuron directional 
preference was supported by local application of GABAA receptor antagonist 
bicuculine, which abolished memory-guided saccade directional tuning by 
increasing activity (likely disinhibition) for nonpreferred directions (Rao et al., 
2000). 
  
	  	  
24 
 
Figure 1.5 
Goldman-Rakic model of the prefrontal working memory circuit. 
In this model of working memory maintenance during memory-guided saccades, 
the location of the peripheral cue is maintained throughout the delay period by 
recurrent connections between layer III pyramidal neurons (triangles) in prefrontal 
cortex. Different cortical columns represent different peripheral angles or 
“memory fields”. For example, after a 270° cue, there is recurrent discharging 
between pyramidal neurons (some in different columns) that are selective for 
270° cues. Further, inhibitory interneurons (circles) suppress activity in pyramidal 
neurons that represent different cue locations (e.g., 90° cue). Modified with 
permission from Goldman-Rakic. (1995) Cellular basis of working memory. 
Neuron. 14(3):477–85. 
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 A circuit model of interneuron function during WM maintenance was 
proposed by Wang et al. (2004). PV neurons have wide horizontal arborizations 
(e.g., basket cells) and are proposed to cause widespread inhibition to pyramidal 
neurons across multiple cortical columns, and also to CR neurons within the 
same column (Fig. 1.6). CB neurons provide local suppression of pyramidal 
dendrites.	  Finally, CR neurons inhibit nearby CB neurons (thus disinhibiting the 
local pyramidal neurons). This model was able to successfully show persistent 
activity of pyramidal neurons during a delay period and was resilient to distractor 
cues. This ability to avoid distractors was related to the ratio of dendritic vs. 
somatic inhibition onto pyramidal neurons. CB interneurons are decreased in SZ 
and AD (Ferrer et al., 1993; Beasley and Reynolds, 1997), but CR neurons (and 
PV neurons in AD) are spared (Woo et al., 1998). 
  
	  	  
26 
 
Figure 1.6 
Diagram of pyramidal neurons and interneurons in proposed microcircuit of 
working memory. 
Similar to the model previously proposed by Goldman-Rakic (Neuron, 1995), 
activation of a pyramidal neuron (P) results in inhibition of nearby pyramidal 
neurons that are responsive to different memory-guided saccade cue locations. 
This lateral inhibition is carried via parvalbumin (PV) GABAergic interneurons. 
Calbindin (CB) interneurons provide local inhibition to pyramidal neurons. 
Calretinin (CR) interneurons inhibit CB interneurons, thus disinhibiting local 
pyramidal cells. Modified with permission from Wang et al. (2004) Division of 
labor among distinct subtypes of inhibitory neurons in a cortical microcircuit of 
working memory. PNAS. 101(5):1368–73.  
PV
CR
CB
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 Future work showing how different neuromodulators are expressed on 
different interneurons in PFC would be very helpful in determining how this circuit 
could be affected in different neuromodulatory states. For example, dopamine D1 
receptor stimulation may increase the dendritic/somatic inhibition ratio and help 
filter out distracting stimuli during WM tasks (Gao et al., 2003; Wang et al., 2004). 
Interestingly, Disney and Aoki (2008) found different interneurons in macaque V1 
showed differential expression of muscarinic M1 receptors, with PV neurons 
being the most likely to express muscarinic M1 receptors. 
  Together, pyramidal and interneurons form microcircuits across the six 
layers of PFC that are important for WM. Superficial layers are most commonly 
associated with task-related activity during WM tasks, especially during the delay 
period (Sawaguchi et al., 1989), which then direct deeper layers that are 
considered the output layer (Song et al., 2012). In the example of oculomotor 
tasks, deep layer pyramidal neurons send projections to SC to influence saccadic 
responses (Goldman and Nauta, 1976; Johnston and Everling, 2009). 
 Until recently, electrophysiological recordings were performed using single 
electrodes and therefore the exact cortical layer of recordings could not be 
reported with high confidence. With the use of laminar electrodes, the roles of 
different cortical layers have now been explored across neocortex (Lakatos et al., 
2007; Takeuchi et al., 2011; Godlove et al., 2014; Chandrasekaran et al., 2017; 
Nandy et al., 2017; Bastos et al., 2018). For example, Opris et al. (2012) found 
similar spatial tuning between prefrontal layer III neurons and layer V neurons 
within the same cortical column. 
 Cortical columns in different cortical regions appear to share patterns of 
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connectivity. Bastos et al. (2012) have proposed a canonical cortical microcircuit 
that details the temporal flow of information between layers and between areas in 
both bottom-up and top-down directions (Fig. 1.7). Briefly, supragranular layer III 
receives feedforward connections from granular layer IV as well as feedback 
information from higher cortical areas. Layer III neurons then project to 
infragranular neurons in the same column, make lateral connections with other 
layer III neurons in the same area, and send projections to higher cortical areas 
as feedforward information (van Kerkoerle et al., 2017). Infragranular output 
layers V and VI send long range projections to subcortical areas, thalamus, and 
also feedback projections to lower cortical areas (typically terminating on supra- 
and infragranular layers, but not layer IV). These deep layers also send intrinsic 
projections to superficial layers of the same column. Recently, alpha oscillations 
from deep layer PFC of macaques (Bastos et al., 2018) and marmosets 
(Johnston et al., 2019) have been reported to inhibit gamma power and spiking 
activity in superficial layers of the same column.  
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Figure 1.7 
Proposed canonical microcircuit of feedforward and feedback cortical 
connections. 
This laminar organization of connections is proposed to be consistent across 
different cortical areas. Feedforward connections such as sensory input enters a 
cortical column in layer IV and next from layer IV to layers II/III. These layers 
project to both higher cortical areas and deep layers V/VI of the same column. 
These deep layers send feedback signals to lower cortical areas, thalamus, and 
output information to brainstem. Feedback information from higher cortical areas 
often enters via layers II/III and V/VI. Reprinted with permission from Bastos et al. 
(2012) Canonical microcircuits for predictive coding. Neuron. 76(4):695–711.  
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1.3 Cholinergic System 
 ACh is a neurotransmitter that was already identified in 1914 (Dale, 1914) 
and acts upon two classes of cholinergic receptors – muscarinic receptors and 
nicotinic receptors – that are found throughout the central and peripheral nervous 
system. Although there are some neurons in rat neocortex that produce ACh 
(Levey et al., 1984; Houser et al., 1985), cholinergic afferents from deep brain 
structures, such as the nucleus basalis of Meynert and medial septal nucleus, are 
the main source of cortical ACh (Fig. 1.8; Kievit and Kuypers, 1975; Mesulam and 
Van Hoesen, 1976; Mesulam et al., 1983). Cholinergic nuclei are referred to as 
Ch1–Ch4. Uncovering the inputs to cholinergic nuclei can reveal what type of 
activity can drive ACh release. For example, top-down attention is a form of 
attention that is driven by higher order processes such as short-term memory 
goals, and may be elicited by connections from PFC to basal forebrain. 
Projections to basal forebrain from rat medial PFC may mediate such top-down 
attention (Gaykema et al., 1991; Zaborszky et al., 1997). In macaques, cortical 
projections to nucleus basalis were not identified from DLPFC, but from 
orbitofrontal cortex and other cortical regions including prepyriform cortex, 
entorhinal cortex, inferotemporal cortex (Mesulam and Mufson, 1984). The basal 
forebrain also receives input from subcortical regions (medial hypothalamus, 
septal nuclei, nucleus accumbens-ventral pallidum, amygdala; Price and Amaral, 
1981; Mesulam and Mufson, 1984) and catecholaminergic nuclei (Smiley and 
Mesulam, 1999; Smiley et al., 1999). 
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Figure 1.8 
Cholinergic nuclei of the human brain. 
Different cholinergic nuclei innervate different brain regions with cholinergic 
afferents. The basal forebrain, including the nucleus basalis of Meynert (nBM), is 
the main contributor of acetylcholine to neocortex. MS, medial septal nucleus; 
DB, diagonal band of Broca; LDT, laterodorsal pontine tegmentum; PPT, 
pedunculopontine tegmental nucleus. Reprinted with permission from Newman et 
al. (2012) Cholinergic modulation of cognitive processing: insights drawn from 
computational models. Front Behav Neurosci. 13:6–24.  
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 The cholinergic system has been associated with a variety of different 
functions, including learning and memory (Saar et al., 2001), perception (Evans, 
1975; Bartus and Johnson, 1976), attention (Kozak et al., 2006), and cognitive 
functions such as WM maintenance (Green et al., 2005). ACh release varies 
greatly during the sleep/wake cycle (Marrosu et al., 1995). High ACh levels 
during rapid eye movement (REM) sleep are a proposed mechanism behind the 
REM deactivation of DLPFC (Braun et al., 1997). ACC activity is increased during 
REM sleep (Buchsbaum et al., 2001) and ACC to PFC terminals (Muzur et al., 
2002) gated by muscarinic M2 receptors have been proposed as a specific locus 
of this REM DLPFC inhibition (Medalla and Barbas, 2012).  
 Lesions of the basal forebrain have been used extensively in rats to 
examine the behavioural effects of removing endogenous ACh. One of the first 
basal forebrain lesions was performed by Dubois et al. (1985), who tested the 
effect on acquisition and reversal of spatial memory. They and others (Hepler et 
al., 1985) observed a variety of behavioural changes including increased 
locomotion and decreased memory capabilities in multiple tasks. The 
methodology was improved with the development of immunotoxins that could 
selectively destroy cholinergic neurons, but not the non-cholinergic neurons of 
basal forebrain (Wiley et al., 1991). These injections indeed produced less 
extensive deficits on learning and memory  (Wenk et al., 1994). McGaughy et al. 
(2002) explored the effects of these cholinergic-specific lesions to rat basal 
forebrain in the five-choice serial reaction time task that probes attention. In this 
task, rats must attend 5 possible locations and perform a nose poke after a light 
is flashed in one of those locations (Robbins, 2002). It was found that these 
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lesions decreased performance in several ways, such as increased omissions 
and response latencies, indicating decreased attention. The authors further 
postulated this effect was not motivational, as increasing the length of the flashed 
cue ameliorated the deficit. Upon histological examination they found choline 
acetyltransferase-reactive neuron count significantly correlated with choice 
accuracy, implicating a role in cholinergic innervation in successful task 
performance. Intriguingly, basal forebrain lesions in rats have also been reported 
to slow recorded frequencies in EEG (Stewart et al., 1984; Buzsaki et al., 1988), 
similar to what is observed in EEG of AD patients with neurodegeneration of the 
cholinergic system (Jeong, 2004). 
 Cholinergic-neuron-specific immunotoxins were eventually tested in 
marmoset and rhesus macaque cortex (Fine et al., 1997), which elicited 
behavioural deficits in learning/memory, visual discrimination, and visual WM 
(Ridley et al., 1999; Turchi et al., 2005). In a landmark study by Croxson et al. 
(2011), cholinergic immunotoxin ME20.4-saporin was injected over several areas 
of PFC to probe the effect of ablating cholinergic input to PFC. These monkeys 
were trained in a variety of tasks including object-in-place learning, strategy 
implementation, reward devaluation, and spatial WM. These monkeys were 
unaffected in all tasks except the spatial WM task, implicating an important role of 
prefrontal cholinergic stimulation in performance of spatial WM. Later chapters of 
this thesis will continue this exploration of the role of cholinergic receptors in PFC 
during WM performance. 
 Deep brain stimulation (DBS) of the basal forebrain has been examined in 
different animal models and is being explored as a potential treatment option for 
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AD (Bittlinger and Muller, 2018). Basal forebrain stimulation in rats can increase 
ACh release in cortex (Kurosawa et al., 1989), increase cerebral blood flow 
(Biesold et al., 1989; Adachi et al., 1990), and may increase nerve growth factor 
via nicotinic stimulation (Hotta et al., 2009). This increased release of ACh may 
be able to improve cognitive performance. Kang et al. (2014) found basal 
forebrain stimulation increased performance of rats in a visual water maze task. 
The potential cognitive benefit of electrically stimulating cholinergic nuclei was 
bolstered by Liu et al. (2017), who reported intermittent stimulation of the nucleus 
basalis of Meynert in rhesus macaques improved performance in the delayed 
match-to-sample task, an effect that was blocked by nicotinic or muscarinic 
blockade. These effects persisted in the following months, even on test days 
without stimulation. In humans, multiple research groups have attempted DBS in 
patient populations, with mixed results (Lozano et al., 2019). A Canadian group 
conducted phase I and II clinical trials performing DBS on the fornix of AD 
patients (Laxton et al., 2010; Lozano et al., 2016). They reported increased 
glucose metabolism and small cognitive improvements, but only on an older 
subgroup of participants. A different group performed DBS to the nucleus basalis 
of Meynert (Kuhn et al., 2015; Hardenacke et al., 2016). Their results suggest 
stimulation may slow disease progression, particularly in cases of milder AD. The 
future of human DBS research for AD is in its infancy, with many technical and 
ethical considerations (Bittlinger and Muller, 2018). 
 Apart from cholinergic lesions, another source of information for the 
functional roles of cholinergic receptors was the systemic administration of 
antagonists. For example, atropine and scopolamine are general muscarinic 
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antagonists and mecamylamine is a general nicotinic antagonist. Scopolamine 
has been used extensively for decades to test the role of muscarinic receptors in 
a variety of cognitive tasks (reviewed by Klinkenberg and Blokland, 2010). 
Scopolamine-induced impairments include signal discrimination (Drinkenburg et 
al., 1995; Harder et al., 1998; Wilson, 2001), attention (Callahan et al., 1993; 
Spinelli et al., 2006), and both learning/long-term memory (Spencer, 1983) and 
short-term WM (Rupniak et al., 1991; Green et al., 2005). Nicotinic blockade also 
elicits cognitive deficits such as attention, alertness, word recall, and spatial 
associative memory (Newhouse et al., 1992; Moran, 1993; Katner et al., 2004; 
Baakman et al., 2017). The cognitive effects of nicotinic blockade are dose-
dependent and typically less extreme than muscarinic blockade, possibly due to 
lesser sedative effects (Baakman et al., 2017). Combined nicotinic and 
muscarinic receptor challenge can synergistically reduce cognitive performance 
(Green et al., 2005; Greenwood et al., 2009). 
 We can also gain insights on the function of the cholinergic system with 
systemic stimulation of receptors. One of the most prevalent examples is the use 
of acetylcholinesterase inhibitors in AD. Repantis et al. (2010) reviewed several 
studies that explored the effects of acetylcholinesterase inhibitors (mostly 
donepezil) on healthy participants. Results were mixed, with some studies 
reporting no effect and two studies reporting disrupted performance after drug 
administration. However, small improvements compared to placebo were 
observed in verbal memory recall, procedural memory, and spatial WM. 
Donepezil was able to improve visual attention and short-term memory in sleep-
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deprived participants (Chuah and Chee, 2008), suggesting acetylcholinesterase 
inhibitors may only be effective in states of impaired cognition. 
 The most commonly occurring exogenous stimulation of cholinergic 
receptors is an activity involving approximately one billion participants worldwide: 
smoking tobacco cigarettes (Ng et al., 2014). Nicotine is naturally occurring in 
tobacco and the main psychoactive ingredient in tobacco smoke. Nicotine is an 
agonist for most nicotinic receptor subtypes, and thus inspired the name of this 
cholinergic receptor class. Systemic nicotine exposure (e.g., smoking a cigarette) 
results in a variety of both central and peripheral effects. Peripheral effects to 
naïve users include increased heart rate and blood pressure, tremor, headache, 
and nausea (Srivastava et al., 1991). A number of studies have reported that the 
central effects of nicotine can include increased cognitive performance in 
attention and WM (e.g., word recall and n-back tasks; Heishman et al., 2010). 
This is one reason some investigators have speculated the higher prevalence of 
smoking in people with SZ (a condition with cognitive deficits) is a form of self-
treatment (Kumari and Postma, 2005).  
 
1.3.1 Cholinergic innervation 
 A large proportion of neuroscience progress is based on work using rodent 
models. Although work with rodents has been invaluable to progress in the 
cholinergic system, many differences have been revealed between the rodent 
and primate (and between NHP and human). Coppola and Disney (2018a) 
provide a detailed review on the differences between rodent and primate 
cholinergic systems.  
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 Cholinergic afferents originate in subcortical cholinergic nuclei Ch1–Ch4 
and are generally thought to be analogous across species (Mesulam et al., 1983; 
Butcher and Semba, 1989). Relevant to work on PFC is Ch4, which refers to the 
nucleus basalis/substantia innominata in primates that has cholinergic afferents 
projecting to various cortical regions, including PFC (principal sulcus), medial 
frontal pole, cingulate, medial parietal cortex, peristriate cortex, and many others 
(Mesulam et al., 1983; Luiten et al., 1987). One striking difference between 
rhesus and rodent cholinergic nuclei is the proportion of cholinergic neurons. 
Gritti et al. (2006) reported only 5% of neurons were cholinergic in the rat basal 
forebrain, whereas the proportion was up to 90% in rhesus macaque Ch4 
(Mesulam et al., 1983). The remaining basal forebrain neurons are either 
glutamatergic or GABAergic. 
 Cortical cholinergic innervation is measured histochemically using 
quantification of acetylcholinesterase or choline acetyltransferase in cholinergic 
axons (Mesulam and Mufson, 1984). Innervation has many differences between 
species, yet an overall pattern appears consistent between primates, cats, and 
rats: the highest density of innervation is present in sensorimotor areas (primary 
motor area and primary somatosensory area), followed by frontal areas, and the -
lowest density of cholinergic innervation is found in primary sensory regions 
(primary visual area and primary auditory area; Coppola and Disney, 2018a). 
 Different cortical layers receive varying degrees of cholinergic innervation. 
The general agreement across studies is that cholinergic fibers are present in all 
layers, but superficial layers I, II, and III receive the strongest cholinergic 
innervation, followed by deeper layers V and VI, and finally layer IV receives the 
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least amount of cholinergic input (Mesulam and Mufson, 1984; DeKosky et al., 
1985; Lewis, 1991; Mrzljak et al., 1995). However, within this general trend there 
are marked differences between species and brain regions. Figure 1.9 shows a 
schematic summary of primary visual cortex cholinergic axon densities across six 
different species (Gu, 2003). 
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Figure 1.9 
Density of cholinergic axons in primary visual cortex of six different species. 
The density of cholinergic innervation in primary visual cortex, measured with 
choline acetyltransferase immunoreactivity, is shown for six different species: 
human, macaque, cat, ferret, rat, and mouse. Reprinted with permission from Gu. 
(2003) Contribution of acetylcholine to visual cortex plasticity. Neurobiol Learn 
Mem. 80(3):291–301.  
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 Raghanti et al., 2008a provides a detailed comparison of cholinergic 
innervation of PFC in human, chimpanzee, and moor macaques. Specifically, 
Brodmann areas 9 (DLPFC), 32 (dorsal ACC), and 4 (primary motor cortex) were 
measured for choline acetyltransferase immunoreactivity. Overall, cholinergic 
innervation appeared similar between species. Innervation was the highest in 
motor cortex for all three species. Humans had less layer I innervation than in 
layer III or layer V/VI. This is seemingly opposite to what was found in rats: 
Mechawar et al. (2000) found layer I medial PFC had the highest density of 
cholinergic axons. Humans and chimps had greater cholinergic axon density in 
layer III and layer V/VI compared to macaques, possibly suggesting a shift over 
the course of evolution. These authors and others (Mesulam et al., 1992) also 
noted clusters of cholinergic axons, similar to dopaminergic and serotonergic 
clusters in human cortex (Raghanti et al., 2008b; Raghanti et al., 2008c). The 
function of these clusters remains unknown, but it is curious that they were 
identified in humans and chimpanzees, but not in macaques. 
 
1.3.2 Wired vs. Volume transmission 
 There is an ongoing debate as to whether ACh is selectively released with 
high spatial and temporal accuracy (wired transmission) or en masse into large 
volumes of tissue during situations of increased attentional requirements (volume 
transmission; Sarter et al., 2009). For example, does the basal forebrain release 
ACh throughout the cortical mantle as a slow arousal system (Coull, 1998)? Or is 
ACh released more precisely to specific areas? My impression from the literature 
is that precise ACh release (wired transmission) is indeed present, although both 
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transmission types may coexist. Firstly, the organization of cholinergic neurons in 
the basal forebrain is not homogenous – cholinergic neurons are clustered 
(Zaborszky, 2002) and certain basal forebrain neurons project to certain cortical 
areas (Price and Stern, 1983; Koliatsos et al., 1988). For example, Zmarowski et 
al. (2007) have shown nucleus accumbens stimulation can cause ACh release in 
PFC but not parietal cortex. More recent work suggests rat basal forebrain may 
have some topographical organization (Zaborszky et al., 2015). Secondly, the 
idea of nonspecific release and slow spread of ACh via volume transmission 
seems impeded by the fact that acetylcholinesterase is one of the fastest known 
enzymes (Lawler, 1961; Soreq and Seidman, 2001). ACh could only spread over 
a large volume if it avoided synapses, wherein acetylcholinesterase is found 
(Quinn, 1987; Coppola et al., 2016). Thirdly, the use of modern enzyme-coated 
arrays has allowed the detection of ACh on a second-to-second scale, a much 
higher temporal resolution than older methods such as microdialysis (Burmeister, 
2001; albeit still slower than synaptic transmission). Parikh et al. (2007) reported 
variable choline levels (precursor and metabolite of ACh, and proxy for its 
extracellular concentration) during a cue detection task, with briefly elevated 
choline on trials after a cue is correctly detected and a lack of transient choline 
surge after missed cues (Fig. 1.10). This work shows that ACh can be released 
transiently on the order of seconds and quickly broken down in the synapse. In a 
corroborating report, neurons in the rhesus nucleus basalis of Meynert were 
found to preferentially discharge at specific times during a delayed response task: 
especially during the cue, stimulus, and reward epochs (Richardson and DeLong, 
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1986). Local ACh may also be finely regulated by presynaptic glutamatergic 
receptors on cholinergic afferents (Parikh et al., 2008).  
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Figure 1.10 
Transient release of choline in rat medial prefrontal cortex. 
Choline signal levels in rat medial prefrontal cortex are shown. Choline is the 
precursor and metabolite of acetylcholine and is used as a proxy for extracellular 
acetylcholine concentration. As a rat performs a task requiring attention, choline 
levels differ depending on whether or not a cue was noticed. Choline levels are 
measured with choline oxidase-coated probes. Modified with permission from 
Parikh et al. (2007) Prefrontal acetylcholine release controls cue detection on 
multiple timescales. Neuron. 56(1):141–54.  
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 Yet, compelling evidence for volume transmission has been reported and 
both wired and volume transmission may be present in cortex. Cholinergic 
receptors have been histologically located at non-cholinergic synapses. Umbriaco 
et al. (1994) found that the predominant expression of choline acetyltransferase 
(enzyme for ACh synthesis) in rat parietal cortex was in nonsynaptic varicosities, 
opposed to synaptic varicosities. There are species differences: in human 
temporal cortex, two thirds of cholinergic varicosities formed synaptic 
specializations (Smiley et al., 1997). However, more recent electron microscopy 
evidence suggests there may be more cholinergic synapses in mouse neocortex 
than previously thought (Takacs et al., 2013). Thus, it’s possible that cholinergic 
innervation of rat cortex is relatively more skewed towards volume transmission 
than human cortex. Many investigators have found that there may be basal levels 
of ACh in the extracellular space, which also supports a volume transmission role 
of ACh (i.e., ACh does not solely exist within the synapse; reviewed by 
Descarries et al., 1997). It should be noted that there are other, nonsynaptic 
reasons for the volume release of ACh, such as effects on microglial 
inflammatory response (Carnevale et al., 2007), myelinating glia (Fields et al., 
2017), and microvasculature (Chedotal et al., 1994). The differences between 
wired and volume transmission holds clinical relevance, as the dynamics of 
systemic administration of cholinergic compounds (such as cholinergic agonists) 
are much more similar to volume transmission than precise, synaptic ACh 
release in wired transmission (e.g., stimulation of extrasynaptic cholinergic 
receptors). 
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1.3.3 Muscarinic receptors 
 ACh acts on two classes of receptors: metabotropic muscarinic receptors 
and ionotropic nicotinic receptors. Nicotinic receptors (discussed below) are 
ligand-gated cation channels, and thus excite membrane potential almost 
immediately after stimulation. Muscarinic receptors are GPCRs linked to Gα 
proteins, and therefore exert their effects on a longer timescale via second 
messenger signaling cascades. These signaling pathways further depend on the 
subtype of muscarinic receptor that is stimulated. Muscarinic receptor subtypes 
are broadly classified into two families: the muscarinic M1 receptor (M1R) family 
(including M1Rs, muscarinic M3 receptors, and muscarinic M5 receptors) and the 
muscarinic M2 receptor (M2R) family (M2Rs and muscarinic M4 receptors). This 
distinction is based on the different Gα proteins targeted. M1R family receptor 
subtypes target Gαq/11 and M2R family subtypes target Gαi. 
 M1R family stimulation, via Gαq/11, leads to a variety of effects, including 
PLC-mediated increase in IP3 and DAG, Ca2+ release from internal endoplasmic 
reticulum stores, PKC activation. Historically, the ultimate result of M1R 
stimulation is thought to be depolarization of the cellular membrane via opening 
of cation channels (allowing entry of Na+ and Ca2+) and closure of potassium 
channels (blocking exit of K+; see Thiele, 2013). However, the effect of M1R 
stimulation may depend on the type of neuron and brain region of interest (Digby 
et al., 2012). M2R family stimulation is typically considered to hyperpolarize 
membrane potential, through activation of potassium channels, inhibition of 
adenyl cyclase, and closure of cation channels. 
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 Until recently, there was a lack of compounds that could selectively bind 
individual muscarinic receptor subtypes. For example, pirenzepine, an M1R-
preferring antagonist, has been a very popular and useful drug to explore the 
actions of the M1R family in general, but since it also has weak activity on M3Rs 
(Pediani et al., 2016), the interpretations from its experiments relating to M1R 
function must come with the disclaimer that M3Rs were also blocked. 
Compounds selective for muscarinic receptor subtypes have been difficult to 
design because of the subtypes’ homologous structure and highly conserved 
ACh-binding pocket (Bubser et al., 2012). Nevertheless, pirenzepine provided 
many insights into the action of M1Rs in the central nervous system. M1R 
stimulation is typically excitatory to in vitro cortical slice preparations (Carr and 
Surmeier, 2007). McCormick and Prince (1985) found transient application of 
ACh onto guinea pig cortical slices produced brief hyperpolarization, followed by 
prolonged depolarization. They found pirenzepine was able to block the slow 
excitatory effect of ACh, but no the inhibition. Egorov et al. (2002) showed 
carbachol could produce persistent activity in rat entorhinal cortex. This excitation 
was determined to be reliant on muscarinic receptor activation, as it could be 
blocked by either muscarinic antagonist atropine or M1R-preferring antagonist 
pirenzepine. 
Due to the wide variety of second messengers of muscarinic receptors, 
one potential clinical research avenue is the targeting of specific signaling 
pathways using compounds with functional selectivity (Urban et al., 2007). 
Sometimes the desired effect of a drug is attributable to one signaling pathway, 
but another coactivated pathway results in unwelcome side effects. For example, 
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some M1R allosteric agonists have been shown to activate some second 
messengers preferentially over others (Thomas et al., 2008). More recently, 
Digby et al. (2012) reported M1R allosteric agonists VU0357017 and VU0364572 
differentially activated M1R-coupling to calcium, beta-arrestin, and MAPK 
pathways. Future drug discovery investigations must continue to probe which 
downstream effectors are being targeted to ensure they are achieving the desired 
therapeutic effect. 
 Of the muscarinic receptor subtypes, M1Rs and M2Rs are the most 
commonly expressed in primate neocortex (Mash et al., 1988; Thiele, 2013). 
Expression of muscarinic receptors varies through different layers of cortex. Most 
investigations have agreed that muscarinic receptors are present in all layers, 
with enhanced expression in superficial layers, and to a lesser extent deeper 
layers (Lidow et al., 1989; Zilles et al., 1989; Vannucchi and Goldman-Rakic, 
1991; Mrzljak et al., 1993; Rodriguez-Puertas et al., 1997). M2Rs are not as 
widely expressed, but appear to show the same laminar pattern (Mrzljak et al., 
1998; Erisir et al., 2001; Medalla and Barbas, 2012). 
Although the aforementioned studies report both receptor subtypes are 
present in both pyramidal and nonpyramidal neurons, Disney et al., 2006 found 
GABAergic neurons are much more likely to express muscarinic receptors than 
pyramidal neurons in rhesus V1. Further, they found muscarinic receptors were 
densely expressed in GABAergic neurons of both rhesus V1 and MT (Disney and 
Aoki, 2008; Disney and Reynolds, 2014; Disney et al., 2014). Finally, they found 
different GABAergic neurons have different likelihoods of expressing M1Rs 
(Coppola and Disney, 2018b), with parvalbumin neurons being the most likely to 
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express M1Rs (~75%), followed by calbindin neurons (~55%), and calretinin 
neurons (10–40%). These anatomical investigations are important for 
understanding how cholinergic innervation affects local circuitry. More detailed 
histological examinations, as performed for M2Rs by Medalla and Barbas, 2012, 
are required for other muscarinic receptor subtypes in PFC and other brain 
regions. 
A noteworthy model of GABAergic inhibitory control is widespread 
inhibition via the ascending layer I axons of SOM interneurons (Wang et al., 
2004). Disinhibition can then excite and “open holes in this blanket of inhibition” 
via VIP interneuron GABAergic connections onto SOM interneurons (Pfeffer et 
al., 2013, Karnani et al., 2016). Notably, VIP interneurons in mouse V1 have 
been shown to receive cholinergic innervation from basal forebrain via VIP 
postsynaptic nicotinic receptors (Alitto and Dan, 2013; Fu et al., 2014). Thus, 
specific cholinergic innervation of VIP interneurons may control excitation of local 
cortical circuits. 
 Although it appears the amyloid hypothesis of AD is losing credence and 
amyloid now appears to be more of a symptom than a root cause, it remains 
important to study the mechanisms of its accumulation. Interestingly, there 
appear to be several connections between M1R stimulation and amyloid beta 
accumulation, linking the amyloid and cholinergic hypotheses of AD (Potter et al., 
2011; Fisher, 2012). In vitro, M1R stimulation has been found to divert the 
amyloid precursor protein pathway away from amyloid beta production (Pittel et 
al., 1996). Many of the downstream effectors of M1Rs influence the processing of 
amyloid precursor protein, such as PKC (Cisse et al., 2011), MAPK (Haring et al., 
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1998), and BACE1 (Zuchner et al., 2004). M1R stimulation has been shown to be 
inversely correlated with amyloid beta expression in several in vitro studies 
(Buxbaum et al., 1992; Nitsch et al., 1992; Slack et al., 1995; Haring et al., 1998; 
Jones et al., 2008), and one rat study (Caccamo et al., 2006). M1R stimulation 
may also prevent hyperphosphorylation of tau protein (Sadot et al., 1996; 
Caccamo et al., 2006), increase prefrontal blood flow (Uslaner et al., 2013) and 
provide long-term neurotrophic effects (Fisher, 1997). Conversely, amyloid 
accumulation may disrupt cholinergic signalling, creating a positive feedback 
loop. Amyloid beta decreases ACh synthesis and release (Kar et al., 1996; Hoshi 
et al., 1997) and has been reported to uncouple M1Rs from G proteins in post-
mortem AD brains (Kelly et al., 1996; Ladner and Lee, 1999; Shiozaki and Iseki, 
2004). In a M1R knock-out mouse model, Davis et al. (2010) observed large 
increases in amyloid beta accumulation. M1Rs continue to be an intriguing 
pharmacological target for the treatment of AD. 
 
1.3.4 Nicotinic receptors 
 Although the focus of this thesis is primarily muscarinic receptors, a brief 
description of cortical nicotinic receptors is provided. Indeed, the experiment 
described in Chapter 2 uses a general cholinergic agonist carbachol, which 
stimulates nicotinic in addition to muscarinic receptors (although carbachol may 
predominantly exert its effects via muscarinic receptors and nicotinic receptors 
have more sparse cortical expression compared to muscarinic receptors; Akk and 
Auerbach, 1999). 
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 Nicotinic receptor subtypes can be broadly classified into two families: 
homomeric and heteromeric receptors. Homomeric α7 nicotinic receptors are 
composed of five identical α7 protein subunits. α7 receptors have a lower binding 
affinity to ACh and lesser net inward change than heteromeric receptors (Wallace 
and Bertrand, 2013). Although seventeen nicotinic receptor subunits have been 
identified (Millar and Gotti, 2009), the most commonly explored heteromeric 
nicotinic receptor is the α4β2 subtype. The α4β2 subtype is the most widely 
expressed in cortex (Gotti et al., 2009) and experiences less desensitization than 
the α7 subtype (Fenster et al., 1997). 
 The α7 nicotinic receptor has received burgeoning interest as a potential 
clinical target in alleviating cognitive deficits (Williams et al., 2011). This is 
partially because it is thought that other nicotinic subtypes such as the high-
affinity α4β2 receptors may be the subtype responsible for addiction (Picciotto 
and Kenny, 2013). For example, knockout of α7 subunits in mice did not affect 
nicotine place preference in mice (Walters et al., 2006) or nicotine self-
administration (Pons et al., 2008) and α7 blockade in rat ventral tegmental area 
reduced food seeking in rats (Schilstrom et al., 1998). For cognitive 
enhancement, positive allosteric modulators of α7 receptors are an intriguing 
option because they do not produce the fast desensitization of orthosteric α7 
agonists. Stimulation of α7 receptors have yielded improved performance in 
multiple cognitive tasks in rats, such as the radial arm maze and Morris water 
maze (Levin et al., 1999; Ng et al., 2007; Timmermann et al., 2007). α7 receptor 
stimulation may also have clinical relevance. Expression of nicotinic α7 receptor 
genes is altered in people with schizophrenia (Grigorenko et al., 2001; Leonard et 
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al., 2002; Lewis et al., 2017; Kalmady et al., 2018). Additionally, amyloid beta 
appears to interact with α7 receptors, which in AD ultimately leads to pathological 
amyloid beta aggregation and receptor inactivation (Parri et al., 2011). α7 
receptor positive allosteric modulators have been tested as a treatment option for 
AD and SZ. Although some studies have shown mild cognitive benefits, a meta-
analysis conducted by Lewis et al. (2017) compiled 18 studies testing systemic 
α7 receptor stimulation and found no significant effects in eight cognitive 
domains. 
 The Arnsten lab has extensively explored the local effects of nicotinic 
receptor stimulation in primate PFC. Briefly, PFC neurons were recorded in 
rhesus monkeys during the performance of memory-guided saccades and 
specific nicotinic agonists were locally ejected via iontophoresis. Using 
compounds selective for different nicotinic receptor subtypes (α7 and α4β2 
receptors), they found stimulation of either subtype was excitatory to neuronal 
discharge rates and could enhance delay period activity for the preferred 
memory-guided saccade location (Yang et al., 2013; Sun et al., 2017). 
Conversely, specific antagonism of either receptor subtype decreased delay 
period firing for the preferred direction. Systemic administration of α7 receptor 
agonist was also examined and revealed a Yerkes-Dodson curve or “inverted-U” 
effect of dose, wherein moderate doses improved task performance and 
excessive doses were not beneficial. 
 
1.4 Antisaccade Task 
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  The study of cognition employs cognitive tasks in both human and animal 
models such that we might discern the mechanisms of cognitive disruption in 
conditions such as AD and SZ. Memory-guided saccades have been used 
extensively to investigate visuospatial WM. The antisaccade task is another 
common oculomotor task (Fig. 2.1A) used to probe executive function, such as 
the use of abstract rules, WM maintenance and manipulation, and inhibition. This 
task was first introduced by Peter Hallett (1978) of the Department of Physiology 
at University of Toronto. There are two trial types: prosaccades and 
antisaccades. A typical trial begins with central fixation, followed by one of two 
cues that specifies the current trial type (“rule”). These cues can be different 
colours or different shapes, etc. Cues can be flashed briefly then removed, or left 
visible for the entire delay period, depending on desired task difficulty. After the 
cue, the delay period begins, which is typically 1–3 s, often with the central 
fixation dot returned. A brief gap period (removal of central fixation) can be 
introduced after the delay period to increase task difficulty (Fischer and Weber, 
1996; Everling and Fischer, 1998). Next, a peripheral stimulus is shown on the on 
the left or right side. During prosaccade trials, the subject must simply make a 
saccade to the peripheral stimulus. During antisaccade trials, the subject must 
inhibit the prepotent response to look towards the stimulus, and instead look at 
the mirror location in order for the trial to be correct. Antisaccade trials result in 
more directional errors (i.e., looking at the stimulus instead of empty space) and 
hypometric saccades, and longer reaction times. 
 A circuit for the antisaccade task has been proposed (Fig. 1.11; Munoz 
and Everling, 2004). Briefly, visual information enters the retina, lateral geniculate 
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nucleus, and visual cortices. This information travels through parietal cortex to 
frontal areas such as the FEF, supplementary eye fields, and DLPFC. For 
example, FEF is thought to be involved in generating and informing SC on 
potential eye movement destinations during voluntary saccades (Gaymard et al., 
1998). Cortical regions influence saccade generators directly, but also indirectly 
through basal ganglia structures. DLPFC was initially thought to play an inhibitory 
role during antisaccade trials, by suppressing SC from initiating a saccade 
towards the prepotent saccade location (i.e., the peripheral stimulus; Guitton et 
al., 1985; Pierrot-Deseilligny et al., 2003).   
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Figure 1.11 
The antisaccade circuit. 
This proposed circuit details how visual information is distributed to different brain 
regions during performance of antisaccades. For example, visual information can 
travel through visual and parietal areas to reach prefrontal cortical regions such 
as dorsolateral prefrontal cortex (DLPFC), frontal eye field (FEF), and 
supplementary eye field (SEF). These frontal areas can influence saccadic 
behaviour through direct and indirect connections to superior colliculus (SC). 
Modified with permission from Munoz and Everling. (2004) Look away: the anti-
saccade task and the voluntary control of eye movement. Nat Rev Neurosci. 
5(3):218–28. 
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 The role of DLPFC in this circuit has been bolstered by findings from 
frontal lesions. Lesions to frontal cortex in humans has been reported to increase 
errors in the antisaccade task, especially during antisaccade trials (Guitton et al., 
1985; Pierrot-Deseilligny et al., 2003; Ploner et al., 2005). DLPFC can be 
deactivated with greater precision using NHP models. Both local muscimol 
activation (Condy et al., 2007) and cryogenic deactivation (Koval et al., 2011) 
increased antisaccade errors in macaques. 
  DLPFC neurons can be selective for various aspects of the antisaccade 
task. For example, some neurons discharge at a higher frequency for one rule 
than the other (pro- or antisaccade-preferring neurons). These “rule neurons” can 
show this task preference in varying task epochs, including during and 
immediately after cue presentation (early delay period), the late delay period 
(preparatory period), during stimulus presentation, or during reward period. 
These neurons are thought to be involved in the cognitive circuitry during 
antisaccade performance. 
 Although the role of DLPFC during antisaccades was initially thought to be 
an inhibitory influence on SC, more recent evidence has challenged this theory. 
Everling and Johnston (2013) note that by the time task-related (i.e., 
preferentially firing for pro- or anti-saccades) PFC activity is established, 
downstream saccade-related neurons in SC have already established preference 
for trial type (Johnston et al., 2009; Koval et al., 2011). Thus, it seems unlikely 
PFC neurons directed this pre-established selectivity in SC. Perhaps the most 
compelling evidence against the inhibition model came from cryogenic 
deactivation of DLPFC and concurrent recording of macaque SC during 
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antisaccade performance (Koval et al., 2011). Cryogenic deactivation produced 
an effect opposite to the inhibition model predictions: ipsilateral SC decreased 
activity when PFC was deactivated. This suggests PFC effect is excitatory 
instead of inhibitory. Everling and Johnston (2013) go on to propose that PFC 
aids in maintaining the current task set (pro- or antisaccade rule) through 
excitatory drive to SC neurons. 
 The antisaccade task can be an important clinical tool to quickly assess 
top-down control at the bedside or to probe executive function in neuropsychiatric 
research (Everling and Fischer, 1998). A number of neuropsychiatric conditions 
show antisaccade errors, including AD and SZ (Fukushima et al., 1990; Broerse 
et al., 2001; Abel et al., 2002; Kaufman et al., 2010). A disrupted cholinergic 
system may contribute further to this aberrant prefrontal function. However, few 
studies have examined cholinergic receptor manipulation during antisaccade 
performance (Depatie et al., 2002; Powell et al., 2002; Major et al., 2015). 
 
1.5 Iontophoresis 
  Iontophoresis a pharmacological technique of drug delivery, which 
employs the use of electrical current to eject small, electrically charged molecules 
such as neurotransmitters. We use glass iontophoretic probes with one tungsten 
recording electrode surrounded by six peripheral drug barrels (Fig. 1.12). In this 
way, we can lower probes into cortex to perform extracellular recordings and 
simultaneously eject one or multiple neuroactive compounds. Although such 
probes are available for purchase, we custom fabricate these probes, as 
described below.  
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Figure 1.12 
Iontophoretic electrode and drug ejection. 
A, Photo of early stage of probe design. Tungsten wire in the central barrel of 
seven-barreled glass capillaries is shown after being heated and pulled though 
PMP107L-e Multipipette Puller, forming a fine tip with a small amount of tungsten 
wire exposed. B, Idealized illustration of the magnified probe tip. Central tungsten 
recording electrode is shown, surround by peripheral drug barrels, which are filled 
to the tip with drug solution. C, Example iontophoretic ejection of glutamate. Each 
vertical line represents an action potential of an extracellularly recorded neuron 
from an iontophoretic electrode. Iontophoretic glutamate application with a 
magnitude of 50 nA increased discharge rate of this neuron with a fast onset.  
Glass barrels containing dissolved drug
Tungsten recording electrode
A
B
-50 nA Glutamate
1 sec
C
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 Tungsten wire (50 µm diameter, Midwest Tungsten Service) was 
electrochemically etched (model EE-ID, Bak Electronics) using a sodium nitrite 
and potassium hydroxide solution (Thiele et al., 2006) and inserted into the 
central barrel of a seven-barreled glass pipette (Friedrich and Dimmock). This 
would ultimately serve as the recording electrode. The glass was then pulled over 
the wire using a PMP107L-e Multipipette Puller (MicroData Instrument), resulting 
in an ~11 cm electrode shaft with a fine tip (approx. 15–30 µm diameter) with a 
small amount of tungsten exposed. Recording impedance ranged from 0.5 to 1 
MΩ (measured at 1 kHz). Carbachol (carbamoylcholine chloride, 100 mM), 
scopolamine (scopolamine hydrobromide 100 mM), and VU0357017 
(VU0357017 hydrochloride, 10 mM; Tocris Biosciences) were dissolved in pH 3 
deionized water and stored in 30 µL aliquots at −20°C. Before use, drug solution 
was thawed and injected into the peripheral glass barrels, then pneumatically 
pushed to the tip remove any air. More tungsten wires were inserted into 
peripheral barrels and secured to ultimately eject current using an iontophoretic 
constant current generator (Neurophore BH-2, Harvard Apparatus). DC 
impedences of drug barrels varied between 50 to 300 MΩ. The electrode was 
mounted on a hydraulic micromanipulator (MO-95, Narishige) and lowered into 
cortex through a 23-gauge dura-penetrating stainless steel guide tube. 
Placement of the probe was guided by a plastic recording grid (1 mm spacing, 
Crist Instruments). During drug conditions, current was manually set by the 
experimenter, ranging from 5 to 100 nA. A constant −8 nA retention current was 
passed over unused drug barrels (e.g., during control conditions) to prevent 
leakage of our positively charged drugs. Current ejection and pH of drug solution 
	  	  
59 
have been shown to not strongly effect neuronal discharge rates in macaque 
cortex (Disney et al., 2007; Vijayraghavan et al., 2007). Further details of 
recording system are discussed in later chapters. 
  The advantage of iontophoretic drug ejection over other local ejection 
techniques is two-fold. Firstly, these probes are very thin (approx. 15–30 µm 
diameter at the tip), meaning there is minimized damaged as it enters cortex. And 
secondly, the ejection is localized to very small volume surrounding the electrode 
tip (Purves, 1979). There are several factors that impact the flow of drug out of 
the probe, including diameter of the tip, angle of taper, acidity of drug solution, 
previous retention currents, and composition of extracellular matrix (Herr and 
Wightman, 2013). Trubatch and Van Harreveld (1972) quantified the spread of 
glutamate out of a micropipette into rat cortical tissue and found that the volumes 
of ejection are on the order of a cortical microcolumn. For example, the authors 
applied glutamate at 250 nA for 1hr and found the diameter of affected area was 
approx. 250 µm. Therefore, the effects of iontophoretic drug ejection typically do 
not affect behaviour. However, when behavioural effects of iontophoretic drug 
ejection are found, they are typically miniscule (e.g., changes in saccadic reaction 
of a few milliseconds; Herrero et al., 2008; Herrero et al., 2013; Ott et al., 2014). 
For comparison, local pressure ejection spreads over a larger area, potentially 
damaging tissue, and is more likely to elicit behavioural effects (Davidson and 
Marrocco, 2000). Further, ejected drug has a tendency to spread vertically along 
the shaft, creating an elliptical volume of affected areas (Hupe et al., 1999) 
instead of spherical, as in iontophoresis. One drawback of iontophoretic ejection 
is that only charged drugs can be used. However, some investigators have 
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reported that neutral drugs can be used as well via “bulk flow” out of the drug 
barrel (i.e., neutral drug molecules follow ionic molecules out of the drug into 
extracellular fluid; Herr et al., 2008). 
 Iontophoresis is a useful technique for focal drug delivery and can be 
combined with extracellular recording to observe the direct effects of drug 
receptor stimulation on neuronal physiology. 
 
1.6 Objectives 
 The PFC sends top-down projections to other brain areas to influence 
functions such as maintenance of task set. Cognitive deficits observed in people 
with conditions such as AD and SZ may be partially attributable to degeneration 
of PFC or altered prefrontal organization. In addition, these conditions are known 
to have altered cholinergic systems. Cholinergic innervation of PFC is necessary 
for optimal WM performance in rhesus macaques (Croxson et al., 2011). 
Although there are between-species differences in cholinergic functioning 
(Coppola and Disney, 2018a), systemic drug administration in humans 
corroborates the idea that prefrontal cholinergic receptors are important for 
optimal cognitive functioning. The objective of this research project was to 
explore the effects of different cholinergic receptors on prefrontal neuronal activity 
involved in an executive task, such that we may ultimately glean insights into 
altered cognitive function in conditions with disrupted cholinergic activity. 
 
1.6.1 Examine the effects of local cholinergic stimulation using general agonist 
carbachol 
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 The cholinergic system has been studied extensively using systemic 
administration of compounds, such as acetylcholinesterase inhibitors for the 
treatment of AD. Similarly, nicotine from cigarettes may benefit alertness and 
certain cognitive domains. However, it is difficult to conclusively derive 
electrophysiological results during systemic drug administration because effects 
on recorded neurons may be due to interregional interactions. For example, even 
though scopolamine is strongly inhibitory to neurons, systemic scopolamine 
administration paradoxically increased stimulus-responsive activity of macaque 
inferotemporal neurons (Miller and Desimone, 1993). Local application of 
cholinergic compounds can be used to determine the direct effects of cholinergic 
receptors stimulation on neurons. Previously, we had shown that local application 
of scopolamine dose-dependently decreased prefrontal neuron discharge rates 
and task-related activity during rhesus performance of the antisaccade task 
(Major et al., 2015). Carbachol is a general cholinergic agonist and mimetic of 
ACh that has been used extensively in electrophysiology. The first objective was 
to explore the effects of general cholinergic agonism on prefrontal neuron 
discharge rate and task-related activity during macaque performance of the 
antisaccade task.  
 
1.6.2 Examine the effects of selective stimulation and blockade of muscarinic 
M1 receptors using VU0357017 and pirenzepine 
 Next, we aspired to determine the effects of individual muscarinic 
receptors subtypes. We had previously speculated that the suppressive effects of 
scopolamine were mediated via blockade of M1Rs, as they had typically been 
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considered excitatory in vitro and are the most widely expressed muscarinic 
receptor subtype in cortex. Exploration of specific muscarinic receptor subtypes 
was historically difficult because of the conserved ACh binding pocket. For 
example, muscarinic agonist McN-A-343, a drug commonly used to probe M1R 
function, also binds muscarinic M4 receptors, and other neuromodulatory 
receptors to a lesser degree (Mitchelson, 2012). More recently, compounds have 
been produced that can selectively target muscarinic subtypes, such as 
VU0357017 that can bind M1Rs at allosteric sites. The second objective was to 
explore the effect of selective stimulation and blockade of M1Rs on prefrontal 
spiking and task-related activity using allosteric agonist VU0357017 and M1R-
preferring antagonist pirenzepine. 
 
1.6.3  Examine the influence local cholinergic receptor perturbation on prefrontal 
LFP power 
 Oscillations of local field potential (LFP) are informative of local neuronal 
events and are important for communication between brain areas. Altered 
oscillatory activity is observed in conditions with cognitive impairment, such as 
AD and SZ (Jeong, 2004; Uhlhaas and Singer, 2010), and during systemic 
administration of cholinergic compounds (Kikuchi et al., 1999; Fisher et al., 2012). 
In addition to interregional communication, LFPs are important for local circuitry 
(Bastos et al., 2018; Johnston et al., 2019) and are important indicators of optimal 
WM circuitry (Miller et al., 2018). The third objective was to examine changes in 
LFP power when prefrontal cholinergic receptors were locally manipulated using 
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general muscarinic antagonist scopolamine and general cholinergic agonist 
carbachol.  
	  	  
64 
1.7 References 
Alzheimer Society of Canada (2010) Rising Tide: The Impact of Dementia on 
Canadian Society. 
Abel LA, Unverzagt F, Yee RD (2002) Effects of stimulus predictability and 
interstimulus gap on saccades in Alzheimer's disease. Dement Geriatr 
Cogn Disord 13:235-243. 
Adachi T, Biesold D, Inanami O, Sato A (1990) Stimulation of the nucleus basalis 
of Meynert and substantia innominata produces widespread increases in 
cerebral blood flow in the frontal, parietal and occipital cortices. Brain Res 
514:163-166. 
Akbarian S, Bunney WE, Jr., Potkin SG, Wigal SB, Hagman JO, Sandman CA, 
Jones EG (1993) Altered distribution of nicotinamide-adenine dinucleotide 
phosphate-diaphorase cells in frontal lobe of schizophrenics implies 
disturbances of cortical development. Arch Gen Psychiatry 50:169-177. 
Akil M, Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR, Lewis DA 
(1999) Lamina-specific alterations in the dopamine innervation of the 
prefrontal cortex in schizophrenic subjects. Am J Psychiatry 156:1580-
1589. 
Akk G, Auerbach A (1999) Activation of muscle nicotinic acetylcholine receptor 
channels by nicotinic and muscarinic agonists. Br J Pharmacol 128:1467-
1476. 
Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of functionally 
segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 
9:357-381. 
Alitto HJ, Dan Y (2012) Cell-type-specific modulation of neocortical activity by 
basal forebrain input. Front Syst Neurosci 6:79. 
Amaral DG, Price JL (1984) Amygdalo-cortical projections in the monkey 
(Macaca fascicularis). J Comp Neurol 230:465-496. 
Arnold SE, Trojanowski JQ, Gur RE, Blackwell P, Han LY, Choi C (1998) 
Absence of neurodegeneration and neural injury in the cerebral cortex in a 
sample of elderly patients with schizophrenia. Arch Gen Psychiatry 
55:225-232. 
Arnsten AF, Wang MJ, Paspalas CD (2012) Neuromodulation of thought: 
flexibilities and vulnerabilities in prefrontal cortical network synapses. 
Neuron 76:223-239. 
Baakman AC, Alvarez-Jimenez R, Rissmann R, Klaassen ES, Stevens J, 
Goulooze SC, den Burger JCG, Swart EL, van Gerven JMA, Groeneveld 
GJ (2017) An anti-nicotinic cognitive challenge model using 
mecamylamine in comparison with the anti-muscarinic cognitive challenge 
using scopolamine. Br J Clin Pharmacol 83:1676-1687. 
Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in 
Alzheimer's disease and related disorders. Nat Rev Neurosci 8:663-672. 
Barbas H, De Olmos J (1990) Projections from the amygdala to basoventral and 
mediodorsal prefrontal regions in the rhesus monkey. J Comp Neurol 
300:549-571. 
	  	  
65 
Barbas H, Pandya DN (1989) Architecture and intrinsic connections of the 
prefrontal cortex in the rhesus monkey. J Comp Neurol 286:353-375. 
Barch DM, Carter CS, Braver TS, Sabb FW, MacDonald A, 3rd, Noll DC, Cohen 
JD (2001) Selective deficits in prefrontal cortex function in medication-
naive patients with schizophrenia. Arch Gen Psychiatry 58:280-288. 
Bartus RT, Dean RL, 3rd, Beer B, Lippa AS (1982) The cholinergic hypothesis of 
geriatric memory dysfunction. Science 217:408-414. 
Bartus RT, Johnson HR (1976) Short-term memory in the rhesus monkey: 
disruption from the anti-cholinergic scopolamine. Pharmacol Biochem 
Behav 5:39-46. 
Bastos AM, Loonis R, Kornblith S, Lundqvist M, Miller EK (2018) Laminar 
recordings in frontal cortex suggest distinct layers for maintenance and 
control of working memory. Proc Natl Acad Sci U S A 115:1117-1122. 
Bastos AM, Usrey WM, Adams RA, Mangun GR, Fries P, Friston KJ (2012) 
Canonical microcircuits for predictive coding. Neuron 76:695-711. 
Bates JF, Goldman-Rakic PS (1993) Prefrontal connections of medial motor 
areas in the rhesus monkey. J Comp Neurol 336:211-228. 
Batuev AS, Shaefer VI, Orlov AA (1985) Comparative characteristics of unit 
activity in the prefrontal and parietal areas during delayed performance in 
monkeys. Behav Brain Res 16:57-70. 
Beasley CL, Reynolds GP (1997) Parvalbumin-immunoreactive neurons are 
reduced in the prefrontal cortex of schizophrenics. Schizophr Res 24:349-
355. 
Biesold D, Inanami O, Sato A, Sato Y (1989) Stimulation of the nucleus basalis of 
Meynert increases cerebral cortical blood flow in rats. Neurosci Lett 98:39-
44. 
Birks JS, Harvey RJ (2018) Donepezil for dementia due to Alzheimer's disease. 
Cochrane Database Syst Rev 6:CD001190. 
Bittlinger M, Muller S (2018) Opening the debate on deep brain stimulation for 
Alzheimer disease - a critical evaluation of rationale, shortcomings, and 
ethical justification. BMC Med Ethics 19:41. 
Boros BD, Greathouse KM, Gentry EG, Curtis KA, Birchall EL, Gearing M, 
Herskowitz JH (2017) Dendritic spines provide cognitive resilience against 
Alzheimer's disease. Ann Neurol 82:602-614. 
Bowen DM, Smith CB, White P, Davison AN (1976) Neurotransmitter-related 
enzymes and indices of hypoxia in senile dementia and other abiotrophies. 
Brain 99:459-496. 
Bowen L, Wallace CJ, Glynn SM, Nuechterlein KH, Lutzker JR, Kuehnel TG 
(1994) Schizophrenic individuals' cognitive functioning and performance in 
interpersonal interactions and skills training procedures. J Psychiatr Res 
28:289-301. 
Braun AR, Balkin TJ, Wesenten NJ, Carson RE, Varga M, Baldwin P, Selbie S, 
Belenky G, Herscovitch P (1997) Regional cerebral blood flow throughout 
the sleep-wake cycle. An H2(15)O PET study. Brain 120 ( Pt 7):1173-
1197. 
	  	  
66 
Brion JP, Couck AM, Bruce M, Anderton B, Flament-Durand J (1991) 
Synaptophysin and chromogranin A immunoreactivities in senile plaques 
of Alzheimer's disease. Brain Res 539:143-150. 
Brodmann K (1905) Beiträge zur histologischen Lokalisation der Grosshirnrinde: 
dritte Mitteilung: Die Rindenfelder der niederen Affen. Journal fuer 
Psychologie und Neurologie 4:177-226. 
Broerse A, Crawford TJ, den Boer JA (2001) Parsing cognition in schizophrenia 
using saccadic eye movements: a selective overview. Neuropsychologia 
39:742-756. 
Bruce C, Desimone R, Gross CG (1981) Visual properties of neurons in a 
polysensory area in superior temporal sulcus of the macaque. J 
Neurophysiol 46:369-384. 
Bubser M, Byun N, Wood MR, Jones CK (2012) Muscarinic receptor 
pharmacology and circuitry for the modulation of cognition. Handb Exp 
Pharmacol 121-166. 
Buchsbaum MS, Hazlett EA, Wu J, Bunney WE, Jr. (2001) Positron emission 
tomography with deoxyglucose-F18 imaging of sleep. 
Neuropsychopharmacology 25:S50-56. 
Burmeister JJG, G.A. (2001) Self-Referencing Ceramic-Based Multisite 
Microelectrodes for the Detection and Elimination of Interferences from the 
Measurement of l-Glutamate and Other Analytes. Analytical Chemistry 
73:1037-1042. 
Butcher LL, Semba K (1989) Reassessing the cholinergic basal forebrain: 
nomenclature schemata and concepts. Trends Neurosci 12:483-485. 
Butters N, Pandya D (1969) Retention of delayed-alternation: effect of selective 
lesions of sulcus principalis. Science 165:1271-1273. 
Buxbaum JD, Oishi M, Chen HI, Pinkas-Kramarski R, Jaffe EA, Gandy SE, 
Greengard P (1992) Cholinergic agonists and interleukin 1 regulate 
processing and secretion of the Alzheimer beta/A4 amyloid protein 
precursor. Proc Natl Acad Sci U S A 89:10075-10078. 
Buzsaki G, Bickford RG, Ponomareff G, Thal LJ, Mandel R, Gage FH (1988) 
Nucleus basalis and thalamic control of neocortical activity in the freely 
moving rat. J Neurosci 8:4007-4026. 
Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla 
FM (2006) M1 receptors play a central role in modulating AD-like 
pathology in transgenic mice. Neuron 49:671-682. 
Callahan MJ, Kinsora JJ, Harbaugh RE, Reeder TM, Davis RE (1993) 
Continuous ICV infusion of scopolamine impairs sustained attention of 
rhesus monkeys. Neurobiol Aging 14:147-151. 
Carbon M, Correll CU (2014) Thinking and acting beyond the positive: the role of 
the cognitive and negative symptoms in schizophrenia. CNS Spectr 19 
Suppl 1:38-52; quiz 35-37, 53. 
Carnevale D, De Simone R, Minghetti L (2007) Microglia-neuron interaction in 
inflammatory and degenerative diseases: role of cholinergic and 
noradrenergic systems. CNS Neurol Disord Drug Targets 6:388-397. 
	  	  
67 
Carr DB, Surmeier DJ (2007) M1 muscarinic receptor modulation of Kir2 
channels enhances temporal summation of excitatory synaptic potentials 
in prefrontal cortex pyramidal neurons. J Neurophysiol 97:3432-3438. 
Chandrasekaran C, Peixoto D, Newsome WT, Shenoy KV (2017) Laminar 
differences in decision-related neural activity in dorsal premotor cortex. 
Nat Commun 8:614. 
Chedotal A, Umbriaco D, Descarries L, Hartman BK, Hamel E (1994) Light and 
electron microscopic immunocytochemical analysis of the neurovascular 
relationships of choline acetyltransferase and vasoactive intestinal 
polypeptide nerve terminals in the rat cerebral cortex. J Comp Neurol 
343:57-71. 
Chuah LY, Chee MW (2008) Cholinergic augmentation modulates visual task 
performance in sleep-deprived young adults. J Neurosci 28:11369-11377. 
Cisse M, Braun U, Leitges M, Fisher A, Pages G, Checler F, Vincent B (2011) 
ERK1-independent alpha-secretase cut of beta-amyloid precursor protein 
via M1 muscarinic receptors and PKCalpha/epsilon. Mol Cell Neurosci 
47:223-232. 
Conde F, Lund JS, Jacobowitz DM, Baimbridge KG, Lewis DA (1994) Local 
circuit neurons immunoreactive for calretinin, calbindin D-28k or 
parvalbumin in monkey prefrontal cortex: distribution and morphology. J 
Comp Neurol 341:95-116. 
Condy C, Wattiez N, Rivaud-Pechoux S, Tremblay L, Gaymard B (2007) 
Antisaccade deficit after inactivation of the principal sulcus in monkeys. 
Cereb Cortex 17:221-229. 
Connors BW, Gutnick MJ (1990) Intrinsic firing patterns of diverse neocortical 
neurons. Trends Neurosci 13:99-104. 
Coppola JJ, Disney AA (2018a) Is There a Canonical Cortical Circuit for the 
Cholinergic System? Anatomical Differences Across Common Model 
Systems. Front Neural Circuits 12:8. 
Coppola JJ, Disney AA (2018b) Most calbindin-immunoreactive neurons, but few 
calretinin-immunoreactive neurons, express the m1 acetylcholine receptor 
in the middle temporal visual area of the macaque monkey. Brain Behav 
8:e01071. 
Coppola JJ, Ward NJ, Jadi MP, Disney AA (2016) Modulatory compartments in 
cortex and local regulation of cholinergic tone. J Physiol Paris 110:3-9. 
Coull JT (1998) Neural correlates of attention and arousal: insights from 
electrophysiology, functional neuroimaging and psychopharmacology. 
Prog Neurobiol 55:343-361. 
Coyle JT (1996) The glutamatergic dysfunction hypothesis for schizophrenia. 
Harv Rev Psychiatry 3:241-253. 
Croxson PL, Johansen-Berg H, Behrens TE, Robson MD, Pinsk MA, Gross CG, 
Richter W, Richter MC, Kastner S, Rushworth MF (2005) Quantitative 
investigation of connections of the prefrontal cortex in the human and 
macaque using probabilistic diffusion tractography. J Neurosci 25:8854-
8866. 
Croxson PL, Kyriazis DA, Baxter MG (2011) Cholinergic modulation of a specific 
memory function of prefrontal cortex. Nat Neurosci 14:1510-1512. 
	  	  
68 
Dale HH (1914) The action of certain esters and ethers of choline, and their 
relation to muscarine. The Journal of pharmacology and experimental 
therapeutics 6:147-190. 
Davidson MC, Marrocco RT (2000) Local infusion of scopolamine into 
intraparietal cortex slows covert orienting in rhesus monkeys. J 
Neurophysiol 83:1536-1549. 
Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in 
Alzheimer's disease. Lancet 2:1403. 
Davis AA, Fritz JJ, Wess J, Lah JJ, Levey AI (2010) Deletion of M1 muscarinic 
acetylcholine receptors increases amyloid pathology in vitro and in vivo. J 
Neurosci 30:4190-4196. 
de Leon J, Diaz FJ (2005) A meta-analysis of worldwide studies demonstrates an 
association between schizophrenia and tobacco smoking behaviors. 
Schizophr Res 76:135-157. 
Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E (2002) Decreased 
muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with 
schizophrenia. Mol Psychiatry 7:1083-1091. 
DeKosky ST, Scheff SW, Markesbery WR (1985) Laminar organization of 
cholinergic circuits in human frontal cortex in Alzheimer's disease and 
aging. Neurology 35:1425-1431. 
Demeulemeester H, Vandesande F, Orban GA, Heizmann CW, Pochet R (1989) 
Calbindin D-28K and parvalbumin immunoreactivity is confined to two 
separate neuronal subpopulations in the cat visual cortex, whereas partial 
coexistence is shown in the dorsal lateral geniculate nucleus. Neurosci 
Lett 99:6-11. 
Depatie L, O'Driscoll GA, Holahan AL, Atkinson V, Thavundayil JX, Kin NN, Lal S 
(2002) Nicotine and behavioral markers of risk for schizophrenia: a double-
blind, placebo-controlled, cross-over study. Neuropsychopharmacology 
27:1056-1070. 
Descarries L, Gisiger V, Steriade M (1997) Diffuse transmission by acetylcholine 
in the CNS. Prog Neurobiol 53:603-625. 
Digby GJ, Noetzel MJ, Bubser M, Utley TJ, Walker AG, Byun NE, Lebois EP, 
Xiang Z, Sheffler DJ, Cho HP, Davis AA, Nemirovsky NE, Mennenga SE, 
Camp BW, Bimonte-Nelson HA, Bode J, Italiano K, Morrison R, Daniels 
JS, Niswender CM, Olive MF, Lindsley CW, Jones CK, Conn PJ (2012) 
Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce 
brain region-specific responses that correspond with behavioral effects in 
animal models. J Neurosci 32:8532-8544. 
Disney AA, Alasady HA, Reynolds JH (2014) Muscarinic acetylcholine receptors 
are expressed by most parvalbumin-immunoreactive neurons in area MT 
of the macaque. Brain Behav 4:431-445. 
Disney AA, Aoki C (2008) Muscarinic acetylcholine receptors in macaque V1 are 
most frequently expressed by parvalbumin-immunoreactive neurons. J 
Comp Neurol 507:1748-1762. 
Disney AA, Aoki C, Hawken MJ (2007) Gain modulation by nicotine in macaque 
v1. Neuron 56:701-713. 
	  	  
69 
Disney AA, Domakonda KV, Aoki C (2006) Differential expression of muscarinic 
acetylcholine receptors across excitatory and inhibitory cells in visual 
cortical areas V1 and V2 of the macaque monkey. J Comp Neurol 499:49-
63. 
Disney AA, Reynolds JH (2014) Expression of m1-type muscarinic acetylcholine 
receptors by parvalbumin-immunoreactive neurons in the primary visual 
cortex: a comparative study of rat, guinea pig, ferret, macaque, and 
human. J Comp Neurol 522:986-1003. 
Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, Nguyen M, 
Haditsch U, Raha D, Griffin C, Holsinger LJ, Arastu-Kapur S, Kaba S, Lee 
A, Ryder MI, Potempa B, Mydel P, Hellvard A, Adamowicz K, Hasturk H, 
Walker GD, Reynolds EC, Faull RLM, Curtis MA, Dragunow M, Potempa J 
(2019) Porphyromonas gingivalis in Alzheimer's disease brains: Evidence 
for disease causation and treatment with small-molecule inhibitors. Sci 
Adv 5:eaau3333. 
Drinkenburg WH, Sondag HN, Coenders CJ, Andrews JS, Vossen JM (1995) 
Effects of selective antagonism or depletion of the cholinergic system on 
visual discrimination performance in rats. Behav Pharmacol 6:695-702. 
Dubois B, Mayo W, Agid Y, Le Moal M, Simon H (1985) Profound disturbances of 
spontaneous and learned behaviors following lesions of the nucleus 
basalis magnocellularis in the rat. Brain Res 338:249-258. 
Dumitriu D, Hao J, Hara Y, Kaufmann J, Janssen WG, Lou W, Rapp PR, 
Morrison JH (2010) Selective changes in thin spine density and 
morphology in monkey prefrontal cortex correlate with aging-related 
cognitive impairment. J Neurosci 30:7507-7515. 
Egorov AV, Hamam BN, Fransen E, Hasselmo ME, Alonso AA (2002) Graded 
persistent activity in entorhinal cortex neurons. Nature 420:173-178. 
Eichenbaum H (2017) Prefrontal-hippocampal interactions in episodic memory. 
Nat Rev Neurosci 18:547-558. 
Elston GN (2001) Interlaminar differences in the pyramidal cell phenotype in 
cortical areas 7 m and STP (the superior temporal polysensory area) of 
the macaque monkey. Exp Brain Res 138:141-152. 
Elston GN (2003) Cortex, cognition and the cell: new insights into the pyramidal 
neuron and prefrontal function. Cereb Cortex 13:1124-1138. 
Erisir A, Levey AI, Aoki C (2001) Muscarinic receptor M(2) in cat visual cortex: 
laminar distribution, relationship to gamma-aminobutyric acidergic 
neurons, and effect of cingulate lesions. J Comp Neurol 441:168-185. 
Evans HL (1975) Scopolamine effects on visual discrimination: modifications 
related to stimulus control. J Pharmacol Exp Ther 195:105-113. 
Everling S, Fischer B (1998) The antisaccade: a review of basic research and 
clinical studies. Neuropsychologia 36:885-899. 
Everling S, Johnston K (2013) Control of the superior colliculus by the lateral 
prefrontal cortex. Philos Trans R Soc Lond B Biol Sci 368:20130068. 
Fenster CP, Rains MF, Noerager B, Quick MW, Lester RA (1997) Influence of 
subunit composition on desensitization of neuronal acetylcholine receptors 
at low concentrations of nicotine. J Neurosci 17:5747-5759. 
	  	  
70 
Ferrer I, Tunon T, Serrano MT, Casas R, Alcantara S, Zujar MJ, Rivera RM 
(1993) Calbindin D-28k and parvalbumin immunoreactivity in the frontal 
cortex in patients with frontal lobe dementia of non-Alzheimer type 
associated with amyotrophic lateral sclerosis. J Neurol Neurosurg 
Psychiatry 56:257-261. 
Fields RD, Dutta DJ, Belgrad J, Robnett M (2017) Cholinergic signaling in 
myelination. Glia 65:687-698. 
Fillman SG, Cloonan N, Miller LC, Weickert CS (2013) Markers of inflammation in 
the prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 
18:133. 
Fine A, Hoyle C, Maclean CJ, Levatte TL, Baker HF, Ridley RM (1997) Learning 
impairments following injection of a selective cholinergic immunotoxin, 
ME20.4 IgG-saporin, into the basal nucleus of Meynert in monkeys. 
Neuroscience 81:331-343. 
Fischer B, Weber H (1996) Effects of procues on error rate and reaction times of 
antisaccades in human subjects. Exp Brain Res 109:507-512. 
Fisher A (1997) Muscarinic agonists for the treatment of Alzheimer's disease: 
progress and perspectives. Expert Opin Investig Drugs 6:1395-1411. 
Fisher A (2012) Cholinergic modulation of amyloid precursor protein processing 
with emphasis on M1 muscarinic receptor: perspectives and challenges in 
treatment of Alzheimer's disease. J Neurochem 120 Suppl 1:22-33. 
Fisher DJ, Daniels R, Jaworska N, Knobelsdorf A, Knott VJ (2012) Effects of 
acute nicotine administration on resting EEG in nonsmokers. Exp Clin 
Psychopharmacol 20:71-75. 
Francis PT, Palmer AM, Snape M, Wilcock GK (1999) The cholinergic hypothesis 
of Alzheimer's disease: a review of progress. J Neurol Neurosurg 
Psychiatry 66:137-147. 
Freedman DJ, Riesenhuber M, Poggio T, Miller EK (2003) A comparison of 
primate prefrontal and inferior temporal cortices during visual 
categorization. J Neurosci 23:5235-5246. 
Fu Y, Tucciarone JM, Espinosa JS, Sheng N, Darcy DP, Nicoll RA, Huang ZJ, 
Stryker MP (2014) A cortical circuit for gain control by behavioral state. 
Cell 156:1139-1152. 
Fukushima J, Morita N, Fukushima K, Chiba T, Tanaka S, Yamashita I (1990) 
Voluntary control of saccadic eye movements in patients with 
schizophrenic and affective disorders. J Psychiatr Res 24:9-24. 
Funahashi S, Bruce CJ, Goldman-Rakic PS (1989) Mnemonic coding of visual 
space in the monkey's dorsolateral prefrontal cortex. J Neurophysiol 
61:331-349. 
Funahashi S, Bruce CJ, Goldman-Rakic PS (1993) Dorsolateral prefrontal lesions 
and oculomotor delayed-response performance: evidence for mnemonic 
"scotomas". J Neurosci 13:1479-1497. 
Fuster JM (1973) Unit activity in prefrontal cortex during delayed-response 
performance: neuronal correlates of transient memory. J Neurophysiol 
36:61-78. 
Fuster JM (1990) Inferotemporal units in selective visual attention and short-term 
memory. J Neurophysiol 64:681-697. 
	  	  
71 
Fuster JM, Alexander GE (1971) Neuron activity related to short-term memory. 
Science 173:652-654. 
Fuster JM, Bauer RH, Jervey JP (1982) Cellular discharge in the dorsolateral 
prefrontal cortex of the monkey in cognitive tasks. Exp Neurol 77:679-694. 
Gao WJ, Wang Y, Goldman-Rakic PS (2003) Dopamine modulation of 
perisomatic and peridendritic inhibition in prefrontal cortex. J Neurosci 
23:1622-1630. 
Gaykema RP, van Weeghel R, Hersh LB, Luiten PG (1991) Prefrontal cortical 
projections to the cholinergic neurons in the basal forebrain. J Comp 
Neurol 303:563-583. 
Gaymard B, Ploner CJ, Rivaud S, Vermersch AI, Pierrot-Deseilligny C (1998) 
Cortical control of saccades. Exp Brain Res 123:159-163. 
Giannakopoulos P, Hof PR, Michel JP, Guimon J, Bouras C (1997) Cerebral 
cortex pathology in aging and Alzheimer's disease: a quantitative survey of 
large hospital-based geriatric and psychiatric cohorts. Brain Res Brain Res 
Rev 25:217-245. 
Gil-da-Costa R, Stoner GR, Fung R, Albright TD (2013) Nonhuman primate 
model of schizophrenia using a noninvasive EEG method. Proc Natl Acad 
Sci U S A 110:15425-15430. 
Glantz LA, Lewis DA (2000) Decreased dendritic spine density on prefrontal 
cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 57:65-
73. 
Glenner GG, Wong CW (1984) Alzheimer's disease: initial report of the 
purification and characterization of a novel cerebrovascular amyloid 
protein. Biochem Biophys Res Commun 120:885-890. 
Godlove DC, Maier A, Woodman GF, Schall JD (2014) Microcircuitry of agranular 
frontal cortex: testing the generality of the canonical cortical microcircuit. J 
Neurosci 34:5355-5369. 
Goldman PS, Nauta WJ (1976) Autoradiographic demonstration of a projection 
from prefrontal association cortex to the superior colliculus in the rhesus 
monkey. Brain Res 116:145-149. 
Goldman-Rakic PS (1995) Cellular basis of working memory. Neuron 14:477-
485. 
Goldman-Rakic PS, Schwartz ML (1982) Interdigitation of contralateral and 
ipsilateral columnar projections to frontal association cortex in primates. 
Science 216:755-757. 
Goldman-Rakic PS, Selemon LD, Schwartz ML (1984) Dual pathways connecting 
the dorsolateral prefrontal cortex with the hippocampal formation and 
parahippocampal cortex in the rhesus monkey. Neuroscience 12:719-743. 
Gonzalez-Burgos G, Krimer LS, Povysheva NV, Barrionuevo G, Lewis DA (2005) 
Functional properties of fast spiking interneurons and their synaptic 
connections with pyramidal cells in primate dorsolateral prefrontal cortex. J 
Neurophysiol 93:942-953. 
Gotti C, Clementi F, Fornari A, Gaimarri A, Guiducci S, Manfredi I, Moretti M, 
Pedrazzi P, Pucci L, Zoli M (2009) Structural and functional diversity of 
native brain neuronal nicotinic receptors. Biochem Pharmacol 78:703-711. 
	  	  
72 
Green A, Ellis KA, Ellis J, Bartholomeusz CF, Ilic S, Croft RJ, Phan KL, Nathan 
PJ (2005) Muscarinic and nicotinic receptor modulation of object and 
spatial n-back working memory in humans. Pharmacol Biochem Behav 
81:575-584. 
Greenwood PM, Lin MK, Sundararajan R, Fryxell KJ, Parasuraman R (2009) 
Synergistic effects of genetic variation in nicotinic and muscarinic 
receptors on visual attention but not working memory. Proc Natl Acad Sci 
U S A 106:3633-3638. 
Gregoriou GG, Rossi AF, Ungerleider LG, Desimone R (2014) Lesions of 
prefrontal cortex reduce attentional modulation of neuronal responses and 
synchrony in V4. Nat Neurosci 17:1003-1011. 
Grigorenko EL, Wood FB, Meyer MS, Pauls JE, Hart LA, Pauls DL (2001) 
Linkage studies suggest a possible locus for developmental dyslexia on 
chromosome 1p. Am J Med Genet 105:120-129. 
Gritti I, Henny P, Galloni F, Mainville L, Mariotti M, Jones BE (2006) Stereological 
estimates of the basal forebrain cell population in the rat, including 
neurons containing choline acetyltransferase, glutamic acid decarboxylase 
or phosphate-activated glutaminase and colocalizing vesicular glutamate 
transporters. Neuroscience 143:1051-1064. 
Gross CG, Weiskrantz L (1962) Evidence for dissociation of impairment on 
auditory discrimination and delayed response following lateral frontal 
lesions in monkeys. Exp Neurol 5:453-476. 
Gu Q (2003) Contribution of acetylcholine to visual cortex plasticity. Neurobiol 
Learn Mem 80:291-301. 
Guitton D, Buchtel HA, Douglas RM (1985) Frontal lobe lesions in man cause 
difficulties in suppressing reflexive glances and in generating goal-directed 
saccades. Exp Brain Res 58:455-472. 
Hallett PE (1978) Primary and secondary saccades to goals defined by 
instructions. Vision Res 18:1279-1296. 
Hardenacke K, Hashemiyoon R, Visser-Vandewalle V, Zapf A, Freund HJ, Sturm 
V, Hellmich M, Kuhn J (2016) Deep Brain Stimulation of the Nucleus 
Basalis of Meynert in Alzheimer's Dementia: Potential Predictors of 
Cognitive Change and Results of a Long-Term Follow-Up in Eight 
Patients. Brain Stimul 9:799-800. 
Harder JA, Baker HF, Ridley RM (1998) The role of the central cholinergic 
projections in cognition: implications of the effects of scopolamine on 
discrimination learning by monkeys. Brain Res Bull 45:319-326. 
Haring R, Fisher A, Marciano D, Pittel Z, Kloog Y, Zuckerman A, Eshhar N, 
Heldman E (1998) Mitogen-activated protein kinase-dependent and 
protein kinase C-dependent pathways link the m1 muscarinic receptor to 
beta-amyloid precursor protein secretion. J Neurochem 71:2094-2103. 
Harrison PJ (1999) The neuropathology of schizophrenia. A critical review of the 
data and their interpretation. Brain 122 ( Pt 4):593-624. 
Harrison PJ (2000) Postmortem studies in schizophrenia. Dialogues Clin 
Neurosci 2:349-357. 
	  	  
73 
Harvey RJ, Skelton-Robinson M, Rossor MN (2003) The prevalence and causes 
of dementia in people under the age of 65 years. J Neurol Neurosurg 
Psychiatry 74:1206-1209. 
Hashimoto T, Volk DW, Eggan SM, Mirnics K, Pierri JN, Sun Z, Sampson AR, 
Lewis DA (2003) Gene expression deficits in a subclass of GABA neurons 
in the prefrontal cortex of subjects with schizophrenia. J Neurosci 23:6315-
6326. 
Hawkes N (2018) Pfizer abandons research into Alzheimer's and Parkinson's 
diseases. BMJ 360:k122. 
Hawkins BT, Davis TP (2005) The blood-brain barrier/neurovascular unit in health 
and disease. Pharmacol Rev 57:173-185. 
Hayden BY, Gallant JL (2013) Working memory and decision processes in visual 
area v4. Front Neurosci 7:18. 
Heishman SJ, Kleykamp BA, Singleton EG (2010) Meta-analysis of the acute 
effects of nicotine and smoking on human performance. 
Psychopharmacology (Berl) 210:453-469. 
Hendry SH, Jones EG, DeFelipe J, Schmechel D, Brandon C, Emson PC (1984) 
Neuropeptide-containing neurons of the cerebral cortex are also 
GABAergic. Proc Natl Acad Sci U S A 81:6526-6530. 
Hepler DJ, Wenk GL, Cribbs BL, Olton DS, Coyle JT (1985) Memory impairments 
following basal forebrain lesions. Brain Res 346:8-14. 
Herr NR, Kile BM, Carelli RM, Wightman RM (2008) Electroosmotic flow and its 
contribution to iontophoretic delivery. Anal Chem 80:8635-8641. 
Herr NR, Wightman RM (2013) Improved techniques for examining rapid 
dopamine signaling with iontophoresis. Front Biosci (Elite Ed) 5:249-257. 
Herrero JL, Gieselmann MA, Sanayei M, Thiele A (2013) Attention-induced 
variance and noise correlation reduction in macaque V1 is mediated by 
NMDA receptors. Neuron 78:729-739. 
Herrero JL, Roberts MJ, Delicato LS, Gieselmann MA, Dayan P, Thiele A (2008) 
Acetylcholine contributes through muscarinic receptors to attentional 
modulation in V1. Nature 454:1110-1114. 
Hoftman GD, Datta D, Lewis DA (2017) Layer 3 Excitatory and Inhibitory Circuitry 
in the Prefrontal Cortex: Developmental Trajectories and Alterations in 
Schizophrenia. Biol Psychiatry 81:862-873. 
Hoshi M, Takashima A, Murayama M, Yasutake K, Yoshida N, Ishiguro K, 
Hoshino T, Imahori K (1997) Nontoxic amyloid beta peptide 1-42 
suppresses acetylcholine synthesis. Possible role in cholinergic 
dysfunction in Alzheimer's disease. J Biol Chem 272:2038-2041. 
Hotta H, Kagitani F, Kondo M, Uchida S (2009) Basal forebrain stimulation 
induces NGF secretion in ipsilateral parietal cortex via nicotinic receptor 
activation in adult, but not aged rats. Neurosci Res 63:122-128. 
Houser CR, Crawford GD, Salvaterra PM, Vaughn JE (1985) 
Immunocytochemical localization of choline acetyltransferase in rat 
cerebral cortex: a study of cholinergic neurons and synapses. J Comp 
Neurol 234:17-34. 
Hupe JM, Chouvet G, Bullier J (1999) Spatial and temporal parameters of cortical 
inactivation by GABA. J Neurosci Methods 86:129-143. 
	  	  
74 
Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys 
H, Seo J, Kritskiy O, Abdurrob F, Adaikkan C, Canter RG, Rueda R, 
Brown EN, Boyden ES, Tsai LH (2016) Gamma frequency entrainment 
attenuates amyloid load and modifies microglia. Nature 540:230-235. 
Jacob SN, Nieder A (2014) Complementary roles for primate frontal and parietal 
cortex in guarding working memory from distractor stimuli. Neuron 83:226-
237. 
Jacobs B, Schall M, Prather M, Kapler E, Driscoll L, Baca S, Jacobs J, Ford K, 
Wainwright M, Treml M (2001) Regional dendritic and spine variation in 
human cerebral cortex: a quantitative golgi study. Cereb Cortex 11:558-
571. 
Jakob H, Beckmann H (1986) Prenatal developmental disturbances in the limbic 
allocortex in schizophrenics. J Neural Transm 65:303-326. 
Javitt DC (1987) Negative schizophrenic symptomatology and the PCP 
(phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry 9:12-35. 
Jeong J (2004) EEG dynamics in patients with Alzheimer's disease. Clin 
Neurophysiol 115:1490-1505. 
Johnston K, DeSouza JF, Everling S (2009) Monkey prefrontal cortical pyramidal 
and putative interneurons exhibit differential patterns of activity between 
prosaccade and antisaccade tasks. J Neurosci 29:5516-5524. 
Johnston K, Everling S (2009) Task-relevant output signals are sent from monkey 
dorsolateral prefrontal cortex to the superior colliculus during a 
visuospatial working memory task. J Cogn Neurosci 21:1023-1038. 
Johnston K, Koval MJ, Lomber SG, Everling S (2014) Macaque dorsolateral 
prefrontal cortex does not suppress saccade-related activity in the superior 
colliculus. Cereb Cortex 24:1373-1388. 
Johnston K, Ma L, Schaeffer L, Everling S (2019) Alpha Oscillations Modulate 
Preparatory Activity in Marmoset Area 8Ad. J Neurosci 39:1855-1866. 
Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, 
Bridges TM, Kennedy JP, Bradley SR, Peterson TE, Ansari MS, Baldwin 
RM, Kessler RM, Deutch AY, Lah JJ, Levey AI, Lindsley CW, Conn PJ 
(2008) Novel selective allosteric activator of the M1 muscarinic 
acetylcholine receptor regulates amyloid processing and produces 
antipsychotic-like activity in rats. J Neurosci 28:10422-10433. 
Kalmady SV, Agrawal R, Venugopal D, Shivakumar V, Amaresha AC, Agarwal 
SM, Subbanna M, Rajasekaran A, Narayanaswamy JC, Debnath M, 
Venkatasubramanian G (2018) CHRFAM7A gene expression in 
schizophrenia: clinical correlates and the effect of antipsychotic treatment. 
J Neural Transm (Vienna) 125:741-748. 
Kang JI, Groleau M, Dotigny F, Giguere H, Vaucher E (2014) Visual training 
paired with electrical stimulation of the basal forebrain improves 
orientation-selective visual acuity in the rat. Brain Struct Funct 219:1493-
1507. 
Kar S, Seto D, Gaudreau P, Quirion R (1996) Beta-amyloid-related peptides 
inhibit potassium-evoked acetylcholine release from rat hippocampal 
slices. J Neurosci 16:1034-1040. 
	  	  
75 
Karnani MM, Jackson J, Ayzenshtat I, Hamzehei Sichani A, Manoocheri K, Kim 
S, Yuste R (2016) Opening Holes in the Blanket of Inhibition: Localized 
Lateral Disinhibition by VIP Interneurons. J Neurosci 36:3471-3480. 
Katner SN, Davis SA, Kirsten AJ, Taffe MA (2004) Effects of nicotine and 
mecamylamine on cognition in rhesus monkeys. Psychopharmacology 
(Berl) 175:225-240. 
Katsuki F, Constantinidis C (2013) Time course of functional connectivity in 
primate dorsolateral prefrontal and posterior parietal cortex during working 
memory. PLoS One 8:e81601. 
Kaufman LD, Pratt J, Levine B, Black SE (2010) Antisaccades: a probe into the 
dorsolateral prefrontal cortex in Alzheimer's disease. A critical review. J 
Alzheimers Dis 19:781-793. 
Kawaguchi Y (1993) Groupings of nonpyramidal and pyramidal cells with specific 
physiological and morphological characteristics in rat frontal cortex. J 
Neurophysiol 69:416-431. 
Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale 
(PANSS) for schizophrenia. Schizophr Bull 13:261-276. 
Kelly JF, Furukawa K, Barger SW, Rengen MR, Mark RJ, Blanc EM, Roth GS, 
Mattson MP (1996) Amyloid beta-peptide disrupts carbachol-induced 
muscarinic cholinergic signal transduction in cortical neurons. Proc Natl 
Acad Sci U S A 93:6753-6758. 
Kievit J, Kuypers HG (1975) Basal forebrain and hypothalamic connection to 
frontal and parietal cortex in the Rhesus monkey. Science 187:660-662. 
Kikuchi M, Wada Y, Nanbu Y, Nakajima A, Tachibana H, Takeda T, Hashimoto T 
(1999) EEG changes following scopolamine administration in healthy 
subjects. Quantitative analysis during rest and photic stimulation. 
Neuropsychobiology 39:219-226. 
Kim D, Jeong H, Lee J, Ghim JW, Her ES, Lee SH, Jung MW (2016) Distinct 
Roles of Parvalbumin- and Somatostatin-Expressing Interneurons in 
Working Memory. Neuron 92:902-915. 
Klinkenberg I, Blokland A (2010) The validity of scopolamine as a 
pharmacological model for cognitive impairment: a review of animal 
behavioral studies. Neurosci Biobehav Rev 34:1307-1350. 
Kojima S, Goldman-Rakic PS (1982) Delay-related activity of prefrontal neurons 
in rhesus monkeys performing delayed response. Brain Res 248:43-49. 
Kojima S, Goldman-Rakic PS (1984) Functional analysis of spatially 
discriminative neurons in prefrontal cortex of rhesus monkey. Brain Res 
291:229-240. 
Koliatsos VE, Martin LJ, Walker LC, Richardson RT, DeLong MR, Price DL 
(1988) Topographic, non-collateralized basal forebrain projections to 
amygdala, hippocampus, and anterior cingulate cortex in the rhesus 
monkey. Brain Res 463:133-139. 
Koval MJ, Lomber SG, Everling S (2011) Prefrontal cortex deactivation in 
macaques alters activity in the superior colliculus and impairs voluntary 
control of saccades. J Neurosci 31:8659-8668. 
Kovelman JA, Scheibel AB (1984) A neurohistological correlate of schizophrenia. 
Biol Psychiatry 19:1601-1621. 
	  	  
76 
Kozak R, Bruno JP, Sarter M (2006) Augmented prefrontal acetylcholine release 
during challenged attentional performance. Cereb Cortex 16:9-17. 
Kritzer MF, Goldman-Rakic PS (1995) Intrinsic circuit organization of the major 
layers and sublayers of the dorsolateral prefrontal cortex in the rhesus 
monkey. J Comp Neurol 359:131-143. 
Kubota K, Niki H (1971) Prefrontal cortical unit activity and delayed alternation 
performance in monkeys. J Neurophysiol 34:337-347. 
Kubota Y, Hattori R, Yui Y (1994) Three distinct subpopulations of GABAergic 
neurons in rat frontal agranular cortex. Brain Res 649:159-173. 
Kuhn J, Hardenacke K, Lenartz D, Gruendler T, Ullsperger M, Bartsch C, Mai JK, 
Zilles K, Bauer A, Matusch A, Schulz RJ, Noreik M, Buhrle CP, Maintz D, 
Woopen C, Haussermann P, Hellmich M, Klosterkotter J, Wiltfang J, 
Maarouf M, Freund HJ, Sturm V (2015) Deep brain stimulation of the 
nucleus basalis of Meynert in Alzheimer's dementia. Mol Psychiatry 
20:353-360. 
Kumari V, Postma P (2005) Nicotine use in schizophrenia: the self medication 
hypotheses. Neurosci Biobehav Rev 29:1021-1034. 
Kurosawa M, Sato A, Sato Y (1989) Stimulation of the nucleus basalis of Meynert 
increases acetylcholine release in the cerebral cortex in rats. Neurosci Lett 
98:45-50. 
Ladner CJ, Lee JM (1999) Reduced high-affinity agonist binding at the M(1) 
muscarinic receptor in Alzheimer's disease brain: differential sensitivity to 
agonists and divalent cations. Exp Neurol 158:451-458. 
Lakatos P, Chen CM, O'Connell MN, Mills A, Schroeder CE (2007) Neuronal 
oscillations and multisensory interaction in primary auditory cortex. Neuron 
53:279-292. 
Laurin D, Verreault R, Lindsay J, MacPherson K, Rockwood K (2001) Physical 
activity and risk of cognitive impairment and dementia in elderly persons. 
Arch Neurol 58:498-504. 
Lautenschlager NT, Cox KL, Flicker L, Foster JK, van Bockxmeer FM, Xiao J, 
Greenop KR, Almeida OP (2008) Effect of physical activity on cognitive 
function in older adults at risk for Alzheimer disease: a randomized trial. 
JAMA 300:1027-1037. 
Lawler HC (1961) Turnover time of acetylcholinesterase. J Biol Chem 236:2296-
2301. 
Laxton AW, Tang-Wai DF, McAndrews MP, Zumsteg D, Wennberg R, Keren R, 
Wherrett J, Naglie G, Hamani C, Smith GS, Lozano AM (2010) A phase I 
trial of deep brain stimulation of memory circuits in Alzheimer's disease. 
Ann Neurol 68:521-534. 
Leichnetz GR (1980) An anterogradely-labeled prefrontal cortico-oculomotor 
pathway in the monkey demonstrated with HRP gel and TMB 
neurohistochemistry. Brain Res 198:440-445. 
Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M, Drebing C, Berger 
R, Venn D, Sirota P, Zerbe G, Olincy A, Ross RG, Adler LE, Freedman R 
(2002) Association of promoter variants in the alpha7 nicotinic 
acetylcholine receptor subunit gene with an inhibitory deficit found in 
schizophrenia. Arch Gen Psychiatry 59:1085-1096. 
	  	  
77 
Levey AI, Wainer BH, Rye DB, Mufson EJ, Mesulam MM (1984) Choline 
acetyltransferase-immunoreactive neurons intrinsic to rodent cortex and 
distinction from acetylcholinesterase-positive neurons. Neuroscience 
13:341-353. 
Levin ED, Bettegowda C, Blosser J, Gordon J (1999) AR-R17779, and alpha7 
nicotinic agonist, improves learning and memory in rats. Behav Pharmacol 
10:675-680. 
Levin ED, McClernon FJ, Rezvani AH (2006) Nicotinic effects on cognitive 
function: behavioral characterization, pharmacological specification, and 
anatomic localization. Psychopharmacology (Berl) 184:523-539. 
Levitt JB, Lewis DA, Yoshioka T, Lund JS (1993) Topography of pyramidal 
neuron intrinsic connections in macaque monkey prefrontal cortex (areas 9 
and 46). J Comp Neurol 338:360-376. 
Lewis AS, van Schalkwyk GI, Bloch MH (2017) Alpha-7 nicotinic agonists for 
cognitive deficits in neuropsychiatric disorders: A translational meta-
analysis of rodent and human studies. Prog Neuropsychopharmacol Biol 
Psychiatry 75:45-53. 
Lewis DA (1991) Distribution of choline acetyltransferase-immunoreactive axons 
in monkey frontal cortex. Neuroscience 40:363-374. 
Lidow MS, Gallager DW, Rakic P, Goldman-Rakic PS (1989) Regional 
differences in the distribution of muscarinic cholinergic receptors in the 
macaque cerebral cortex. J Comp Neurol 289:247-259. 
Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in 
neurodegenerative diseases. Nature 443:787-795. 
Lister WT, Holmes G (1916) Disturbances of Vision from Cerebral Lesions, with 
Special Reference to the Cortical Representation of the Macula. Proc R 
Soc Med 9:57-96. 
Liu R, Crawford J, Callahan PM, Terry AV, Jr., Constantinidis C, Blake DT (2017) 
Intermittent Stimulation of the Nucleus Basalis of Meynert Improves 
Working Memory in Adult Monkeys. Curr Biol 27:2640-2646 e2644. 
Liu RH (2003) Health benefits of fruit and vegetables are from additive and 
synergistic combinations of phytochemicals. Am J Clin Nutr 78:517S-
520S. 
Lozano AM, Fosdick L, Chakravarty MM, Leoutsakos JM, Munro C, Oh E, Drake 
KE, Lyman CH, Rosenberg PB, Anderson WS, Tang-Wai DF, 
Pendergrass JC, Salloway S, Asaad WF, Ponce FA, Burke A, Sabbagh M, 
Wolk DA, Baltuch G, Okun MS, Foote KD, McAndrews MP, Giacobbe P, 
Targum SD, Lyketsos CG, Smith GS (2016) A Phase II Study of Fornix 
Deep Brain Stimulation in Mild Alzheimer's Disease. J Alzheimers Dis 
54:777-787. 
Lozano AM, Lipsman N, Bergman H, Brown P, Chabardes S, Chang JW, 
Matthews K, McIntyre CC, Schlaepfer TE, Schulder M, Temel Y, 
Volkmann J, Krauss JK (2019) Deep brain stimulation: current challenges 
and future directions. Nat Rev Neurol 15:148-160. 
Lu MT, Preston JB, Strick PL (1994) Interconnections between the prefrontal 
cortex and the premotor areas in the frontal lobe. J Comp Neurol 341:375-
392. 
	  	  
78 
Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, 
Rydel RE, Rogers J (1999) Soluble amyloid beta peptide concentration as 
a predictor of synaptic change in Alzheimer's disease. Am J Pathol 
155:853-862. 
Luiten PG, Gaykema RP, Traber J, Spencer DG, Jr. (1987) Cortical projection 
patterns of magnocellular basal nucleus subdivisions as revealed by 
anterogradely transported Phaseolus vulgaris leucoagglutinin. Brain Res 
413:229-250. 
Lundqvist M, Compte A, Lansner A (2010) Bistable, irregular firing and population 
oscillations in a modular attractor memory network. PLoS Comput Biol 
6:e1000803. 
Lundqvist M, Herman P, Warden MR, Brincat SL, Miller EK (2018) Gamma and 
beta bursts during working memory readout suggest roles in its volitional 
control. Nat Commun 9:394. 
Lundqvist M, Rose J, Herman P, Brincat SL, Buschman TJ, Miller EK (2016) 
Gamma and Beta Bursts Underlie Working Memory. Neuron 90:152-164. 
Ma L, Skoblenick K, Johnston K, Everling S (2018) Ketamine alters lateral 
prefrontal oscillations in a rule-based working memory task. J Neurosci. 
Major AJ, Vijayraghavan S, Everling S (2015) Muscarinic Attenuation of 
Mnemonic Rule Representation in Macaque Dorsolateral Prefrontal Cortex 
during a Pro- and Anti-Saccade Task. J Neurosci 35:16064-16076. 
Markram H, Toledo-Rodriguez M, Wang Y, Gupta A, Silberberg G, Wu C (2004) 
Interneurons of the neocortical inhibitory system. Nat Rev Neurosci 5:793-
807. 
Marrosu F, Portas C, Mascia MS, Casu MA, Fa M, Giagheddu M, Imperato A, 
Gessa GL (1995) Microdialysis measurement of cortical and hippocampal 
acetylcholine release during sleep-wake cycle in freely moving cats. Brain 
Res 671:329-332. 
Mash DC, White WF, Mesulam MM (1988) Distribution of muscarinic receptor 
subtypes within architectonic subregions of the primate cerebral cortex. J 
Comp Neurol 278:265-274. 
Masliah E, Terry RD, Alford M, DeTeresa R, Hansen LA (1991) Cortical and 
subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's 
disease. Am J Pathol 138:235-246. 
Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K 
(1985) Amyloid plaque core protein in Alzheimer disease and Down 
syndrome. Proc Natl Acad Sci U S A 82:4245-4249. 
McClave AK, McKnight-Eily LR, Davis SP, Dube SR (2010) Smoking 
characteristics of adults with selected lifetime mental illnesses: results 
from the 2007 National Health Interview Survey. Am J Public Health 
100:2464-2472. 
McCormick DA, Prince DA (1985) Two types of muscarinic response to 
acetylcholine in mammalian cortical neurons. Proc Natl Acad Sci U S A 
82:6344-6348. 
McGaughy J, Dalley JW, Morrison CH, Everitt BJ, Robbins TW (2002) Selective 
behavioral and neurochemical effects of cholinergic lesions produced by 
	  	  
79 
intrabasalis infusions of 192 IgG-saporin on attentional performance in a 
five-choice serial reaction time task. J Neurosci 22:1905-1913. 
McGrath J, Saha S, Chant D, Welham J (2008) Schizophrenia: a concise 
overview of incidence, prevalence, and mortality. Epidemiol Rev 30:67-76. 
Mechawar N, Cozzari C, Descarries L (2000) Cholinergic innervation in adult rat 
cerebral cortex: a quantitative immunocytochemical description. J Comp 
Neurol 428:305-318. 
Medalla M, Barbas H (2012) The anterior cingulate cortex may enhance inhibition 
of lateral prefrontal cortex via m2 cholinergic receptors at dual synaptic 
sites. J Neurosci 32:15611-15625. 
Melchitzky DS, Gonzalez-Burgos G, Barrionuevo G, Lewis DA (2001) Synaptic 
targets of the intrinsic axon collaterals of supragranular pyramidal neurons 
in monkey prefrontal cortex. J Comp Neurol 430:209-221. 
Melchitzky DS, Sesack SR, Pucak ML, Lewis DA (1998) Synaptic targets of 
pyramidal neurons providing intrinsic horizontal connections in monkey 
prefrontal cortex. J Comp Neurol 390:211-224. 
Mesik L, Ma WP, Li LY, Ibrahim LA, Huang ZJ, Zhang LI, Tao HW (2015) 
Functional response properties of VIP-expressing inhibitory neurons in 
mouse visual and auditory cortex. Front Neural Circuits 9:22. 
Mesulam MM, Hersh LB, Mash DC, Geula C (1992) Differential cholinergic 
innervation within functional subdivisions of the human cerebral cortex: a 
choline acetyltransferase study. J Comp Neurol 318:316-328. 
Mesulam MM, Mufson EJ (1984) Neural inputs into the nucleus basalis of the 
substantia innominata (Ch4) in the rhesus monkey. Brain 107 ( Pt 1):253-
274. 
Mesulam MM, Mufson EJ, Levey AI, Wainer BH (1983) Cholinergic innervation of 
cortex by the basal forebrain: cytochemistry and cortical connections of the 
septal area, diagonal band nuclei, nucleus basalis (substantia innominata), 
and hypothalamus in the rhesus monkey. J Comp Neurol 214:170-197. 
Mesulam MM, Van Hoesen GW (1976) Acetylcholinesterase-rich projections from 
the basal forebrain of the rhesus monkey to neocortex. Brain Res 109:152-
157. 
Millar NS, Gotti C (2009) Diversity of vertebrate nicotinic acetylcholine receptors. 
Neuropharmacology 56:237-246. 
Miller EK, Cohen JD (2001) An integrative theory of prefrontal cortex function. 
Annu Rev Neurosci 24:167-202. 
Miller EK, Desimone R (1993) Scopolamine affects short-term memory but not 
inferior temporal neurons. Neuroreport 4:81-84. 
Miller EK, Lundqvist M, Bastos AM (2018) Working Memory 2.0. Neuron 100:463-
475. 
Milner B (1963) Effects of different brain lesions on card sorting: The role of the 
frontal lobes. Archives of Neurology 9:100-110. 
Minakawa EN, Wada K, Nagai Y (2019) Sleep Disturbance as a Potential 
Modifiable Risk Factor for Alzheimer's Disease. Int J Mol Sci 20. 
Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P (2000) Molecular 
characterization of schizophrenia viewed by microarray analysis of gene 
expression in prefrontal cortex. Neuron 28:53-67. 
	  	  
80 
Mishkin M, Manning FJ (1978) Non-spatial memory after selective prefrontal 
lesions in monkeys. Brain Res 143:313-323. 
Mitchelson FJ (2012) The pharmacology of McN-A-343. Pharmacol Ther 
135:216-245. 
Moran PM (1993) Differential effects of scopolamine and mecamylamine on 
working and reference memory in the rat. Pharmacol Biochem Behav 
45:533-538. 
Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, 
Aggarwal N, Schneider J (2003) Consumption of fish and n-3 fatty acids 
and risk of incident Alzheimer disease. Arch Neurol 60:940-946. 
Moulton PV, Yang W (2012) Air pollution, oxidative stress, and Alzheimer's 
disease. J Environ Public Health 2012:472751. 
Mrzljak L, Levey AI, Belcher S, Goldman-Rakic PS (1998) Localization of the m2 
muscarinic acetylcholine receptor protein and mRNA in cortical neurons of 
the normal and cholinergically deafferented rhesus monkey. J Comp 
Neurol 390:112-132. 
Mrzljak L, Levey AI, Goldman-Rakic PS (1993) Association of m1 and m2 
muscarinic receptor proteins with asymmetric synapses in the primate 
cerebral cortex: morphological evidence for cholinergic modulation of 
excitatory neurotransmission. Proc Natl Acad Sci U S A 90:5194-5198. 
Mrzljak L, Pappy M, Leranth C, Goldman-Rakic PS (1995) Cholinergic synaptic 
circuitry in the macaque prefrontal cortex. J Comp Neurol 357:603-617. 
Munoz DP, Everling S (2004) Look away: the anti-saccade task and the voluntary 
control of eye movement. Nat Rev Neurosci 5:218-228. 
Muzur A, Pace-Schott EF, Hobson JA (2002) The prefrontal cortex in sleep. 
Trends Cogn Sci 6:475-481. 
Nandy AS, Nassi JJ, Reynolds JH (2017) Laminar Organization of Attentional 
Modulation in Macaque Visual Area V4. Neuron 93:235-246. 
Newhouse PA, Potter A, Corwin J, Lenox R (1992) Acute nicotinic blockade 
produces cognitive impairment in normal humans. Psychopharmacology 
(Berl) 108:480-484. 
Newman EL, Gupta K, Climer JR, Monaghan CK, Hasselmo ME (2012) 
Cholinergic modulation of cognitive processing: insights drawn from 
computational models. Front Behav Neurosci 6:24. 
Ng HJ, Whittemore ER, Tran MB, Hogenkamp DJ, Broide RS, Johnstone TB, 
Zheng L, Stevens KE, Gee KW (2007) Nootropic alpha7 nicotinic receptor 
allosteric modulator derived from GABAA receptor modulators. Proc Natl 
Acad Sci U S A 104:8059-8064. 
Ng M, Freeman MK, Fleming TD, Robinson M, Dwyer-Lindgren L, Thomson B, 
Wollum A, Sanman E, Wulf S, Lopez AD, Murray CJ, Gakidou E (2014) 
Smoking prevalence and cigarette consumption in 187 countries, 1980-
2012. JAMA 311:183-192. 
Niki H (1974a) Differential activity of prefrontal units during right and left delayed 
response trials. Brain Res 70:346-349. 
Niki H (1974b) Prefrontal unit activity during delayed alternation in the monkey. I. 
Relation to direction of response. Brain Res 68:185-196. 
	  	  
81 
Niki H (1974c) Prefrontal unit activity during delayed alternation in the monkey. II. 
Relation to absolute versus relative direction of response. Brain Res 
68:197-204. 
Niki H, Watanabe M (1976) Prefrontal unit activity and delayed response: relation 
to cue location versus direction of response. Brain Res 105:79-88. 
Nilsson L, Nordberg A, Hardy J, Wester P, Winblad B (1986) Physostigmine 
restores 3H-acetylcholine efflux from Alzheimer brain slices to normal 
level. J Neural Transm 67:275-285. 
Nitsch RM, Slack BE, Wurtman RJ, Growdon JH (1992) Release of Alzheimer 
amyloid precursor derivatives stimulated by activation of muscarinic 
acetylcholine receptors. Science 258:304-307. 
O'Neill PK, Gordon JA, Sigurdsson T (2013) Theta oscillations in the medial 
prefrontal cortex are modulated by spatial working memory and 
synchronize with the hippocampus through its ventral subregion. J 
Neurosci 33:14211-14224. 
Opris I, Hampson RE, Gerhardt GA, Berger TW, Deadwyler SA (2012) Columnar 
processing in primate pFC: evidence for executive control microcircuits. J 
Cogn Neurosci 24:2334-2347. 
Ott T, Jacob SN, Nieder A (2014) Dopamine receptors differentially enhance rule 
coding in primate prefrontal cortex neurons. Neuron 84:1317-1328. 
Owen AM, Downes JJ, Sahakian BJ, Polkey CE, Robbins TW (1990) Planning 
and spatial working memory following frontal lobe lesions in man. 
Neuropsychologia 28:1021-1034. 
Pandya DN, Yeterian EH (1990) Prefrontal cortex in relation to other cortical 
areas in rhesus monkey: architecture and connections. Prog Brain Res 
85:63-94. 
Panza F, Lozupone M, Seripa D, Imbimbo BP (2019) Amyloid-beta 
immunotherapy for alzheimer disease: Is it now a long shot? Ann Neurol 
85:303-315. 
Parikh V, Kozak R, Martinez V, Sarter M (2007) Prefrontal acetylcholine release 
controls cue detection on multiple timescales. Neuron 56:141-154. 
Parikh V, Man K, Decker MW, Sarter M (2008) Glutamatergic contributions to 
nicotinic acetylcholine receptor agonist-evoked cholinergic transients in the 
prefrontal cortex. J Neurosci 28:3769-3780. 
Parri HR, Hernandez CM, Dineley KT (2011) Research update: Alpha7 nicotinic 
acetylcholine receptor mechanisms in Alzheimer's disease. Biochem 
Pharmacol 82:931-942. 
Passingham RE (1985) Memory of monkeys (Macaca mulatta) with lesions in 
prefrontal cortex. Behav Neurosci 99:3-21. 
Pediani JD, Ward RJ, Godin AG, Marsango S, Milligan G (2016) Dynamic 
Regulation of Quaternary Organization of the M1 Muscarinic Receptor by 
Subtype-selective Antagonist Drugs. J Biol Chem 291:13132-13146. 
Perlstein WM, Carter CS, Noll DC, Cohen JD (2001) Relation of prefrontal cortex 
dysfunction to working memory and symptoms in schizophrenia. Am J 
Psychiatry 158:1105-1113. 
	  	  
82 
Pesaran B, Pezaris JS, Sahani M, Mitra PP, Andersen RA (2002) Temporal 
structure in neuronal activity during working memory in macaque parietal 
cortex. Nat Neurosci 5:805-811. 
Peters A, Sethares C, Luebke JI (2008) Synapses are lost during aging in the 
primate prefrontal cortex. Neuroscience 152:970-981. 
Petrides M, Pandya DN (1999) Dorsolateral prefrontal cortex: comparative 
cytoarchitectonic analysis in the human and the macaque brain and 
corticocortical connection patterns. Eur J Neurosci 11:1011-1036. 
Pfeffer CK, Xue M, He M, Huang ZJ, Scanziani M (2013) Inhibition of inhibition in 
visual cortex: the logic of connections between molecularly distinct 
interneurons. Nat Neurosci 16:1068-1076. 
Picciotto MR, Kenny PJ (2013) Molecular mechanisms underlying behaviors 
related to nicotine addiction. Cold Spring Harb Perspect Med 3:a012112. 
Pierrot-Deseilligny C, Muri RM, Ploner CJ, Gaymard B, Demeret S, Rivaud-
Pechoux S (2003) Decisional role of the dorsolateral prefrontal cortex in 
ocular motor behaviour. Brain 126:1460-1473. 
Pierrot-Deseilligny C, Rivaud S, Gaymard B, Agid Y (1991) Cortical control of 
reflexive visually-guided saccades. Brain 114 ( Pt 3):1473-1485. 
Pittel Z, Heldman E, Barg J, Haring R, Fisher A (1996) Muscarinic control of 
amyloid precursor protein secretion in rat cerebral cortex and cerebellum. 
Brain Res 742:299-304. 
Ploner CJ, Gaymard BM, Rivaud-Pechoux S, Pierrot-Deseilligny C (2005) The 
prefrontal substrate of reflexive saccade inhibition in humans. Biol 
Psychiatry 57:1159-1165. 
Pons S, Fattore L, Cossu G, Tolu S, Porcu E, McIntosh JM, Changeux JP, 
Maskos U, Fratta W (2008) Crucial role of alpha4 and alpha6 nicotinic 
acetylcholine receptor subunits from ventral tegmental area in systemic 
nicotine self-administration. J Neurosci 28:12318-12327. 
Porrino LJ, Crane AM, Goldman-Rakic PS (1981) Direct and indirect pathways 
from the amygdala to the frontal lobe in rhesus monkeys. J Comp Neurol 
198:121-136. 
Potter PE, Rauschkolb PK, Pandya Y, Sue LI, Sabbagh MN, Walker DG, Beach 
TG (2011) Pre- and post-synaptic cortical cholinergic deficits are 
proportional to amyloid plaque presence and density at preclinical stages 
of Alzheimer's disease. Acta Neuropathol 122:49-60. 
Powell J, Dawkins L, Davis RE (2002) Smoking, reward responsiveness, and 
response inhibition: tests of an incentive motivational model. Biol 
Psychiatry 51:151-163. 
Preuss TM (1995) Do rats have prefrontal cortex? The rose-woolsey-akert 
program reconsidered. J Cogn Neurosci 7:1-24. 
Price JL, Amaral DG (1981) An autoradiographic study of the projections of the 
central nucleus of the monkey amygdala. J Neurosci 1:1242-1259. 
Price JL, Stern R (1983) Individual cells in the nucleus basalis--diagonal band 
complex have restricted axonal projections to the cerebral cortex in the rat. 
Brain Res 269:352-356. 
	  	  
83 
Pucak ML, Levitt JB, Lund JS, Lewis DA (1996) Patterns of intrinsic and 
associational circuitry in monkey prefrontal cortex. J Comp Neurol 
376:614-630. 
Purves RD (1979) The physics of iontophoretic pipettes. J Neurosci Methods 
1:165-178. 
Qi XL, Katsuki F, Meyer T, Rawley JB, Zhou X, Douglas KL, Constantinidis C 
(2010) Comparison of neural activity related to working memory in primate 
dorsolateral prefrontal and posterior parietal cortex. Front Syst Neurosci 
4:12. 
Quinn DM (1987) Acetylcholinesterase: enzyme structure, reaction dynamics, 
and virtual transition states. Chemical Reviews 87:955. 
Raghanti MA, Stimpson CD, Marcinkiewicz JL, Erwin JM, Hof PR, Sherwood CC 
(2008a) Cholinergic innervation of the frontal cortex: differences among 
humans, chimpanzees, and macaque monkeys. J Comp Neurol 506:409-
424. 
Raghanti MA, Stimpson CD, Marcinkiewicz JL, Erwin JM, Hof PR, Sherwood CC 
(2008b) Cortical dopaminergic innervation among humans, chimpanzees, 
and macaque monkeys: a comparative study. Neuroscience 155:203-220. 
Raghanti MA, Stimpson CD, Marcinkiewicz JL, Erwin JM, Hof PR, Sherwood CC 
(2008c) Differences in cortical serotonergic innervation among humans, 
chimpanzees, and macaque monkeys: a comparative study. Cereb Cortex 
18:584-597. 
Rao SG, Williams GV, Goldman-Rakic PS (1999) Isodirectional tuning of 
adjacent interneurons and pyramidal cells during working memory: 
evidence for microcolumnar organization in PFC. J Neurophysiol 81:1903-
1916. 
Rao SG, Williams GV, Goldman-Rakic PS (2000) Destruction and creation of 
spatial tuning by disinhibition: GABA(A) blockade of prefrontal cortical 
neurons engaged by working memory. J Neurosci 20:485-494. 
Rempel-Clower NL, Barbas H (1998) Topographic organization of connections 
between the hypothalamus and prefrontal cortex in the rhesus monkey. J 
Comp Neurol 398:393-419. 
Repantis D, Laisney O, Heuser I (2010) Acetylcholinesterase inhibitors and 
memantine for neuroenhancement in healthy individuals: a systematic 
review. Pharmacol Res 61:473-481. 
Richardson RT, DeLong MR (1986) Nucleus basalis of Meynert neuronal activity 
during a delayed response task in monkey. Brain Res 399:364-368. 
Ridley RM, Barefoot HC, Maclean CJ, Pugh P, Baker HF (1999) Different effects 
on learning ability after injection of the cholinergic immunotoxin 
ME20.4IgG-saporin into the diagonal band of Broca, basal nucleus of 
Meynert, or both in monkeys. Behav Neurosci 113:303-315. 
Rilling JK, Insel TR (1999) The primate neocortex in comparative perspective 
using magnetic resonance imaging. J Hum Evol 37:191-223. 
Robbins TW (2002) The 5-choice serial reaction time task: behavioural 
pharmacology and functional neurochemistry. Psychopharmacology (Berl) 
163:362-380. 
	  	  
84 
Rodriguez-Puertas R, Pascual J, Vilaro T, Pazos A (1997) Autoradiographic 
distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in 
Alzheimer's disease. Synapse 26:341-350. 
Rogers JH, Resibois A (1992) Calretinin and calbindin-D28k in rat brain: patterns 
of partial co-localization. Neuroscience 51:843-865. 
Roth G, Dicke U (2005) Evolution of the brain and intelligence. Trends Cogn Sci 
9:250-257. 
Rudy B, Fishell G, Lee S, Hjerling-Leffler J (2011) Three groups of interneurons 
account for nearly 100% of neocortical GABAergic neurons. Dev Neurobiol 
71:45-61. 
Rupniak NM, Samson NA, Tye SJ, Field MJ, Iversen SD (1991) Evidence against 
a specific effect of cholinergic drugs on spatial memory in primates. Behav 
Brain Res 43:1-6. 
Rylett RJ, Ball MJ, Colhoun EH (1983) Evidence for high affinity choline transport 
in synaptosomes prepared from hippocampus and neocortex of patients 
with Alzheimer's disease. Brain Res 289:169-175. 
Saar D, Grossman Y, Barkai E (2001) Long-lasting cholinergic modulation 
underlies rule learning in rats. J Neurosci 21:1385-1392. 
Sadot E, Gurwitz D, Barg J, Behar L, Ginzburg I, Fisher A (1996) Activation of m1 
muscarinic acetylcholine receptor regulates tau phosphorylation in 
transfected PC12 cells. J Neurochem 66:877-880. 
Salat DH, Kaye JA, Janowsky JS (2001) Selective preservation and degeneration 
within the prefrontal cortex in aging and Alzheimer disease. Arch Neurol 
58:1403-1408. 
Sarter M, Parikh V, Howe WM (2009) Phasic acetylcholine release and the 
volume transmission hypothesis: time to move on. Nat Rev Neurosci 
10:383-390. 
Sawaguchi T, Iba M (2001) Prefrontal cortical representation of visuospatial 
working memory in monkeys examined by local inactivation with muscimol. 
J Neurophysiol 86:2041-2053. 
Sawaguchi T, Matsumura M, Kubota K (1989) Depth distribution of neuronal 
activity related to a visual reaction time task in the monkey prefrontal 
cortex. J Neurophysiol 61:435-446. 
Schilstrom B, Svensson HM, Svensson TH, Nomikos GG (1998) Nicotine and 
food induced dopamine release in the nucleus accumbens of the rat: 
putative role of alpha7 nicotinic receptors in the ventral tegmental area. 
Neuroscience 85:1005-1009. 
Schoenemann PT, Sheehan MJ, Glotzer LD (2005) Prefrontal white matter 
volume is disproportionately larger in humans than in other primates. Nat 
Neurosci 8:242-252. 
Schwartz ML, Goldman-Rakic PS (1984) Callosal and intrahemispheric 
connectivity of the prefrontal association cortex in rhesus monkey: relation 
between intraparietal and principal sulcal cortex. J Comp Neurol 226:403-
420. 
Seeman P, Niznik HB (1990) Dopamine receptors and transporters in Parkinson's 
disease and schizophrenia. FASEB J 4:2737-2744. 
	  	  
85 
Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer's disease at 25 
years. EMBO Mol Med 8:595-608. 
Serra L, Perri R, Cercignani M, Spano B, Fadda L, Marra C, Carlesimo GA, 
Caltagirone C, Bozzali M (2010) Are the behavioral symptoms of 
Alzheimer's disease directly associated with neurodegeneration? J 
Alzheimers Dis 21:627-639. 
Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, Dunstan R, 
Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate 
S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber 
T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch 
RM, Sandrock A (2017) Addendum: The antibody aducanumab reduces 
Abeta plaques in Alzheimer's disease. Nature 546:564. 
Shafi M, Zhou Y, Quintana J, Chow C, Fuster J, Bodner M (2007) Variability in 
neuronal activity in primate cortex during working memory tasks. 
Neuroscience 146:1082-1108. 
Shiozaki K, Iseki E (2004) Decrease in GTP-sensitive high affinity agonist binding 
of muscarinic acetylcholine receptors in autopsied brains of dementia with 
Lewy bodies and Alzheimer's disease. J Neurol Sci 223:145-148. 
Slack BE, Breu J, Petryniak MA, Srivastava K, Wurtman RJ (1995) Tyrosine 
phosphorylation-dependent stimulation of amyloid precursor protein 
secretion by the m3 muscarinic acetylcholine receptor. J Biol Chem 
270:8337-8344. 
Smiley JF, Mesulam MM (1999) Cholinergic neurons of the nucleus basalis of 
Meynert receive cholinergic, catecholaminergic and GABAergic synapses: 
an electron microscopic investigation in the monkey. Neuroscience 
88:241-255. 
Smiley JF, Morrell F, Mesulam MM (1997) Cholinergic synapses in human 
cerebral cortex: an ultrastructural study in serial sections. Exp Neurol 
144:361-368. 
Smiley JF, Subramanian M, Mesulam MM (1999) Monoaminergic-cholinergic 
interactions in the primate basal forebrain. Neuroscience 93:817-829. 
Sofi F, Cesari F, Abbate R, Gensini GF, Casini A (2008) Adherence to 
Mediterranean diet and health status: meta-analysis. BMJ 337:a1344. 
Song D, Opris I, Chan RH, Marmarelis VZ, Hampson RE, Deadwyler SA, Berger 
TW (2012) Functional connectivity between Layer 2/3 and Layer 5 neurons 
in prefrontal cortex of nonhuman primates during a delayed match-to-
sample task. Conf Proc IEEE Eng Med Biol Soc 2012:2555-2558. 
Soreq H, Seidman S (2001) Acetylcholinesterase--new roles for an old actor. Nat 
Rev Neurosci 2:294-302. 
Spencer DGL, H. (1983) Effects of anticholinergic drugs on learning and memory. 
Drug Development Research 3:489-502. 
Spinelli S, Ballard T, Feldon J, Higgins GA, Pryce CR (2006) Enhancing effects of 
nicotine and impairing effects of scopolamine on distinct aspects of 
performance in computerized attention and working memory tasks in 
marmoset monkeys. Neuropharmacology 51:238-250. 
	  	  
86 
Srivastava ED, Russell MA, Feyerabend C, Masterson JG, Rhodes J (1991) 
Sensitivity and tolerance to nicotine in smokers and nonsmokers. 
Psychopharmacology (Berl) 105:63-68. 
Stanton GB, Bruce CJ, Goldberg ME (1993) Topography of projections to the 
frontal lobe from the macaque frontal eye fields. J Comp Neurol 330:286-
301. 
Stewart DJ, MacFabe DF, Vanderwolf CH (1984) Cholinergic activation of the 
electrocorticogram: role of the substantia innominata and effects of 
atropine and quinuclidinyl benzilate. Brain Res 322:219-232. 
Stocchi F, Brusa L (2000) Cognition and emotion in different stages and subtypes 
of Parkinson's disease. J Neurol 247 Suppl 2:II114-121. 
Sun Y, Yang Y, Galvin VC, Yang S, Arnsten AF, Wang M (2017) Nicotinic 
alpha4beta2 Cholinergic Receptor Influences on Dorsolateral Prefrontal 
Cortical Neuronal Firing during a Working Memory Task. J Neurosci 
37:5366-5377. 
Suzuki M, Gottlieb J (2013) Distinct neural mechanisms of distractor suppression 
in the frontal and parietal lobe. Nat Neurosci 16:98-104. 
Takacs VT, Freund TF, Nyiri G (2013) Neuroligin 2 is expressed in synapses 
established by cholinergic cells in the mouse brain. PLoS One 8:e72450. 
Takeuchi D, Hirabayashi T, Tamura K, Miyashita Y (2011) Reversal of 
interlaminar signal between sensory and memory processing in monkey 
temporal cortex. Science 331:1443-1447. 
Tamura M, Spellman TJ, Rosen AM, Gogos JA, Gordon JA (2017) Hippocampal-
prefrontal theta-gamma coupling during performance of a spatial working 
memory task. Nat Commun 8:2182. 
Thiele A (2013) Muscarinic signaling in the brain. Annu Rev Neurosci 36:271-
294. 
Thiele A, Delicato LS, Roberts MJ, Gieselmann MA (2006) A novel electrode-
pipette design for simultaneous recording of extracellular spikes and 
iontophoretic drug application in awake behaving monkeys. J Neurosci 
Methods 158:207-211. 
Thomas RL, Mistry R, Langmead CJ, Wood MD, Challiss RA (2008) G protein 
coupling and signaling pathway activation by m1 muscarinic acetylcholine 
receptor orthosteric and allosteric agonists. J Pharmacol Exp Ther 
327:365-374. 
Timmermann DB, Gronlien JH, Kohlhaas KL, Nielsen EO, Dam E, Jorgensen TD, 
Ahring PK, Peters D, Holst D, Christensen JK, Malysz J, Briggs CA, 
Gopalakrishnan M, Olsen GM (2007) An allosteric modulator of the alpha7 
nicotinic acetylcholine receptor possessing cognition-enhancing properties 
in vivo. J Pharmacol Exp Ther 323:294-307. 
Trubatch J, Van Harreveld A (1972) Spread of iontophoretically injected ions in a 
tissue. J Theor Biol 36:355-366. 
Turchi J, Saunders RC, Mishkin M (2005) Effects of cholinergic deafferentation of 
the rhinal cortex on visual recognition memory in monkeys. Proc Natl Acad 
Sci U S A 102:2158-2161. 
Uhlhaas PJ, Singer W (2010) Abnormal neural oscillations and synchrony in 
schizophrenia. Nat Rev Neurosci 11:100-113. 
	  	  
87 
Umbriaco D, Watkins KC, Descarries L, Cozzari C, Hartman BK (1994) 
Ultrastructural and morphometric features of the acetylcholine innervation 
in adult rat parietal cortex: an electron microscopic study in serial sections. 
J Comp Neurol 348:351-373. 
Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, 
Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, 
Mailman RB (2007) Functional selectivity and classical concepts of 
quantitative pharmacology. J Pharmacol Exp Ther 320:1-13. 
Uslaner JM, Eddins D, Puri V, Cannon CE, Sutcliffe J, Chew CS, Pearson M, 
Vivian JA, Chang RK, Ray WJ, Kuduk SD, Wittmann M (2013) The 
muscarinic M1 receptor positive allosteric modulator PQCA improves 
cognitive measures in rat, cynomolgus macaque, and rhesus macaque. 
Psychopharmacology (Berl) 225:21-30. 
van Kerkoerle T, Self MW, Roelfsema PR (2017) Layer-specificity in the effects of 
attention and working memory on activity in primary visual cortex. Nat 
Commun 8:13804. 
Vannucchi MG, Goldman-Rakic PS (1991) Age-dependent decrease in the 
affinity of muscarinic M1 receptors in neocortex of rhesus monkeys. Proc 
Natl Acad Sci U S A 88:11475-11479. 
Vigneswaran G, Kraskov A, Lemon RN (2011) Large identified pyramidal cells in 
macaque motor and premotor cortex exhibit "thin spikes": implications for 
cell type classification. J Neurosci 31:14235-14242. 
Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AF (2007) 
Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged 
in working memory. Nat Neurosci 10:376-384. 
Walker AE (1940) A cytoarchitectural study of the prefrontal area of the macaque 
monkey. Journal of Comparative Neurology 73:59-86. 
Wallace TL, Bertrand D (2013) Importance of the nicotinic acetylcholine receptor 
system in the prefrontal cortex. Biochem Pharmacol 85:1713-1720. 
Walters CL, Brown S, Changeux JP, Martin B, Damaj MI (2006) The beta2 but 
not alpha7 subunit of the nicotinic acetylcholine receptor is required for 
nicotine-conditioned place preference in mice. Psychopharmacology (Berl) 
184:339-344. 
Wang XJ, Tegner J, Constantinidis C, Goldman-Rakic PS (2004) Division of labor 
among distinct subtypes of inhibitory neurons in a cortical microcircuit of 
working memory. Proc Natl Acad Sci U S A 101:1368-1373. 
Wang Y, Markram H, Goodman PH, Berger TK, Ma J, Goldman-Rakic PS (2006) 
Heterogeneity in the pyramidal network of the medial prefrontal cortex. Nat 
Neurosci 9:534-542. 
Wang Y, Toledo-Rodriguez M, Gupta A, Wu C, Silberberg G, Luo J, Markram H 
(2004) Anatomical, physiological and molecular properties of Martinotti 
cells in the somatosensory cortex of the juvenile rat. J Physiol 561:65-90. 
Wang YY, Wang S, Zheng W, Zhong BL, Ng CH, Ungvari GS, Wang CX, Xiang 
YT, Li XH (2019) Cognitive functions in smoking and non-smoking patients 
with schizophrenia: A systematic review and meta-analysis of comparative 
studies. Psychiatry Res 272:155-163. 
	  	  
88 
Watanabe Y, Funahashi S (2004) Neuronal activity throughout the primate 
mediodorsal nucleus of the thalamus during oculomotor delayed-
responses. I. Cue-, delay-, and response-period activity. J Neurophysiol 
92:1738-1755. 
Weinberger DR, Berman KF, Zec RF (1986) Physiologic dysfunction of 
dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood 
flow evidence. Arch Gen Psychiatry 43:114-124. 
Wenk GL, Stoehr JD, Quintana G, Mobley S, Wiley RG (1994) Behavioral, 
biochemical, histological, and electrophysiological effects of 192 IgG-
saporin injections into the basal forebrain of rats. J Neurosci 14:5986-
5995. 
Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR (1982) 
Alzheimer's disease and senile dementia: loss of neurons in the basal 
forebrain. Science 215:1237-1239. 
Wiley RG, Oeltmann TN, Lappi DA (1991) Immunolesioning: selective destruction 
of neurons using immunotoxin to rat NGF receptor. Brain Res 562:149-
153. 
Williams DK, Wang J, Papke RL (2011) Positive allosteric modulators as an 
approach to nicotinic acetylcholine receptor-targeted therapeutics: 
advantages and limitations. Biochem Pharmacol 82:915-930. 
Wilson DA (2001) Scopolamine enhances generalization between odor 
representations in rat olfactory cortex. Learn Mem 8:279-285. 
Wilson FA, O'Scalaidhe SP, Goldman-Rakic PS (1994) Functional synergism 
between putative gamma-aminobutyrate-containing neurons and 
pyramidal neurons in prefrontal cortex. Proc Natl Acad Sci U S A 91:4009-
4013. 
Woo TU, Whitehead RE, Melchitzky DS, Lewis DA (1998) A subclass of 
prefrontal gamma-aminobutyric acid axon terminals are selectively altered 
in schizophrenia. Proc Natl Acad Sci U S A 95:5341-5346. 
Yang Y, Paspalas CD, Jin LE, Picciotto MR, Arnsten AF, Wang M (2013) 
Nicotinic alpha7 receptors enhance NMDA cognitive circuits in dorsolateral 
prefrontal cortex. Proc Natl Acad Sci U S A 110:12078-12083. 
Young ME, Ohm DT, Dumitriu D, Rapp PR, Morrison JH (2014) Differential 
effects of aging on dendritic spines in visual cortex and prefrontal cortex of 
the rhesus monkey. Neuroscience 274:33-43. 
Zaborszky L (2002) The modular organization of brain systems. Basal forebrain: 
the last frontier. Prog Brain Res 136:359-372. 
Zaborszky L, Csordas A, Mosca K, Kim J, Gielow MR, Vadasz C, Nadasdy Z 
(2015) Neurons in the basal forebrain project to the cortex in a complex 
topographic organization that reflects corticocortical connectivity patterns: 
an experimental study based on retrograde tracing and 3D reconstruction. 
Cereb Cortex 25:118-137. 
Zaborszky L, Gaykema RP, Swanson DJ, Cullinan WE (1997) Cortical input to 
the basal forebrain. Neuroscience 79:1051-1078. 
Zhao LN, Long H, Mu Y, Chew LY (2012) The toxicity of amyloid beta oligomers. 
Int J Mol Sci 13:7303-7327. 
	  	  
89 
Zhou YD, Fuster JM (1996) Mnemonic neuronal activity in somatosensory cortex. 
Proc Natl Acad Sci U S A 93:10533-10537. 
Zilles K, Schroder H, Schroder U, Horvath E, Werner L, Luiten PG, Maelicke A, 
Strosberg AD (1989) Distribution of cholinergic receptors in the rat and 
human neocortex. EXS 57:212-228. 
Zmarowski A, Sarter M, Bruno JP (2007) Glutamate receptors in nucleus 
accumbens mediate regionally selective increases in cortical acetylcholine 
release. Synapse 61:115-123. 
Zuchner T, Perez-Polo JR, Schliebs R (2004) Beta-secretase BACE1 is 
differentially controlled through muscarinic acetylcholine receptor 
signaling. J Neurosci Res 77:250-257. 
  
	  	  
90 
CHAPTER 2 – CHOLINERGIC OVERSTIMULATION ATTENUATES RULE 
SELECTIVITY IN MACAQUE PREFRONTAL CORTEX 
 
2.1 Introduction 
 Acetylcholine (ACh) is central to optimal cognitive performance in primates 
(Ballinger et al., 2016). Lesions of the basal forebrain nuclei, which provide 
corticopetal cholinergic innervation in primates (Mesulam et al., 1983), cause 
deficits in a variety of contexts, including acquisition of visual discriminations 
(Ridley et al., 1984), shifting of spatial attention (Voytko et al., 1994), and 
mnemonic tasks such as delayed match-to-sample (Aigner et al., 1991). The 
importance of prefrontal cholinergic tone was delineated by Croxson et al. (2011), 
who tested macaques on a variety of tasks after cholinergic deafferentation of 
prefrontal cortex (PFC). Ablation of cholinergic neurons revealed selective, delay-
dependent deficits in spatial working memory performance, but not in other PFC-
dependent behavioural tasks. 
 Extensive degeneration of cholinergic neurons is also a hallmark of 
Alzheimer's disease (Whitehouse et al., 1982). Cholinesterase inhibitors are the 
mainstay of pharmacological treatment, but their efficacy has been questioned 
(Amenta et al., 2001). Alternative measures of enhancing cholinergic stimulation 
are being investigated as treatment strategies (Caccamo et al., 2009; Foucault-
Fruchard and Antier, 2017). For example, recent evidence indicates that 
intermittent electrical stimulation of the basal forebrain cholinergic nuclei is 
beneficial to working memory performance (Liu et al., 2017). In addition, 
advancements in the design of cholinergic agonists allow researchers to 
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dissociate the actions of specific receptor subtypes (Bubser et al., 2012; Ferreira-
Vieira et al., 2016). Although cholinergic stimulation has shown some promise in 
improving cognitive performance in macaques (Buccafusco and Terry, 2004; 
Tsukada et al., 2004) and Alzheimer's disease patients (Bodick et al., 1997), its 
influence on local PFC neurophysiology has been less examined in primates 
(Inoue et al., 1983; Sawaguchi and Matsumura, 1985). 
 Previously, we examined the role of muscarinic receptors in macaque 
dorsolateral PFC (DLPFC) by iontophoretically applying the general muscarinic 
receptor antagonist scopolamine during performance of a conditional saccade 
task, in which subjects made a saccade toward a peripheral stimulus 
(prosaccade) or made an antisaccade away from a stimulus, depending on a 
previous instruction cue (Major et al., 2015). This cognitive control task, which 
incorporates working memory for task rules, prepotent response inhibition, and 
flexible stimulus–response associations, is sensitive to DLPFC integrity (Pierrot-
Deseilligny et al., 2003; Condy et al., 2007; Hussein et al., 2014). Moreover, 
deficits in antisaccade performance are a reliable indicator of prefrontal 
dysfunction in neuropsychiatric disorders, including Alzheimer's disease and 
schizophrenia (Fukushima et al., 1994; Kaufman et al., 2010). Iontophoretic 
blockade of muscarinic receptors resulted in general inhibition of prefrontal 
neuron activity and decreased selectivity related to rule, stimulus, and response 
encoding (Major et al., 2015), exemplifying the cortical basis of cognitive deficits 
following pharmacological insults to the cholinergic system (Klinkenberg and 
Blokland, 2010). Here, we explored the neurophysiological consequences of 
locally stimulating cholinergic receptors in macaque DLPFC using the general 
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cholinergic agonist carbachol. Carbachol is a cholinomimetic, more resistant to 
cholinesterase-mediated breakdown than ACh, and therefore hypothesized to 
have longer-lasting effects than ACh (Rosenberry et al., 2008). Extensively 
explored for its effects on neuronal physiology, carbachol results in the 
generation of graded persistent activity in rodent entorhinal cortical neurons 
(Egorov et al., 2002) and augments gamma oscillations in the mouse medial 
PFC, which are associated with working memory performance (Pafundo et al., 
2013). Based on our previous results (Major et al., 2015), and other studies which 
found that stimulation of DLPFC nicotinic receptor subtypes enhanced spatial 
working memory representations (Yang et al., 2013; Sun et al., 2017), we 
hypothesized that iontophoretic application of carbachol in macaque DLPFC 
would increase neuronal discharge rates and augment neuronal representation of 
task attributes during performance of prosaccades and antisaccades. 
 We found that carbachol had complex effects on DLPFC neuronal 
excitability, increasing discharge rates in putative pyramidal neurons. Contrary to 
our hypothesis, cholinergic stimulation of DLPFC disrupted neuronal 
representation of task rules in working memory and diminished saccade direction 
selectivity in putative pyramidal neurons. Our findings indicate that continuous 
pharmacological stimulation of the DLPFC cholinergic system is detrimental to 
cognitive performance. 
 
2.2 Materials and Methods 
  Experimental procedures were performed on two adult male macaque 
monkeys (Macaca mulatta; age 8–11 years, weight 9–12 kg) in accordance with 
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the Canadian Council of Animal Care policy and a protocol approved by the 
Animal Care Committee of the University of Western Ontario Council on Animal 
Care. These two monkeys were previously the subjects of other published 
studies, including iontophoretic investigations of muscarinic blockade (Major et 
al., 2015), dopaminergic receptors (Vijayraghavan et al., 2016), and a 
multielectrode investigation of the systemic effects of ketamine on prefrontal 
cortex (Skoblenick and Everling, 2012, 2014; Ma et al., 2015; Skoblenick et al., 
2016). Both animals had a plastic head restraint and plastic recording chambers 
implanted above their right lateral PFC as described previously (Skoblenick and 
Everling, 2012). 
 
2.2.1 Behavioural task 
  The behavioural task and physiological techniques are similar to those 
described in previous reports (Major et al., 2015; Vijayraghavan et al., 2016). 
Briefly, animals performed a variant of the prosaccade and antisaccade task 
(Everling et al., 1998), in which the task rule had to be maintained in working 
memory (Fig. 2.1A). After the monkey fixates on a central white spot (0.2°, 300 
ms, fixation window 4° × 4°), this fixation spot briefly changed colour to red or 
green (100 ms), indicating the task rule, before reverting to white. The rule cue 
had to be maintained in working memory, while the subject maintained fixation 
over the delay period (800–1300 ms). Subsequently, the fixation spot 
disappeared and after a brief gap period (150–300 ms) a peripheral stimulus was 
presented pseudorandomly to the left or right of the fixation spot (17° 
eccentricity). Subjects had to make the appropriate saccade, specified by the 
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current rule, either toward (prosaccade) or away from (antisaccade) the stimulus 
within 500 ms to receive liquid reward. Task, behaviour monitoring, and reward 
delivery were controlled using CORTEX (National Institutes of Mental Health). 
The gap period was used to increase task difficulty (Everling et al., 1998). Rule 
colours were counterbalanced between subjects and rule/stimulus combinations 
were presented in pseudorandom order. 
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Figure 2.1  
Experimental paradigm and single neuron recording with concurrent 
iontophoresis. 
A, After central fixation, a green or red cue was flashed, signifying a prosaccade 
or antisaccade trial, respectively. This task rule was maintained over an 800–
1300 ms delay and a short gap. Monkeys then performed a saccade toward 
(prosaccade) or away from (antisaccade) the peripheral stimulus to receive liquid 
reward. Dashed circles represent gaze of the animal and white arrows represent 
saccade direction. ITI, Intertrial interval. B, Single neuron extracellular recordings 
were performed in the right dorsolateral prefrontal cortices of two rhesus 
macaques. Custom-made glass iontophoretic electrodes were used to eject 
general cholinergic receptor agonist carbachol onto neurons. Beige area 
represents recording locus. AC, Arcuate sulcus; PS, principal sulcus. C, Effect of 
carbachol on discharge rate over experiment time course. Left, Discharge rate of 
an example neuron is shown over the course of the recording. This neuron was 
inhibited during application of carbachol (shaded gray). Right, Carbachol 
application excited neuronal discharge rate of a different example neuron. 
Discharge rates were derived from 1 s bins and smoothed with a 200 s width. 
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2.2.2 Neuronal recordings and pharmacology 
 Carbachol was iontophoretically administered using custom-made seven-
barreled glass iontophoretic electrodes, which were modified from the design of 
Millar and Williams (1989) and fabricated as described previously (Major et al., 
2015). Briefly, a 50 µm diameter tungsten wire (Midwest Tungsten Service), 
which served as the recording electrode, was electrochemically etched and 
inserted into the central capillary of a seven-barreled glass pipette (Friedrich and 
Dimmock). The glass was then pulled over the wire resulting in a multi-barrelled 
electrode with a fine tip (PMP107L-e Multipipette Puller, MicroData Instrument). 
Typical recording electrode impedances ranged from 0.5 to 1 MΩ (measured at 1 
kHz). Carbachol (carbamoylcholine chloride; Tocris Bioscience; 100 mm in pH 3 
deionized water) was top-filled into the peripheral capillaries of the multi-barrelled 
glass and pushed pneumatically to the tip of the iontophoretic electrode. Drugs 
were ejected using a Neuro Phore BH-2 iontophoretic ejection system (Harvard 
Apparatus). Constant ejection currents (5–100 nA, median: 30 nA) were manually 
set and a retention current of −8 nA was used to prevent leakage of drug from the 
barrel when ejection currents were not applied. Current balancing was not used 
as drug ejection with such low current strengths typically does not stimulate 
neurons or create electrophysiological noise with the electrode design used here 
(Vijayraghavan et al., 2007). Previous iontophoretic studies have shown there is 
no effect of pH of the drug solution on neuronal discharge rate (Disney et al., 
2007; Vijayraghavan et al., 2007). Carbachol was used as a proxy for ACh due to 
its greater resistance to acetylcholinesterase-mediated breakdown (Rosenberry 
et al., 2008), which we hypothesized would result in more reliable stimulation of 
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cholinergic receptors. Carbachol has been shown to have slightly larger 
magnitudes and duration of effect than ACh in cat (Crawford et al., 1966) and rat 
cortex (Bassant et al., 1990). The electrode was mounted on a hydraulic 
micromanipulator (MO-95, Narishige Group) and lowered into DLPFC (Fig. 2.1B) 
through a 23-gauge dura-penetrating stainless steel guide tube. 
 Neuronal signals were amplified, digitized, and filtered (300 Hz–6 kHz, 
four-pole Bessel) with an OmniPlex Neural Data Acquisition System (Plexon). 
Neuron waveforms were sorted offline in principal component space (Offline 
Sorter, Plexon) and analyzed offline (MATLAB, MathWorks). Spike density 
functions were created by convolving spike trains with a 50 ms Gaussian 
activation function (Richmond et al., 1987). 
 We collected data from blocks of trials with no drug application (control 
condition), followed by drug delivery (drug condition). For some sessions, an 
additional recovery condition was collected after cessation of drug application. 
Conditions typically lasted longer than 10 min (Fig. 2.1C) and neurons with <8 
correct trials for each rule (prosaccade/antisaccade) and saccade direction 
(leftward/rightward) combination in any of the conditions were discarded from 
further analysis (n = 5). Behavioural effects are not usually expected with 
microiontophoretic drug application because the small amount of drug released 
does not spread to a large enough volume of cortical neuropil to affect behaviour, 
especially in areas of broad specialization like PFC (Vijayraghavan et al., 2007). 
 
2.2.3 Data analysis 
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 Discharge rate analyses were performed in several epochs over the 
course of the trial: “entire” trial epoch (1500 ms before to 1000 ms after stimulus 
onset), fixation epoch (0–200 ms after fixation onset), cue epoch (0–200 ms after 
coloured cue onset), and delay epoch (600 ms before to 70 ms after peripheral 
stimulus onset). Based on prior studies, this delay epoch is when PFC neurons 
are found to display maximal rule discriminability (Everling and DeSouza, 2005; 
Bongard and Nieder, 2010). We also analyzed the stimulus epoch (0–400 ms 
after peripheral stimulus onset), post-saccade epoch (0–400 ms after saccade 
onset), and intertrial interval (0–1000 ms after reward onset). We excluded 
neurons with very low discharge rates (<1 spike/s in both control and drug 
conditions) from the analysis as the low firing rates precluded reliable analysis of 
physiological effects of the drug. The task-selectivity profile of each included 
neuron was determined by performing an ANOVA on the trial discharge rates in 
the cue and delay epochs with two factors: drug condition and rule. Neurons with 
a significant main effect of rule or an interaction of rule and drug (p < 0.05) were 
classified as rule-selective neurons (“rule neurons”). Magnitude of rule selectivity 
was further quantified using area under the receiver operating characteristic 
curve (AUROC; 1000 steps; Green and Swets, 1966). AUROCs were computed 
from the mean discharge rates during the delay epoch for prosaccades and 
antisaccades. AUROC values range from 0 to 1. By convention, neurons showing 
higher activity (preference) for the prosaccade rule were deemed to possess 
AUROC values >0.5. The AUROC values for neurons with greater activity for the 
antisaccade rule would thus be <0.5 and were subtracted from 1, therefore 
reported AUROC values were for preferred versus nonpreferred rule. An AUROC 
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of 1 signified a completely selective neuron with nonoverlapping distributions of 
preferred and nonpreferred rule discharge rates. An AUROC of 0.5 signified a 
lack of rule discriminability, wherein preferred and nonpreferred rule discharge 
rate distributions completely overlapped. Analysis of task selectivity was also 
performed on the stimulus epoch with three-way ANOVA (factors: drug condition, 
rule, and peripheral stimulus direction), where neurons with a significant main 
effect of stimulus direction or a significant interaction between stimulus direction 
and condition were classified as “visual neurons”. These neurons significantly 
discriminated between peripheral stimuli on the left versus right side of the 
screen, regardless of trial rule. Similarly, discharge rates in the post-saccade 
epoch were explored with three-way ANOVA (factors: drug condition, rule, and 
saccade direction) to classify “saccade neurons”, with a significant main effect of 
saccade direction or significant interaction between saccade direction and drug 
condition. Activity of these neurons discriminated between leftward and rightward 
saccade directions. Selectivities of visual and saccade neurons were also 
quantified with AUROC between the contralateral and ipsilateral stimulus 
directions or saccade directions, respectively. AUROC data are reported for the 
preferred versus nonpreferred direction. Since a change in AUROC can be 
explained by changes in either the mean discharge rates or trial-to-trial discharge 
rate variances between trial types (e.g., prosaccade vs. antisaccade trials), 
neuronal reliability was measured with Fano factor: trialwise discharge rate 
variance divided by the mean. Fano factors for preferred and nonpreferred rule 
trials were determined separately then averaged together, as these two trials 
types intrinsically vary between each other in rule-selective neurons. 
	  	  
100 
 To compare discharge rate changes across task-selective neurons, mean 
discharge rates for preferred and nonpreferred trial types in the control and drug 
conditions were normalized as follows: 𝑥!"#$ = 𝑥! −   𝑥!"#𝑥!"# − 𝑥!"# 
The preferred and nonpreferred trial type would be the preferred rule and 
nonpreferred rule in the case of rule selectivity, and would be preferred and 
nonpreferred saccade direction in the case of saccade direction selectivity. xt is 
the mean discharge rate for a given trial type in control or drug (e.g., activity in 
control preferred rule trials); xmin and xmax are the minimum and maximum 
discharge rates among the four values: control preferred, control nonpreferred, 
drug condition preferred, and drug condition nonpreferred mean discharge rate; 
and xnorm is the normalized mean discharge rate for that given trial type (e.g., 
preferred rule trials in control condition). Relative contributions of changes in 
mean and variability of discharge rate on changes in neuronal selectivity were 
estimated for the population of rule-selective neurons with the following multiple 
linear regression model: Δ𝐴𝑈𝑅𝑂𝐶 =   𝛼 +   𝛽!Δ𝐹𝑅!"#$ + 𝛽!Δ𝐹𝑅!"!#$%& +   𝛽!Δ𝑉𝑎𝑟!"#$ +   𝛽!Δ𝑉𝑎𝑟!"!#$%& +   𝜀 
Here, ΔFRpref represents the carbachol-induced change in normalized discharge 
rate for the preferred rule between the control and carbachol conditions. β 
coefficients represent the slope between the respective predictor and change in 
AUROC when all other predictors are held constant. 
 We also performed an analysis of action potential waveforms to classify 
neuronal types (“broad-spiking” putative pyramidal neurons and “narrow-spiking” 
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putative nonpyramidal neurons), using methodology derived from previous 
studies (Mountcastle et al., 1969; Mitchell et al., 2007; Johnston et al., 2009). 
Action potential waveforms were extracted from the delay epoch during the 
control condition at a temporal resolution of 25 µs (40 kHz sampling frequency) 
and increased to 1 µs resolution with spline interpolation. After aligning to voltage 
trough and averaging all waveforms, duration from waveform trough (negative 
deflection) to peak (positive deflection) was measured. Neurons that did not show 
the typical shape of a downward trough, followed by a positive peak in voltage, 
were removed from further waveform analysis (n = 15; Jacob et al., 2013). A 
neuron was defined as a broad-spiking neuron (putative pyramidal neuron) if 
trough to peak duration was >270 µs (Johnston et al., 2009; Ma et al., 2015) and 
defined as a narrow-spiking neuron (putative nonpyramidal neuron) if trough to 
peak duration was <270 µs. 
 Wilcoxon rank sum test was used for determining significance of changes 
in discharge rate among individual neurons. Significance of changes in 
population discharge rate, Fano factor, and selectivity (AUROC) were determined 
using the Wilcoxon signed rank test. Fisher's exact test was used to determine 
whether excitability or suppression of discharge rate of task-selective neurons 
was contingent on trial preference (e.g., preference for prosaccades or 
antisaccades, or ipsilateral or contralateral saccade directions). To determine 
unimodality of the distribution of trough to peak durations of narrow- and broad-
spiking neurons, we performed Hartigan's Dip Test (Hartigan and Hartigan, 
1985). 
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2.3 Results 
 Extracellular recordings and microiontophoretic carbachol application were 
performed in 100 DLPFC neurons. After exclusion of neurons due to cutoff 
criteria (see Materials and Methods) 83 neurons (50 from Monkey T, 33 from 
Monkey O) over the course of 79 recording sessions remained for further 
analysis (37 from Monkey T, 42 from Monkey O). Throughout control and drug 
conditions, monkeys performed the prosaccade and antisaccade task (described 
in Materials and Methods). Recovery from drug effects was tested in 28 recording 
sessions. Although minute decreases in performance were observed for both 
prosaccade (correct performance; mean ± SEM; control: 95.1 ± 0.01%, 
carbachol: 93.4 ± 0.01%) and antisaccade trials (control: 90.7 ± 0.02%, 
carbachol: 88.0 ± 0.02%), this declining trend continued into the recovery 
condition (recovery prosaccade: 92.7 ± 0.01%, recovery antisaccade: 86.4 ± 
0.02%), and therefore was more likely a consequence of non-drug-related 
factors, such as waning motivation over the course of the experiment. Similarly, 
reaction times were longer in the carbachol condition (control prosaccade: 138 ± 
1 ms, carbachol prosaccade: 142 ± 1 ms; control antisaccade: 192 ± 3 ms, 
carbachol antisaccade: 194 ± 3 ms), but continued to increase in recovery 
conditions (recovery prosaccade: 144 ± 1 ms, recovery antisaccade: 196 ± 3 ms). 
 
2.3.1 Effect of carbachol on discharge rates 
 We examined the effects of microiontophoretic application of carbachol at 
various current doses on discharge rates of 83 prefrontal neurons. We found that 
carbachol had heterogeneous effects on population activity. Figure 2.2A shows 
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the mean discharge rate of each neuron in control (abscissa) and after drug 
application (ordinate). Carbachol application did not have a significant overall 
effect on population neuronal activity (p = 0.212, Wilcoxon signed rank test; 
median change in discharge rate of +0.4 spikes/s), although individual neurons 
were excited or suppressed. Of the 83 neurons, discharge rates of 41 neurons 
(49%) were significantly increased (entire epoch, p < 0.05; Wilcoxon rank sum 
test), 32 neurons (39%) were inhibited, and discharge rates of 10 neurons (12%) 
were unaffected after carbachol application (Fig. 2.2A). Further, change in 
population discharge rate was nonsignificant in every task epoch (fixation epoch: 
p = 0.241, cue: p = 0.124, delay: p = 0.238, stimulus: p = 0.256, post-saccade: p 
= 0.364, intertrial interval: p = 0.316; Wilcoxon signed rank test), indicating that 
the drug did not differentially affect discharge rate during a specific component of 
the task. 
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Figure 2.2  
Effects of carbachol on prefrontal neuron discharge rate. 
A, Discharge rates during control (abscissa) and carbachol application (ordinate) 
are plotted (filled circles: neurons significantly excited or inhibited by carbachol 
application; open circles: no significant effect of carbachol application; entire 
epoch, p < 0.05, Wilcoxon rank sum test). Dashed equality line is shown. Median 
change in discharge rate was +0.4 spikes/s, although discharge rates were not 
significantly affected by carbachol as a population (p = 0.212, Wilcoxon signed 
rank test). Inset, Pie chart with proportions of neurons that were significantly 
excited (red; n = 41, 49%), inhibited (blue; n = 32, 39%), or not affected (white; n 
= 10, 12%) by carbachol application. Discharge rates are calculated from 1500 
ms before stimulus onset to 1000 ms after stimulus onset. B, Bar charts depicting 
the mean trial discharge rates for two example neurons. Top, Increasing dose of 
carbachol progressively increased discharge rate of this neuron. Cessation of 
drug ejection resulted in a significant, partial recovery of discharge rate. All 
changes between sequential doses or recovery were significant. Bottom, In 
another neuron, increasing doses of carbachol resulted in gradually stronger 
inhibition of neuronal excitability. Partial recovery was observed. Statistical 
significances were determined by Wilcoxon ranked sum test with Holm-
Bonferroni correction for multiple comparisons. C, Population effects of carbachol 
dose are shown. Mean discharge rates during control, low (≤30 nA), and high 
(>30 nA) doses of carbachol (dose ranges based on median split of all applied 
doses) are shown for neurons that were significantly excited (top) or inhibited 
(bottom) by carbachol. In excited neurons, higher doses resulted in a further 
significant increase to discharge rate. Among suppressed neurons, higher doses 
of carbachol did not result in further suppression of discharge rate. Significance 
determined by Wilcoxon signed rank test with Holm–Bonferroni correction for 
multiple comparisons. D, Recovery of population discharge rates after cessation 
of carbachol application. Top, Neurons significantly excited by carbachol (p < 
0.05, Wilcoxon rank sum test) that were tested for recovery exhibited partial, 
albeit nonsignificant (p = 0.169) recovery after cessation of carbachol application. 
Bottom, Suppressed neurons did not recover discharge rates during our 
observed recovery condition. Error bars indicate SEM. In all panels, asterisks 
indicate significant (p < 0.05) comparisons with Holm–Bonferroni correction for 
multiple comparisons, where applicable. 
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  To further explore the heterogeneous effects of carbachol application on 
prefrontal neuronal activity, we examined 23 neurons on which successive doses 
of carbachol were applied, and wherein drug application resulted in a significant 
change (increase or decrease) in the discharge rate (entire epoch, p < 0.05; 
Wilcoxon rank sum test). Figure 2.2B demonstrates the effects of progressively 
increasing doses of carbachol on two of these DLPFC neurons that were excited 
and suppressed by cholinergic stimulation (top and bottom, respectively). 
Increasing doses of carbachol application on the neuron depicted in the top 
progressively and significantly increased discharge rate (control: 5.3 ± 0.1 
spikes/s; highest dose of carbachol: 14.2 ± 0.3 spikes/s). After cessation of drug 
application, there was significant partial recovery from carbachol-induced 
excitation, with neuronal discharge rate declining to 12.2 ± 0.2 spikes/s. However, 
carbachol application did not have an excitatory effect on all recorded neurons. 
This trend is illustrated by the neuron depicted in Figure 2.2B (bottom). This 
neuron was gradually suppressed after successive doses of carbachol (control: 
9.1 ± 0.2 spikes/s; highest dose of carbachol: 3.2 ± 0.1 spikes/s), followed by 
partial recovery of discharge rate (control: 8.0 ± 0.2 spikes/s). 
 We further analyzed effects of dose on discharge rates in the 23 
aforementioned neurons with multiple carbachol dose applications (13 excited, 10 
inhibited) by grouping doses into “low” and “high”, based on a median split of the 
applied dose range (median carbachol dose = 30 nA). Figure 2.2C shows the 
effects of low and high doses of carbachol on neurons that were excited (top) and 
inhibited (bottom) by drug application. Discharge rates of carbachol-excited 
neurons increased monotonically with carbachol dose. Low-dose application 
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caused significant increase in excitability compared with control, and high-dose 
application resulted in further increases to neuronal discharge rate (Fig. 2.2C, 
top; entire epoch). Carbachol-suppressed neurons, however, did not show 
monotonicity of suppression with drug dose (Fig. 2.2C, bottom). High-dose 
carbachol application (>30 nA) could not further suppress neuronal discharge 
rates. It is noteworthy that this was not due to a floor effect, as neurons still had 
substantial activity after high-dose application. 
  We tested 27 neurons (15 excited, 12 inhibited) for recovery from 
physiological effects after cessation of drug application. Figure 2.2D shows these 
data for neurons that were significantly excited (top) or inhibited (bottom) by 
carbachol application. Neurons that were excited by carbachol had a reduction in 
discharge rates after drug cessation, though not reaching significance, thus 
indicating partial recovery from drug effects (entire epoch, p = 0.169; Wilcoxon 
signed rank test). However, in neurons that were significantly suppressed, 
recoveries did not occur during our recording sessions of ∼10 min (p = 1). Thus, 
differential effects of carbachol on neuronal excitability were accompanied by 
different post-drug physiological effects. 
 
2.3.2 Effect of carbachol on task-selective neurons 
 Next, we examined the effects of cholinergic stimulation with carbachol on 
task selectivity of neurons in the prosaccade and antisaccade task. Our task 
involved retaining the specified rule in working memory, and we explored the 
effects of carbachol on working memory representation of the rule in prefrontal 
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neuronal activity (Everling and DeSouza, 2005). We identified task selectivity in 
prefrontal neurons using a two-way ANOVA with factors: rule (prosaccade or 
antisaccade trial) and drug condition (control or carbachol), using discharge rates 
during the delay epoch of the task. Based on the ANOVA, we classified 24 
neurons as possessing rule selectivity (rule neurons; significant main effect of 
rule or interaction of rule and drug). We assessed the magnitude of rule 
selectivity in this population with the AUROC metric (see Materials and Methods). 
Figure 2.3A displays an example neuron that had a greater delay epoch 
discharge rate in the control condition during antisaccade trials (17.4 ± 1.4 
spikes/s) compared with prosaccade trials (9.0 ± 1.3 spikes/s). Upon carbachol 
application, the baseline activity of this neuron was excited (fixation epoch control 
vs. carbachol discharge rate: p < 0.0001; Wilcoxon rank sum test) and selectivity 
for the task rule was decreased (carbachol antisaccade: 16.3 ± 0.8 spikes/s, 
carbachol prosaccade: 11.5 ± 0.8 spikes/s; control AUROC: 0.74, carbachol 
AUROC: 0.67). Another prefrontal neuron (Fig. 2.3B) displayed a preference for 
antisaccades during the control condition delay epoch (antisaccade: 11.2 ± 0.4 
spikes/s, prosaccade: 8.3 ± 0.3 spikes/s). Similar to the first example, this neuron 
was excited in the fixation (p < 0.0001) and delay epochs (control: 9.8 ± 0.2 
spikes/s, carbachol: 12.5 ± 0.1 spikes/s, p < 0.0001) after carbachol application 
and rule selectivity was diminished (control AUROC: 0.76, carbachol AUROC: 
0.59). 
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Figure 2.3  
Effect of carbachol application on two representative rule-selective prefrontal 
neurons. 
A, Rasters (top; each row of dots is from a single trial) and spike density 
functions (bottom; mean ± SEM) are shown for a neuron with preferentially higher 
discharge rate during antisaccade trials (red) compared with prosaccade trials 
(blue) during the delay epoch, before (left) and after (right) iontophoretic 
application of carbachol. Delay epoch is shaded in gray (see Materials and 
Methods). Qualitative schematic of main trial events is shown above. After 
carbachol application, this rule neuron increases delay epoch discharge rate and 
preference for antisaccade trials is reduced. Rasters and spike density functions 
are aligned to onset of peripheral stimulus. B, A neuron with selectivity for 
antisaccades during the delay epoch is shown. All colours and conventions like 
A. After carbachol application, discharge rate is increased, especially during 
prosaccade trials, and rule preference is diminished. 
	  	  
109 
 For the 24 rule neurons, we examined changes in population rule 
selectivity due to carbachol application (15 from Monkey T, 9 from Monkey O; 14 
prosaccade-preferring, 10 antisaccade-preferring). Figure 2.4A shows the 
population normalized spike density functions (mean ± SEM) of rule neurons 
before (left; blue: preferred rule, green: nonpreferred rule) and after carbachol 
application (right). Change in rule selectivity was quantified using AUROC. Figure 
2.4B shows the AUROCs for each rule neuron during control (abscissa) and 
carbachol conditions (ordinate). Although drug effects on selectivity of individual 
neurons varied, carbachol significantly decreased population rule selectivity (p = 
0.0397, Wilcoxon signed rank test; blue: prosaccade-rule-preferring, red: 
antisaccade-rule-preferring). We also examined Fano factor as a measure of trial-
to-trial variability of neuronal spike count. Fano factor was not significantly 
affected during application of carbachol (control: 2.7 ± 0.4, carbachol: 2.4 ± 0.3, p 
= 0.0675). As reduced rule AUROC can be due to either reduced difference in 
prosaccade versus antisaccade discharge rates or increased neuronal variability, 
we explored the relative contributions of changes in neuronal discharge rate and 
variability using multiple linear regression with four predictors: change in 
normalized preferred rule discharge rate, change in normalized nonpreferred rule 
discharge rate, change in preferred rule variance, and change in nonpreferred 
rule variance (see Materials and Methods). This multiple regression model was 
significant (F(4,19) = 25.56, p < 0.0001) with R2 = 0.843. As seen in Table 2.1, 
carbachol-induced change in normalized preferred and nonpreferred rule 
discharge rates and change in preferred rule variance were significant predictors 
of change in AUROC. Of these three factors, change in preferred and 
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nonpreferred rule discharge rate contributed the most to altered selectivity, as the 
magnitude of their β coefficients were much larger than that of preferred rule 
variance. 
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Figure 2.4  
Effects of carbachol on population rule selectivity. 
A, Mean normalized spike density functions of preferred (blue) and nonpreferred 
(green) rule trials for 24 DLPFC rule-selective neurons during control (left) and 
carbachol conditions (right) are shown. Neurons were identified as rule-selective 
by ANOVA (see Materials and Methods). Overall difference between discharge 
rates for preferred and nonpreferred rules diminished. B, Rule selectivity 
(measured by AUROC) is shown for each rule neuron during control (abscissa) 
and carbachol application (ordinate). Drug application significantly decreased 
selectivity of rule neurons, as quantified by AUROC (p = 0.0397, Wilcoxon signed 
rank test). Prosaccade-preferring and antisaccade-preferring rule neurons are 
represented in blue and red, respectively. Dashed equality line is shown. C, 
Change in normalized discharge rate during preferred rule trials for 24 rule 
neurons (abscissa) is compared with change in normalized discharge rate of 
nonpreferred rule trials (ordinate). Based on k-means cluster analysis (k = 2), two 
clusters of neurons were identified (labeled pink and orange; filled circles: 
neurons with decreased AUROC; open circles: neurons with increased AUROC) 
with centroids shown as black crosshairs. D, Dose-dependent effects on rule 
selectivity by carbachol. Mean delay epoch rule AUROCs are shown for seven 
rule neurons that were subject to both low (≤30 nA) and high doses (>30 nA) of 
carbachol (split by median of applied dose range). High doses of carbachol 
resulted in significant diminishment of delay epoch rule selectivity in this subset of 
rule neurons whereas low-dose carbachol did not. Significance determined by 
Wilcoxon signed rank test (p < 0.05; asterisk indicates significant comparison) 
with Holm–Bonferroni correction for multiple comparisons. 
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Table 2.1 
Summary of multiple linear regression analysis for rule-selective neurons. 𝛽 coefficients and p values from the multiple regression analysis (see Materials 
and Methods) are shown to asses the impact of four predictors on change in rule 
AUROC: Δ𝐹𝑅!"#$, change in mean normalized discharge rate during preferred 
rule trials; Δ𝐹𝑅!"!#$%&, change in mean normalized discharge rate during 
nonpreferred rule trials; Δ𝑉𝑎𝑟!"#$, change in normalized variance during preferred 
rule trials; Δ𝑉𝑎𝑟!"!"#$%, change in normalized variance during nonpreferred rule 
trials.   
 
  
Predictor of ΔAUROC β coefficient p
ΔFRpref 0.231 1.04E-7
ΔFRnonpref -0.193 9.32E-6
ΔVarpref -0.0494 0.0162
ΔVarnonpref 0.000602 0.983
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 We further explored the relative changes in preferred and nonpreferred 
discharge rate in Figure 2.4C. Change in normalized preferred discharge rate is 
plotted (abscissa) against change in normalized nonpreferred discharge rate 
(ordinate). Neurons in which carbachol application reduced or increased the 
AUROC are labeled with filled and unfilled circles, respectively. Because change 
in AUROC is largely determined by the change in preferred and nonpreferred 
discharge rate, neurons above the equality line (dark gray dashed line) generally 
experienced decreased AUROC and neurons below the line increased AUROC. 
We observed two distinct clusters of neurons (k-means clustering, k = 2; 
centroids shown as crosshairs), one of suppressed neurons (n = 10, 42%; 
labeled in purple), and one of excited neurons (n = 14, 58%; orange). Carbachol 
reduced selectivity of almost all suppressed neurons, although the change in 
selectivity did not reach significance (n = 10, p = 0.0840). This decreased 
selectivity was due to greater inhibition during preferred rule trials compared with 
nonpreferred rule trials. Carbachol had more equivocal effects on the AUROC of 
excited rule neurons (n = 14, p = 0.296). Some neurons decreased selectivity due 
to relatively greater excitation of nonpreferred rule (above equality line), and 
others increased selectivity due to greater excitation of preferred rule. Thus, 
carbachol both excited and suppressed discharge rate of rule neurons, often 
resulting in decreased selectivity, which can be attributed to either a relatively 
greater suppression of activity for preferred rules or a relatively greater increase 
in nonpreferred rule discharge rate. 
 Selectivity of prosaccade-preferring rule neurons (Fig. 2.4B, blue) were not 
significantly affected by carbachol (n = 14, p = 0.463), but selectivity of 
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antisaccade-preferring rule neurons (red) was significantly decreased (n = 10, p = 
0.0371). The preference of rule neurons for prosaccade or antisaccade did not 
have any bearing on whether rule neurons were excited or inhibited by carbachol 
(p = 0.421, Fisher's exact test). 
 In some rule neurons (n = 7), multiple doses of carbachol were applied 
(Fig. 2.4C). In these rule neurons, low doses (<30 nA) did not significantly change 
AUROC values (p = 0.688), but high doses (>30 nA) resulted in significant 
diminishment of rule selectivity (p = 0.0156). Thus, disruption of rule selectivity in 
the delay period by cholinergic stimulation is dose-dependent. 
 Unlike the disruptive effects on rule representation in the delay epoch, 
population rule selectivities were unaffected in the cue epoch (n = 11, p = 0.0830, 
Wilcoxon signed rank test; 4 prosaccade-preferring, 7 antisaccade-preferring), 
stimulus epoch (n = 25, p = 0.757; 11 prosaccade-preferring, 14 antisaccade-
preferring), and post-saccade epoch (n = 24, p = 0.265; 6 prosaccade-preferring, 
18 antisaccade-preferring). 
 We examined the effects of cholinergic stimulation on neurons with 
selectivity for other attributes observed in the task. We identified 19 prefrontal 
neurons that were selective for peripheral stimulus location during the stimulus 
epoch (8 contralateral-stimulus-preferring, 11 ipsilateral-stimulus-preferring). 
Additionally, 40 neurons were selective for the direction of saccade in the post-
saccade epoch (32 contralateral-saccade-preferring, 8 ipsilateral-saccade-
preferring). Carbachol application had equivocal effects on population selectivity 
of both peripheral stimulus direction (control vs. carbachol stimulus direction 
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AUROC: p = 0.968, Wilcoxon signed rank test) and for the saccade direction 
(control vs. carbachol saccade direction AUROC: p = 0.122). 
 
2.3.3 Effects of carbachol on putative pyramidal and nonpyramidal neurons 
 Past studies have reported that drug-induced modulation of discharge 
characteristics, signal-to-noise ratio, and coding of task attributes can be different 
between cortical neuronal classes (Mountcastle et al., 1969; Jacob et al., 2013; 
Ma et al., 2015; Thiele et al., 2016). To ascertain whether cholinergic stimulation 
had differential effects on putative pyramidal neurons and interneurons defined 
by electrophysiological characteristics, we performed a similar analysis, whereby 
we classified prefrontal neurons (n = 68; see Materials and Methods) as broad-
spiking (putative pyramidal neurons) or narrow-spiking (putative nonpyramidal 
neurons; see Materials and Methods; Johnston et al., 2009). The distribution of 
waveform trough to peak durations was not unimodal (Fig. 2.5A; p = 0.00910, 
Hartigans' Dip Test; Hartigan and Hartigan, 1985). Based on a previous study in 
our laboratory, neurons with a waveform trough to peak duration <270 µs were 
classified as narrow-spiking and neurons with a trough to peak duration >270 µs 
were classified as broad-spiking (Fig. 2.5B; green: mean narrow-spiking 
waveforms, pink: broad-spiking waveforms), yielding 21 narrow waveform 
neurons (31%) and 47 broad waveform neurons (69%). 
  
	  	  
117 
 
Figure 2.5  
Effects of carbachol on putative pyramidal and nonpyramidal neurons. 
Waveforms were extracted and trough to peak duration was measured in 68 
neurons (see Materials and Methods). A, Histogram of trough to peak durations. 
Trough to peak duration distribution was not unimodal as determined by 
Hartigans' Dip Test (p = 0.00910). Similar to previous reports, a threshold of 270 
µs (dashed line) was used to classify neuronal waveforms as narrow-spiking 
(green, putative nonpyramidal neurons) or broad-spiking (pink, putative pyramidal 
neurons). 30 µs bin width. B, Normalized waveforms aligned to initial trough 
(negative inflection) are shown with narrow-spiking (green) or broad-spiking 
(pink) label. C, Discharge rates among narrow-spiking neurons were not 
significantly affected by carbachol (entire epoch, p = 0.876, Wilcoxon signed rank 
test). Shown as filled circles, discharge rates of 8 neurons (38%) were 
significantly excited (p < 0.05, Wilcoxon rank sum test) and 10 (48%) were 
significantly suppressed. D, Broad-spiking neurons were significantly excited by 
carbachol (p = 0.0444, Wilcoxon signed rank test). Discharge rates of 27 neurons 
(57%) were significantly excited (p < 0.05, Wilcoxon rank sum test) and 16 (34%) 
were significantly suppressed. 
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 Discharge rates of narrow-spiking neurons were not significantly affected 
by carbachol application at the population level (Fig. 2.5C; entire epoch, p = 
0.876, Wilcoxon signed rank test). Population discharge rate of narrow-spiking 
neurons was not significantly excited or suppressed in any task epoch (fixation 
epoch: p = 0.639, cue: p = 0.664, delay: p = 0.931, stimulus: p = 0.986, post-
saccade: p = 0.848, intertrial interval: p = 0.903). In addition to the lack of 
significant effect on discharge rates, carbachol also did not affect the selectivity of 
task-selective narrow-spiking neurons for any task attributes, including rule 
selectivity during the delay and cue epochs, stimulus direction selectivity in the 
stimulus epoch, and saccade direction selectivity in the post-saccade epoch. 
 In contrast, we found that broad-spiking neurons were significantly excited 
by carbachol application at the population level (Fig. 2.5D; p = 0.0444), 
notwithstanding some individual neurons that were suppressed. Broad-spiking 
neurons were also significantly excited in the fixation, cue, delay, and stimulus 
epochs (p = 0.0235, p = 0.0163, p = 0.0490, p = 0.0455, respectively), but not in 
the post-saccade (p = 0.0865) or intertrial interval epochs (p = 0.0904). 
 Carbachol did not significantly affect selectivity of broad-spiking rule-
selective neurons in the cue or delay epochs, or broad-spiking visual neurons in 
the stimulus epoch. However, although we found that saccade direction 
selectivity in the population of 40 saccade neurons was not significantly changed 
by carbachol, we found that the subset of this population comprised of broad-
spiking neurons did show changes in population saccade selectivity. Figure 2.6A 
shows a prefrontal neuron with higher discharge rate for contralateral saccades 
(2.9 ± 0.4 spikes/s) than for ipsilateral saccades (1.8 ± 0.3 spikes/s) during the 
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post-saccade epoch, regardless of trial rule. Although the baseline activity of this 
neuron was not significantly excited (fixation epoch control vs. carbachol, p = 
0.06, Wilcoxon rank sum test) this neuron was excited in the post-saccade epoch 
(control: 2.4 ± 0.3 spikes/s, carbachol: 3.8 ± 0.2 spikes/s, p = 0.000415) and 
selectivity for saccade direction was reduced (control AUROC: 0.61, carbachol 
AUROC: 0.53). Population normalized spike density functions of broad-spiking 
saccade neurons show this augmentation of population discharge rates (Fig. 
2.6B). Analysis of saccade direction selectivity by AUROC (Fig. 2.6C; red: 
contralateral, n = 14; blue: ipsilateral, n = 4) revealed that carbachol application 
resulted in a small, but significant, decrease in population selectivity (mean 
control AUROC: 0.66 ± 0.02, mean carbachol AUROC: 0.62 ± 0.01, p = 0.0429; 
Wilcoxon signed rank test). We also examined Fano factor as a measure of trial-
to-trial variability of neuronal spike count. Fano factor was not significantly 
affected during application of carbachol (control: 1.5 ± 0.2, carbachol: 1.6 ± 0.2, p 
= 0.286). We explored the relative contributions of changes in neuronal discharge 
rate and variability in decreasing selectivity in broad-spiking saccade neurons 
using a multiple linear regression model similar to that used for rule neurons. This 
multiple regression model was significant (F(4,13) = 14.43, p = 0.000104) with R2 = 
0.816. Carbachol-induced change in normalized preferred and nonpreferred 
saccade direction discharge rates and change in preferred rule variance were 
significant predictors of change in AUROC (Table 2.2). Change in preferred and 
nonpreferred direction discharge rate contributed more to altered selectivity than 
change in preferred direction variance, as measured by their β coefficients. 
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Figure 2.6  
Effect of carbachol on saccade direction selectivity of broad-spiking, putative 
pyramidal neurons. 
A, Rasters (above) and spike density functions (bottom) aligned on saccade 
onset are shown for a neuron with preferentially higher discharge rate during 
contralateral saccade trials (green) compared with ipsilateral saccade trials 
(purple) during the post-saccade epoch is shown before (left) and after (right) 
iontophoretic application of carbachol. The post-saccade epoch is shaded in gray 
(see Materials and Methods). Qualitative schematic of main trial events is shown 
above. After carbachol application, this saccade neuron increased discharge rate 
in the post-saccade epoch, with a greater increase for ipsilateral trials, thereby 
reducing saccade direction selectivity. B, Mean normalized spike-density 
functions of preferred (blue) and nonpreferred (green) saccade trials for 18 
DLPFC saccade-direction-selective neurons during control (left) and carbachol 
conditions (right) are shown. C, Carbachol significantly decreased selectivity of 
broad-spiking saccade neurons, as quantified by AUROC (abscissa: control 
AUROC values, ordinate: drug AUROC values; n = 18, p = 0.0429, Wilcoxon 
signed rank test). Ipsilateral-saccade-preferring and contralateral-saccade-
preferring neurons are represented in blue and red, respectively. Dashed equality 
line is shown. D, Change in normalized discharge rate during preferred saccade 
direction trials of the 18 saccade neurons is compared with change in normalized 
discharge rate during nonpreferred saccade direction trials. Based on k-means 
cluster analysis (k = 2), two clusters of neurons are shown (pink and orange; filled 
circles: neurons with decreased AUROC, open circles: neurons with increased 
AUROC) with centroids shown as black crosshairs. 
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Table 2.2 
Summary of multiple linear regression analysis for broad-spiking saccade-
direction-selective neurons. 𝛽 coefficients and p values from the multiple regression analysis (see Materials 
and Methods) are shown to asses the impact of four predictors on change in 
saccade direction AUROC: Δ𝐹𝑅!"#$, change in mean normalized discharge rate 
during preferred saccade direction trials; Δ𝐹𝑅!"!#$%&, change in mean normalized 
discharge rate during nonpreferred saccade direction trials; Δ𝑉𝑎𝑟!"#$, change in 
normalized variance during preferred saccade direction trials; Δ𝑉𝑎𝑟!"!#$%&, 
change in normalized variance during nonpreferred saccade direction trials. 
 
  
Predictor of ΔAUROC β coefficient p
ΔFRpref 0.194 1.69E-5
ΔFRnonpref -0.144 0.00520
ΔVarpref -0.0599 0.00140
ΔVarnonpref 0.0195 0.414
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 We further explored the relative changes in preferred and nonpreferred 
discharge rate in Figure 2.6D. Neurons are labeled with filled and unfilled circles, 
indicating carbachol condition AUROC was less than or greater than control 
AUROC, respectively. Because change in AUROC is largely determined by these 
two variables, change in preferred and nonpreferred discharge rate, neurons 
above the equality line (dark gray dashed line) often had decreased AUROCs 
and neurons below the line, increased selectivity. Similar to the overall subset of 
broad-spiking neurons, saccade-direction-selective broad-spiking neurons were 
more often excited (n = 13, 72%; orange) by carbachol than suppressed (n = 5, 
28%; purple). Carbachol reduced selectivity of almost all excited neurons (n = 13, 
p = 0.0479). There was no relationship between whether a neuron was excited or 
suppressed by carbachol and whether it preferred ipsilateral or contralateral 
saccade (p = 1, Fisher's exact test). 
 Thus, carbachol-induced effects on saccade selectivity were found in 
broad-spiking, putative pyramidal neurons, but not in narrow-spiking, putative 
nonpyramidal neurons. Carbachol mostly excited discharge rate of broad-spiking 
saccade neurons, resulting in decreased selectivity, which can be attributed to 
relatively greater increase in nonpreferred saccade direction discharge rate. 
 
2.4 Discussion 
 In this study we examined the effects of localized cholinergic stimulation 
on primate DLPFC neurons engaged in a clinically relevant oculomotor task, 
which involved using a rule maintained in working memory to produce the 
appropriate saccadic responses to visual stimuli. Local carbachol application both 
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excited and suppressed DLPFC neurons. Surprisingly, we also found carbachol 
disrupted neuronal rule representation in working memory, due to either 
suppression of preferred rule activity or excitation of nonpreferred rule activity. 
Moreover, broad-spiking putative pyramidal neurons were excited after 
cholinergic agonist application, and postsaccadic directional selectivity in these 
neurons was attenuated largely due to preferentially increased activity for the 
nonpreferred saccade direction. 
 
2.4.1 Effect of carbachol on neuronal discharge rate in DLPFC 
 We found that local cholinergic stimulation excited a greater proportion of 
DLPFC neurons than those that were inhibited. However, our observation of both 
facilitation and inhibition with carbachol is consistent with previous iontophoretic 
applications of ACh in macaque DLPFC (Inoue et al., 1983; Sawaguchi and 
Matsumura, 1985), orbitofrontal (Aou et al., 1983), premotor (Nelson et al., 1973), 
motor (Matsumura et al., 1990), and primary visual cortex (V1; Soma et al., 
2012). Mixed effects of ACh on neuronal activity have also been observed in 
marmoset V1 (Roberts et al., 2005; Zinke et al., 2006), cat V1 (Sato et al., 1987), 
rat medial PFC (Pirch et al., 1992; Nagy et al., 2014), and in guinea pig cortical 
slices (McCormick and Prince, 1985). Intriguingly, Sawaguchi and Matsumura 
(1985) found that ACh-excited and ACh-inhibited DLPFC neurons were found in 
separate layers. 
 We also found that carbachol increased activity in putative pyramidal 
neurons, while having equivocal effects in putative interneurons. Heterogeneity in 
responses to carbachol on interneurons has also been reported previously in 
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rodent medial PFC (Pafundo et al., 2013), hippocampal slices (Zheng et al., 
2011), and insular cortical slices (Yamamoto et al., 2010). 
 
2.4.2 Effects of carbachol on task selectivity of DLPFC neurons 
 Systemic blockade of muscarinic receptors has detrimental effects on 
cognitive performance in a variety of tasks (Klinkenberg and Blokland, 2010), 
including spatial working memory. In macaque DLPFC, systemic injections of 
muscarinic antagonist scopolamine disrupted spatial working memory (Zhou et 
al., 2011), whereas local iontophoretic application strongly attenuated selectivity 
for all task attributes, including rule selectivity (Major et al., 2015). We therefore 
hypothesized that stimulation of DLPFC neuronal cholinergic receptors would 
augment the selectivity of rule representation in working memory. Contrary to our 
prediction, we found that carbachol reduced selectivity of rule neurons and broad-
spiking neurons with saccade direction selectivity. Selectivity of rule neurons was 
reduced by two different mechanisms: in carbachol-inhibited neurons, preferred 
rule activity was suppressed more than nonpreferred rule activity, whereas in 
carbachol-excited neurons, activity for the nonpreferred rule increased more than 
preferred. Additionally, carbachol decreased postsaccadic selectivity in putative 
pyramidal saccade-direction-selective neurons, due to greater increase in 
nonpreferred saccade direction activity. 
 Our results suggest that cholinergic stimulation can weaken DLPFC task 
representations. Herrero et al. (2008) examined cholinergic modulation and 
attentional enhancement in macaque V1. They found that lower dose ACh 
application increased neuronal activity and enhanced attentional modulation, 
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whereas at higher doses, attentional modulation was unaffected or even 
disrupted due to nonspecific increase in neuronal activity. Although we did not 
find systematic enhancement in rule selectivity at lower doses (Fig. 2.4D), 
disruption of rule at higher doses in carbachol-excited neurons agree with 
Herrero et al. (2008), wherein ceiling effects in increased excitability impaired 
task representation. Similarly, Zinke et al. (2006) found that ACh iontophoresis 
broadened orientation tuning of most ACh-excited neurons in marmoset V1, 
possibly due to ceiling effects in optimal stimulus-induced responses and 
increased activity to stimuli with nonpreferred orientations. Regardless of stimulus 
orientation, Sato et al. (1987) found that ACh increased stimulus-evoked 
responses in cat V1, resulting in no systematic effects on orientation selectivity. 
These findings from several groups suggest that cholinergic stimulation of cortical 
regions resulted in “inverted-U” dose-dependency of physiological effects on 
cortical neurons, whereby too little or too much ACh is detrimental to task 
performance and neuronal selectivity. This phenomenon has also been 
demonstrated in the dopaminergic system (Vijayraghavan et al., 2007). Our 
carbachol results may reflect the rightmost portion of a cholinergic inverted-U, 
whereby excessive cholinergic stimulation is disruptive to cognitive processing. 
Unlike the aforementioned investigations, we did not observe population 
enhancement of task-related selectivity during low-dose cholinergic stimulation. 
However, we cannot discount that the relative potency of carbachol compared 
with ACh may have precluded the potential observation of improvements in 
neuronal task-selectivity. Future experiments contrasting ACh and carbachol in 
the same paradigm may clarify this possibility. 
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 We found trial-to-trial variance was not significantly affected after 
carbachol. Moreover, regression analysis suggested that effects on trial 
discharge rate variability had less impact on rule selectivity relative to changes in 
activity. Similarly, Herrero et al. (2008) found that ACh-induced changes in Fano 
factor did not contribute to attentional modulation of macaque V1 neurons. 
 Recently, Liu et al. (2017) examined the effects of electrical stimulation of 
the macaque nucleus basalis during performance of a delayed match-to-sample 
task. Intriguingly, they found that continuous stimulation was detrimental to task 
performance, but intermittent stimulation resulted in significant improvement. Our 
results showing reduced task selectivity during continuous iontophoretic 
carbachol application in DLPFC suggest overstimulation of the cholinergic system 
can be detrimental to cognitive performance. 
 Because carbachol is a general cholinergic agonist, both nicotinic and 
muscarinic receptors could potentially mediate these effects on physiology and 
task selectivity. Previously it was reported that muscarinic receptor antagonism 
blocked the effects of ACh iontophoresis on orbitofrontal cortex (Aou et al., 1983) 
and DLPFC (Inoue et al., 1983). We found that carbachol inhibited a significant 
population of DLPFC neurons and disrupted rule selectivity in some neurons with 
activity suppression. Because nicotinic actions in macaque DLPFC reported 
heretofore were excitatory (Yang et al., 2013; Sun et al., 2017), the inhibitory 
actions of carbachol may be muscarinic. Indeed, muscarinic receptors can 
directly suppress prefrontal neurons via activation of G-protein coupled inward-
rectifying potassium or SK channels (Gulledge and Stuart, 2005). Although 
activation of nearby interneurons is another potential mechanism to inhibit 
	  	  
128 
neuronal activity (Disney and Aoki, 2008; Disney et al., 2014), we believe this is 
less likely as we did not observe significant excitation in narrow-spiking neurons, 
similar to previous reports (Gulledge et al., 2007; Pafundo et al., 2013). Further 
supporting a role of muscarinic receptors, and akin to previous studies applying 
ACh to DLPFC (Nelson et al., 1973; Sawaguchi and Matsumura, 1985), we 
generally found that carbachol effects had longer latencies of onset and partial 
recovery (seconds to minutes; Fig. 2.1C). This is inconsistent with fast ionotropic 
actions mediated by nicotinic receptors, since recoveries from nicotinic agonist 
stimulation are rapid (Disney et al., 2007). 
 However, we cannot discount nicotinic involvement in carbachol's actions 
reported here. Although nicotinic receptor stimulation can augment working 
memory activity in PFC (Yang et al., 2013; Sun et al., 2017) and can improve 
cognitive performance (Terry et al., 2015), other studies have shown that low 
doses of nicotinic antagonist enhanced attentional performance in rodents (Hahn 
et al., 2011) and improved delayed match-to-sample performance in monkeys 
(Terry et al., 1999). In the physiological context, Yang et al. (2013) showed that 
low-dose iontophoretic stimulation of α7 nicotinic receptors during oculomotor 
delayed responses increased macaque DLPFC neuronal excitability and 
improved memory period spatial tuning, whereas α7 receptor antagonist reduced 
delay period activity and spatial tuning. Moreover, high-dose α7 receptor 
stimulation eroded tuning due to general activity increase for nonpreferred spatial 
directions, similar to the effects on DLPFC task selectivity reported here. Sun et 
al. (2017), in the same paradigm, found that nicotinic α4β2 receptor stimulation 
strengthened delay period activity for preferred spatial locations, while, 
	  	  
129 
interestingly, having no effect on neurons with saccade direction selectivity 
(Wang et al., 2004). Because we found that carbachol disrupted saccade 
direction selectivity of putative pyramidal cells, this suggests muscarinic receptors 
mediate carbachol's effects on postsaccadic activity. Notably, carbachol has a 
lower affinity and channel opening rate constant for nicotinic receptors than ACh 
(Akk and Auerbach, 1999). Thus, both muscarinic and nicotinic mechanisms may 
have contributed to carbachol's actions. Future experiments examining these 
receptor families with subtype-specific compounds will be necessary to delineate 
the signaling mechanisms that mediate the actions of carbachol on PFC task-
related activity reported here. 
 The data reported here and previously (Major et al., 2015; Liu et al., 2017), 
suggest that continuous cholinergic receptor stimulation or blockade can be 
detrimental to prefrontal neuronal representations in cognitive tasks. Endogenous 
ACh is transiently released with high temporal precision (Parikh et al., 2007; 
Sarter et al., 2009) and continuous stimulation of cholinergic receptors may not 
be beneficial to cognitive performance (Bentley et al., 2011). Subtype-selective 
cholinergic agonists are being actively investigated to ameliorate cognitive 
dysfunction in neuropsychiatric disorders, including Alzheimer's disease and 
schizophrenia (Bodick et al., 1997; Wienrich et al., 2002; Shekhar et al., 2008). 
Our findings offer a cautionary note and suggest that general cholinergic 
stimulation using pharmacology may in fact be detrimental to cognitive functions. 
Future work with more selective agonists may shed light on which downstream 
signaling mechanisms are beneficial in treatment of cognitive dysfunction. 
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CHAPTER 3 – MUSCARINIC M1 RECEPTOR OVERSTIMULATION DISRUPTS 
WORKING MEMORY ACTIVITY FOR RULES IN PRIMATE PREFRONTAL 
CORTEX 
 
3.1 Introduction 
 Corticopetal innervation of the prefrontal cortex (PFC) by the basal 
forebrain cholinergic system has a critical modulatory role in cognition and 
controlled behaviour (Croxson et al., 2011, Mesulam, 2013). Acetylcholine (ACh), 
through synaptic specializations and volume transmission (Mrzljak et al., 1995), 
acts on pre- and postsynaptic cholinergic receptors to influence cortical function 
in a variety of contexts, including working memory (WM; Croxson et al., 2011, 
Zhou et al., 2011) and attentional gating of visual stimuli (Herrero et al., 2008, 
Parikh et al., 2007). ACh exerts its influence through ionotropic nicotinic (Picciotto 
et al., 2012) and metabotropic muscarinic receptors (Thiele, 2013). The 
dorsolateral PFC (DLPFC) is a crucial node in a network of areas involved in 
higher-order cognitive functions, including WM (Fuster and Alexander, 1971), 
attentional processing (Miller and Cohen, 2001), maintenance of abstract rules to 
guide responses (Everling and DeSouza, 2005, Wallis et al., 2001), and inhibition 
of inappropriate responses (Condy et al., 2007). Dysfunction of the PFC 
accompanies many disorders of cognition (Arnsten et al., 2012), and cholinergic 
system pathology is widely implicated in the etiology of psychiatric disorders with 
cognitive pathology, including Alzheimer’s disease (Mesulam, 2013) and 
schizophrenia (Carruthers et al., 2015). 
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  While behavioural studies have established that muscarinic receptor 
blockade is detrimental to cognition (Klinkenberg and Blokland, 2010), and to 
specific PFC executive functions (Chudasama et al., 2004, Zhou et al., 2011), the 
downstream mechanisms by which muscarinic actions regulate PFC function and 
receptor subtype contributions thereof remain poorly understood. Both cholinergic 
deafferentation of PFC (Croxson et al., 2011) and systemic injections of the 
general muscarinic antagonist scopolamine (Zhou et al., 2011) cause spatial WM 
performance deficits in monkeys. We have previously reported that iontophoretic 
application of scopolamine on monkey DLPFC neurons suppresses DLPFC 
neuronal activity and diminishes rule representation, stimulus, and saccade 
direction selectivity in neuronal responses in a task in which rules maintained in 
WM specify oculomotor responses (Major et al., 2015). However, the muscarinic 
receptor subtypes involved in this suppression of PFC neuronal activity and task 
representation in primates remain enigmatic. 
  There are five muscarinic receptor subtypes, comprised of the Gq-coupled 
M1, M3, and M5 receptors and Gi/o-coupled M2 and M4 receptors (Jones et al., 
2012). M1 receptors (M1Rs) are the most prominently expressed subtype in 
primate PFC, found in postsynaptic specializations on dendritic spines of 
pyramidal neurons (Mrzljak et al., 1993), and have an excitatory influence on 
cortical physiology in brain slices (Carr and Surmeier, 2007). M2 receptors 
(M2Rs) are also expressed in PFC, both as a presynaptic autoreceptor on 
cholinergic axons and as a postsynaptic heteroreceptor on glutamatergic and 
GABAergic synapses, and are posited to have an inhibitory influence on neuronal 
activity (Medalla and Barbas, 2012). Since the ACh binding site on muscarinic 
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receptor subtypes is homologous and highly conserved, orthosteric agonists 
targeting this site do not possess high subtype selectivity (Bubser et al., 2012). 
The recent synthesis of muscarinic compounds possessing high subtype 
selectivity, by acting on allosteric sites on muscarinic receptors, enables analysis 
of the contributions of individual receptor subtypes in PFC cognitive physiology 
during normal behaviour and in models of cognitive disorders (Bubser et al., 
2012, Conn et al., 2009, Digby et al., 2012). 
  Muscarinic stimulation improves cognitive indicators in patients with 
Alzheimer’s disease (Bodick et al., 1997) and schizophrenia (Shekhar et al., 
2008). M1R activators improve cognitive performance during self-ordered spatial 
search in monkeys (Uslaner et al., 2013) and augment medial PFC activity in 
rodents (Shirey et al., 2009). M1R stimulation facilitates hippocampal long-term 
potentiation (LTP) (Buchanan et al., 2010), and is expected to engender cognitive 
enhancement due to increased excitability of PFC cortical neurons by blockade of 
potassium currents, including the M-current (Wang et al., 2011). 
  Here, we examined the effects of local M1R stimulation and blockade on 
PFC neuronal physiology in rhesus monkeys while they performed a task in 
which a rule, maintained in WM, directed the execution of a prosaccade toward a 
peripheral stimulus, or inhibition of that reflexive response, and execution of a 
saccade away from the stimulus (antisaccade; Hallett, 1978). This task, 
incorporating many PFC-dependent functions, including maintenance of task set, 
automatic-response inhibition, and motor reprogramming, is sensitive to PFC 
integrity in humans (Guitton et al., 1985, Rivaud et al., 1994) and monkeys 
(Condy et al., 2007, Koval et al., 2011). Impairment of antisaccade execution is a 
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clinical manifestation of Alzheimer’s disease (Fletcher and Sharpe, 1986) and 
schizophrenia (Fukushima et al., 1988). Based on previous results with general 
muscarinic blockade (Major et al., 2015, Zhou et al., 2011) and other studies 
summarized above, we hypothesized that M1R blockade would suppress 
excitability and disrupt task selectivity of PFC neurons, while M1R stimulation 
would enhance rule representation by increasing PFC excitability. 
  Unexpectedly, we found that M1R stimulation predominantly and dose-
dependently inhibited PFC neurons, with disruption of trial rule representation at 
higher doses. Moreover, M1R blockade also suppressed PFC excitability, but had 
no consistent effects on trial rule representation, in contrast with the strong 
suppression of rule representation in WM observed upon general muscarinic 
blockade (Major et al., 2015). Our results suggest that M1R overstimulation may 
be detrimental to PFC activity in behaving subjects with endogenous cholinergic 
tone, and that other muscarinic receptor subtypes mediate the disruptive effects 
of muscarinic blockade on cognitive representations in PFC neuronal activity. 
 
3.2 Methods 
3.2.1 Experimental Model and Subject Details 
 These experiments were performed with two adult male rhesus monkeys 
(Macaca mulatta, age 9–11 years, weight 9–12 kg). Subjects were individually or 
pair-housed in temperature and humidity controlled environments maintained in a 
12-hour light cycle. All procedures were performed in accordance with the 
Canadian Council on Animal Care policy and a protocol approved by the Animal 
Care Committee of the University of Western Ontario. Both subjects have 
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previously served as subjects in other publications (Major et al., 2015, Major 
et al., 2018, Skoblenick and Everling, 2012, Vijayraghavan et al., 2016). All 
experimental procedures and data analysis were similar to Vijayraghavan et al. 
(2016). Surgical procedures for implantation of a head-post and plastic recording 
chamber were as described previously (Skoblenick and Everling, 2012). The 
recording chamber was placed over the right DLPFC, as guided by MRI, in both 
subjects, under anesthesia and employing standard aseptic techniques 
(Figure 3.1A). Subjects were administered post-operative antibiotics and 
analgesics and monitored by the university veterinarian. 
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Figure 3.1 
Recording Locus, Iontophoretic Electrophysiology, and Behavioural Task 
(A) Schematic of recording location in PFC (pink oval). Most recordings were in 
the dorsal bank of caudal principal sulcus (PS). AS, arcuate sulcus. 
(B) Schematic illustrating the iontophoretic technique. M1R agonist (red dots) and 
M1R antagonist (blue dots) were ejected from a multibarreled electrode by 
current application. 
(C) Schematic of behavioural task with time courses of a prosaccade (left) and 
antisaccade trial (right) is shown. Black rectangles indicate the display. Timing of 
salient epochs is indicated on the left. 
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3.2.2 Behavioural Paradigm 
 The behavioural task, monitoring and reward delivery were implemented 
with the stimulus presentation system CORTEX (National Institutes of Mental 
Health, Bethesda, MD). The subjects performed a variant of the pro- and 
antisaccade task (Everling and DeSouza, 2005, Hallett, 1978), where the trial rule 
had to be retained in working memory (Koval et al., 2011). The subjects fixated 
on a white fixation spot (0.5°), appearing centrally on a CRT monitor 
(Figure 3.1C). After 300 ms, the fixation spot briefly changed to green or red 
(100 ms), indicating the rule that was to be eventually applied to generate the 
motor response: pro- or antisaccades. Rule cue colours indicating prosaccade 
and antisaccade trials were counterbalanced between monkeys. In some 
experiments, the red and green fixation spots were made isoluminant. In a few 
sessions, the rule was instead indicated by central isoluminant horizontal or 
vertical bars (1° width). We pooled the data from these experiments because 
several groups, including ours, have previously shown that rule-selective activity 
of PFC neurons is robust, and occurs regardless of the sensory attributes of the 
rule cue (Vijayraghavan et al., 2016, Wallis et al., 2001). The fixation spot 
reverted to white after 100 ms and the subject had to maintain the trial rule in 
working memory. Central fixation was further maintained for 800–1300 ms 
(pseudorandomly generated duration for each trial). In some sessions, we 
maintained a constant delay of 1200 ms. Subsequently, the fixation spot 
extinguished and after 200 ms (gap period), when the screen was blank, a 
peripheral stimulus (0.5° white spot) was presented at 13° eccentricity at one of 
two pseudorandomly chosen locations on the horizontal meridian to the left or 
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right of the fixation spot. The subject had 500 ms to execute a saccade, and then 
held post-saccade fixation for 120 ms. The subjects made saccadic response 
based on the previously remembered task rule, which could be a prosaccade 
toward the stimulus or an antisaccade away from the stimulus toward the 
opponent location on the horizontal meridian. Correct responses were reinforced 
with a water reward (approximately 125 ms after the saccade). The intertrial 
interval was 2 s after reward onset. The gap period was introduced to increase 
task difficulty (Bell et al., 2000). The rule presented on each trial and the stimulus 
location was pseudorandomly chosen, and thus the subjects could not predict 
which rule or stimulus location would be presented on a given trial. 
 
3.2.3 Neuronal recordings with microiontophoresis and pneumatic injections 
 The M1R allosteric agonist, VU0357017 hydrochloride, M1R-preferring 
agonist McN-A-343, and the M1R antagonist, pirenzepine dihydrochloride (Tocris 
Bioscience, Sigma-Aldrich) were dissolved (10 mM) in pH 3.5 deionized water 
and stored at −20°C in 30 µL aliquots. 
 Multi-barrel tungsten-in-glass electrodes were custom-fabricated and the 
design was derived from previous studies (Vijayraghavan et al., 2016). Tungsten 
wire (50 µm diameter; Midwest Tungsten Service), cut to a length of 
approximately 11.2 cm, was tapered to a fine point by etching the wire in a 
solution of sodium nitrite and potassium hydroxide as previously described 
(Vijayraghavan et al., 2016). Seven-barreled, non-filamented borosilicate glass 
(Friedrich-Dimmock) was pulled with the 50 µm tapered tungsten wire in the 
central barrel using a micropipette puller (PMP107el, MicroData Instrument). 
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Figure 3.1B illustrates the electrode design and the iontophoresis technique. The 
resultant glass-coated recording tip was approximately 15–30 µm in diameter. 
Typical impedance at 1 kHz was 0.5–1.0 MΩ. The remaining barrels were top-
filled with the drug solutions (VU0357017, pirenzepine, McN-A-343) and saline. 
The solutions were pneumatically pushed to the tip using air pressure. Barrel 
impedances (measured for direct current) of the drugs used in this study typically 
ranged from 35–300 MΩ. Electrode impedances and tip integrity were also 
examined upon conclusion of the recording session. Tungsten wires were then 
inserted into the drug barrels and used to pass current through them employing a 
iontophoretic constant current generator (NeuroPhore BH-2, Harvard Apparatus). 
The electrode was mounted on a hydraulic micro-manipulator (MO-95, Narishige 
Group, Tokyo, Japan) and inserted through a 23-gauge dura-penetrating 
stainless steel guide tube into the brain. The location in the recording chamber 
was determined using a custom recording grid (Neuronitek) modified from the 
Crist grid (Crist Instrument). Grid coordinates for recordings were cross-
referenced with MRI images. 
  Neuronal signals were buffered using a unity-gain headstage and the 
Omniplex system (Plexon), amplified 1000X, band-pass filtered (300–6000 Hz, 
4–pole Bessel filter) for spike activity isolation and digitized at 40 kHz. Spikes 
were detected online using amplitude thresholding, followed by offline 
classification with principal component analysis using Offline Sorter (Plexon). 
 A holding/retention current was applied to barrels (−8 nA) when drugs 
were not being ejected to prevent leakage. In most experiments, current 
balancing was not employed, as it has been previously shown that there are no 
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effects of currents of this magnitude on neuronal physiology in monkeys with this 
electrode design (Vijayraghavan et al., 2007). Further, several studies have 
shown that different drugs ejected with identical currents and polarities have 
dissociable functional effects on physiological activity, often selective to cell type 
(Vijayraghavan et al., 2007, Vijayraghavan et al., 2016, Wang et al., 2004). 
Additionally, to ensure that our results were not artifacts due to current 
application, in some sessions, we successively ejected Na+ (from saline) and the 
M1R agonist with identical currents and polarity and found that Na+ ejection did 
not result in comparable physiological effects as ejections of pharmacological 
substances (see Results; also see similar results from Vijayraghavan et al., 
2007). Further, Disney et al. (2007) have demonstrated that the pH adjustment of 
the drug solutions to optimize drug ionization does not affect neuronal physiology. 
  In some experiments (n = 6), in order to further ensure that drug effects 
were not an artifact of the iontophoretic methodology used for drug delivery, we 
ejected drugs using pneumatic pressure pulses for brief periods of time (50–
125 ms) using a precision solenoid (PPM2 module, Harvard Apparatus). 
Electrode fabrication and drug loading was identical to the iontophoretic 
experiments, except that drugs were dissolved in normal saline for these 
experiments. We sealed Tygon tubing to the top opening of each filled drug barrel 
(instead of a wire for ejecting current) using cyanoacrylate and epoxy resin, which 
was then connected to the output of the solenoid valve system through a fluid 
circuit that allowed us to eject specific drugs loaded in the electrode. We 
empirically determined the pulse schedule range at which we were able to eject 
drugs without causing displacement of the neuron or neuronal death, as 
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assessed by lack of effect of saline ejections or by recovery after drug ejections. 
We activated the solenoid using gating pulses driven by an Arduino ATmega2560 
board. Gating pulse durations varied, but typically we applied 25–60 psi pulses of 
50–125 ms at 1–2 Hz. Although we have not precisely quantified the volumes 
ejected with each pulse in the experiments described here, we estimate the 
volume is in the order of 10–30 picoliters per pulse. Since, our objective with 
these experiments was to qualitatively establish the direction of drug effects on 
the physiology of PFC neurons without using current based ejection, we do not 
think that the caveat posed by the lack of precise volume information detracts 
from the objective of the experiments here. Further, we did not include these 
neurons in any of the subsequent population analyses presented in the study. 
 
3.2.4 Data Analysis 
  Our experimental design involved data collection during a control condition 
followed by iontophoretic application of an M1R agonist/antagonist (or saline) by 
continuous ejection. Multiple doses of the drugs were tested, sometimes 
successively in the same session, and in some sessions, a recovery condition 
was obtained after termination of drug application. At least 8 correct trials were 
obtained per rule and per stimulus direction combination, typically more. 
Recordings with less than 8 correct trials in each rule and stimulus direction 
combination in each condition were excluded from further analysis. Iontophoresis 
results in the ejection of very small amounts of charged drugs in the neuronal 
milieu, and is thus not expected to have behavioural consequences in areas with 
diffuse specialization such as the PFC (Major et al., 2015, Major et al., 2018, 
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Vijayraghavan et al., 2016). Thus, in this study we have restricted ourselves to 
presenting the physiological consequences of M1R neuromodulation, and not the 
effects on behaviour. 
 After waveform sorting, all data was analyzed with custom-written scripts 
in MATLAB (MathWorks, Natick, MA). Cortical neurons can be classified into 
narrow-spiking (NS) and broad-spiking (BS) based on width of the spike 
waveform (Mountcastle et al., 1969). NS neurons are generally thought to 
comprise of neocortical basket and chandelier cells expressing parvalbumin, and 
thus comprise a subset of cortical interneurons (Kawaguchi and Kubota, 1993). 
However, the presence of thin-spiking regular spiking cells in cortex (Nowak 
et al., 2003) and of pyramidal tract neurons in macaque motor cortex with thin 
extracellular waveforms (Vigneswaran et al., 2011) may complicate this 
categorical correspondence. Nevertheless, identified pyramidal neurons in 
DLPFC have been shown mostly have broad spike waveforms and narrow-
spiking neurons in macaque PFC were found to correspond to parvalbumin-
expressing basket and chandelier cells (Krimer et al., 2005). Further, Johnston 
et al. (2009) found that antidromically identified corticotectal neurons were broad-
spiking. Since prior work that has found differences in neuromodulation of narrow 
and broad spiking neurons (Jacob et al., 2013), we performed an analysis of 
spike waveform based categorization. 
 Waveforms were first spline interpolated to 1 µs resolution (Johnston et al., 
2009). We then normalized the average interpolated waveform from each 
recorded neuron, such that the normalized waveform ranged from −0.5 to 0.5. 
Waveforms were then aligned on the waveform trough (negative inflection) and 
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the waveform peak (positive inflection) was marked for each neuron. We then 
computed the trough–peak time for each neuron, which has been correlated with 
the width of the intracellular action potential at half maximum (Krimer et al., 
2005). To examine the distribution of spike widths, and ensure that our 
distribution was robust to sample size, trough-peak time distribution for the 
population was pooled with a larger dataset that comprised of 179 recordings for 
which we have conducted spike width analysis in this and previous studies (Major 
et al., 2015). We tested for unimodality of the trough-peak distribution using the 
Hartigan’s dip test (Hartigan and Hartigan, 1985). We found that trough-peak 
times were not distributed unimodally (n = 179; p = 0.03). Based on findings from 
previous studies, which examined antidromically identified macaque PFC 
projection neurons (Johnston et al., 2009), and intracellular recordings from 
macaque PFC slices (Krimer et al., 2005), we classified neurons as NS if the 
trough-peak duration was less than 250 µs. Our analysis yielded 20/94 NS 
neurons with median peak-trough duration of 195 µs (range: 133–244 µs), and 
BS neurons with median peak-trough duration of 465 µs (range: 276–626 µs). 
  Spike density functions were constructed by convolving spike trains with a 
kernel reminiscent of the alpha function (Thompson et al., 1996, Vijayraghavan 
et al., 2016):  
𝑠 𝑡 = (1− 𝑒!!α ) ∙ 𝑒!!τ  
where s is the convolved spike density function, t is time and the parameters α 
and τ are the time constants for the growth and decline phases of the exponential 
function. We used α of 2 ms, and τ of 100 ms to account for higher variability in 
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PFC responses compared with sensory areas. Unlike the more commonly 
employed Gaussian convolution kernel, which results in a symmetric convolution 
around the spike and could thus erroneously attribute some of the impact of the 
spike prior to its occurrence, the spike impact using this kernel occurs completely 
after the occurrence of the spike (Thompson et al., 1996). 
  We excluded neurons with negligible activity (<1 Hz throughout the control 
and relevant drug conditions) from further analysis. We calculated average 
activity (firing rate) across the entire trial (average trial denoted throughout the 
manuscript with the term) from each neuron tested with a drug. We delineated 
the effects of the drug on individual neuronal activity by performing nonparametric 
Wilcoxson rank sum tests on the trial activity for each neuron between control 
and drug conditions. Neurons were deemed to have excited or inhibited on the 
basis of the test (p < 0.05). We counted the number of neurons that were excited, 
inhibited or unaffected using this analysis and constructed pie charts of the 
proportions of neurons. This analysis also extended to measuring the effects of 
individual dose-ranges of the drug. The Fisher exact test was used to assess if 
proportions of excited and inhibited neurons were significantly different from each 
other and to test if different doses of the drugs resulted in progressive inhibition 
or excitation of the population (see Results). 
 We also calculated the population average activity for control and drug 
conditions for all doses, and low/high dose ranges. We examined whether there 
was significant effect of the drugs on average population activity using the paired 
Wilcoxon sign rank test (p < 0.05). We further examined physiological effects of 
the drugs in different epochs of the trial. For this analysis, we divided the trial into 
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three epochs: early rule (0–600 ms after rule cue onset), late-rule (last 600 ms 
prior to peripheral stimulus onset) and post-stimulus epoch (0–500 ms after 
stimulus onset). We computed the average activity in these epochs as described 
above. 
 We classified task-selectivity of neurons in our population using ANOVAs 
as described previously (Vijayraghavan et al., 2016). We performed the ANOVA 
analysis in task-relevant epochs defined as follows: 
(1) Delay epoch: 600 ms before stimulus-onset to 70 ms after stimulus-onset (to 
account for the afferent delay in stimulus-related responses in DLPFC). We 
performed 2-way ANOVAs (factors: rule and drug) on trial activity in this epoch to 
delineate neurons with rule-selectivity. Previous studies (Major et al., 2015, 
Vijayraghavan et al., 2016), have found that prominent rule-selectivity during pro- 
and antisaccades in PFC occurs at a latency of about 600ms prior to stimulus 
onset. Further, we were interested in rule selectivity in the time period directly 
preceding stimulus onset, when it could most directly have an impact on task 
performance. Based on the ANOVAs, we identified neurons as possessing rule-
selectivity if there was a significant main effect of rule or a significant rule X drug 
interaction in this epoch. (2) Stimulus epoch: 70 ms after peripheral stimulus 
onset to 400 ms after stimulus onset. We performed 3-way ANOVAs (factors: 
rule, drug and stimulus location) on trial activity in this epoch from each neuron to 
identify stimulus location-selective neurons. Neurons were classified as selective 
for stimulus location if there was significant main effect of stimulus location or 
significant stimulus location X drug interaction in this epoch. (3) Postsaccadic 
epoch: 400 ms period after saccade onset. We performed 3-way ANOVAs 
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(factors: rule, drug and saccade direction) on trial activity from each neuron in this 
epoch to identify postsaccade direction-selective neurons, which were defined by 
a significant main effect of saccade direction or significant saccade direction X 
drug interaction in this epoch. After data collection, saccade onsets were 
precisely marked using an eye-velocity threshold of 70°/s. 
 Neurons classified by ANOVA were included in further analysis of drug 
effects on task selectivity. The proportions with which DLPFC neurons displayed 
individual activity types in the overall population are shown in Table 3.1. 
 We then quantified rule, saccade direction and stimulus location selectivity 
in these individual populations defined by the ANOVA using signal detection 
theory and computing the area under the Receiver-Operating characteristic 
curves (AUROC) from spike counts (Green and Swets, 1966) in the relevant 
epoch, as described before (Vijayraghavan et al., 2016). The AUROC metric has 
been extensively employed in analyzing categorical selectivity. The AUROC 
ranged from 0 to 1 with 0.5 indicating no selectivity, and values toward 0 or 1 
indicating increasing selectivity for one of the opponent discriminants (i.e., 
prosaccade or antisaccade rule; contralateral or ipsilateral saccade; contralateral 
or ipsilateral stimulus location). By convention, we computed AUROC values 
such that AUROC > 0.5 indicated a preference for prosaccades, contralateral 
saccade direction and contralateral stimulus location, while AUROC < 0.5 
indicated a preference for antisaccades, ipsilateral saccades and ipsilateral 
stimulus location. Neuronal selectivity (preferred rule, saccade direction or 
stimulus location versus nonpreferred) was determined based AUROC values in 
both control and drug conditions, to include neurons in which selectivity arose as 
	  	  
152 
a consequence of drug application (Vijayraghavan et al., 2007, Williams and 
Goldman-Rakic, 1995). AUROC values were then reported based on preferred 
versus nonpreferred task rule, saccade direction or stimulus location. For 
example, for a neuron deemed to be antisaccade rule preferring, where the 
AUROC would be less than 0.5, we report the AUROC value for the neuron as [1-
AUROC] for control and drug conditions. Population analysis of drug-induced 
changes in selectivity were performed by comparing pairwise neuronal AUROCs 
in the control and drug conditions using the sign rank test. The AUROC metric 
reflects only differences between activity for opponent task attributes. However, it 
is not sensitive to the raw neuronal activity that contributes to the selectivity. It is 
conceivable that increase/decrease in task selectivity in a minority of neurons 
accompanied by strong changes in neuronal activity can offset more numerous 
opponent changes in selectivity in a majority of the neurons with weaker 
opponent changes in activity. To address this possibility, we also performed 
another population analysis, wherein we randomly sampled the activity from 1 
trial from each neuron in the population for a given task attribute and given 
condition (control or drug), and created bootstrapped trials with average activity 
from these randomly sampled trials across neurons. Thus, this averaged “trial” 
activity represented activity from all neurons. We repeated this to create a 
dataset of averaged activity bootstrapped trials for each task attribute (i.e., 
preferred rule trials or nonpreferred rule trials). To ensure that we maintained 
comparable sample sizes with the experiments, we adjusted the repetition so that 
the number of trials generated would be equal to the median trial counts in the 
neuronal dataset condition. From these trial sets we computed AUROCs. We ran 
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the simulation for 1000 such datasets. AUROCs from this dataset would reflect 
many possible combinations of trial activity of these neurons, as if they were 
recorded simultaneously. If the changes in activity in individual neurons was 
much stronger than weaker changes in other neurons in the opponent direction, 
this analysis would provide an estimate of population selectivity changes that 
reflected such an effect. 
 After determining the preferred and nonpreferred trial type for each type of 
task selectivity (rule, saccade direction, stimulus location), we constructed min-
max normalized spike density functions from each neuron to generate population 
normalized spike density functions as described previously (Vijayraghavan et al., 
2016). 
 
3.3 Results 
 We pharmacologically tested 152 neurons from the DLPFC of two rhesus 
macaques (monkey O, 58; monkey T, 94; Figures 3.1A and 3.1B) performing the 
rule working memory antisaccade task (Figure 3.1C). We tested 56 neurons with 
iontophoretic application of M1R allosteric agonist, VU0357017; 17 neurons with 
saline followed by VU0357017; 24 neurons with M1R-preferring agonist, McN-A-
343; and 55 neurons with M1R-preferring antagonist, pirenzepine. After excluding 
neurons whose average activity throughout the session was less than 1 Hz 
(Methods), we analyzed the effects of VU0357017 (n = 47), McN-A-343 (n = 18), 
and pirenzepine (n = 47) on general neuronal physiology and task selectivity. 
Behavioural trial count statistics for the population are shown in Table 3.S1.  
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3.3.1 Effects of M1R Agents on DLPFC Neuronal Physiology 
 Based on our previously published findings and other studies with 
muscarinic antagonist scopolamine (Major et al., 2015, Zhou et al., 2011), we 
hypothesized that M1R stimulation with VU0357017 would increase DLPFC 
neuronal excitability, while M1R blockade with pirenzepine would suppress 
activity. We found that VU0357017 application suppressed average trial activity 
of DLPFC neurons (Figure 3.2A, top panel; n = 47; p = 0.005, Wilcoxon sign-rank 
test, control versus drug activity). A majority of neurons (62%; p < 0.05, Wilcoxon 
rank-sum test on each neuron) were significantly inhibited by M1R stimulation 
(Figure 3.2A, bottom panel). We then examined the dose dependence of effects 
of VU0357017 on neuronal activity to ascertain if neuronal suppression was 
monotonic with drug dose. We found that M1R stimulation at lower doses (≤20 
nA) had no significant effects on population activity (Figure 3.2B, left; n = 35), 
while higher ejection doses (21–100 nA) induced significant neuronal activity 
suppression (Figure 3.2B, right; n = 26, p = 0.001). At lower doses, 49% of 
neurons tested were significantly inhibited, while 31% were excited (Figure 3.2B, 
left pie chart). Higher dose application significantly inhibited most DLPFC 
neurons (81%) while only 4 neurons were excited (Figure 3.2B, right pie chart). 
The proportion of DLPFC neurons inhibited by drug application was significantly 
different between the dose ranges (low versus high doses; p = 0.016, Fisher 
exact test). In 23 neurons (Figure 3.2C), we found that mean activity showed 
significant recovery after drug-induced suppression (pcontrol-drug = 0.006; pdrug-
recovery = 0.019) with two-thirds of significantly inhibited neurons exhibiting 
successful recovery (Table 3.S1). 
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Figure 3.2 
M1R Stimulation Dose-Dependently Suppresses Population Activity of PFC 
Neurons 
(A) Average population activity of PFC neurons during control (black) and M1R 
stimulation (gray). Pie chart (bottom) shows the proportion of PFC neurons that 
were significantly excited (pink) or inhibited (blue) by the drug or where the drug 
had no effect (yellow). Significance was determined on each neuron with the 
rank-sum test (p < 0.05). Error bars: ± SEM. 
(B) Average PFC neuronal activity for neurons tested with M1R stimulation at 
low-dose range (0–20 nA; left) and high-dose range (21–100 nA; right). Control, 
black bars; low-dose M1R stimulation, gray; high-dose stimulation, light gray. Pie 
charts below show the proportion of neurons by effect for low (left) and high 
(right) dose ranges (same format as A). 
(C) Average population activity of PFC neurons is shown for control (black), M1R 
stimulation (gray), and recovery (brown) after drug application. Significance 
testing with sign-rank test and Holm-Bonferroni correction for multiple 
comparisons. 
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 Microiontophoresis involves passage of very small currents (0–100 nA 
range) to electrically repulse charged molecules with the same polarity into the 
neuronal milieu. Previous studies have demonstrated that current application 
itself does not affect neuronal physiology (Vijayraghavan et al., 2007). To further 
confirm this, we tested Na+ (saline) application in 17 DLPFC neurons, which did 
not result in inhibition (pcontrol-Na+ = 0.99, one-tailed sign-rank test), while 
subsequent comparable application of VU0357017 at positive ejection current 
polarities inhibited those neurons (pNa+–drug = 0.001). Further, in 12 neurons tested 
with saline, M1R agonist, and recovery, neuronal activity recovered after M1R 
agonist application (pdrug-recovery = 0.003, sign-rank test with Holm-Bonferroni 
correction). Thus, activity suppression due to M1R stimulation by VU0357017 
was not an artifact of iontophoretic currents. To further confirm that neuronal 
suppression was not an artifact of the drug ejection protocol or technique, we 
also stimulated M1R by pulsed pneumatic pressure ejection of VU0357017 onto 
neurons. This allowed us to rapidly apply small amounts of drugs with a pulse 
schedule and mitigated potential consequences of prolonged current-induced 
ejection. Pressure ejection of VU0357017 reliably resulted in suppression of the 
activity of PFC neurons (Figures 3.S1A and 3.S1B), while comparable ejection of 
saline had no effect (Figure 3.S1A). Thus, neuronal inhibition by the M1R 
allosteric agonist was not a consequence of the drug application methodology 
and was also reproduced when the drug was intermittently applied with 
pneumatic ejection. Moreover, to preclude the possibility that neuronal 
suppression observed after M1R blockade was an idiosyncrasy of the 
pharmacology of the M1R-selective agent used (VU0357017), we also tested 
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DLPFC neurons with McN-A-343, an M1R-preferring agonist with high functional 
M1R selectivity that has been widely used to delineate M1R effects (Davies et al., 
2001, Mitchelson, 2012). McN-A-343 iontophoresis resulted in suppression of 
DLPFC neuronal trial activity (n = 18; p = 0.043, sign-rank test; Figure 3.S2A), 
whereby 61% of neurons (n = 11) were significantly suppressed. The proportion 
of suppressed neurons was similar between both M1R agonists. 
 Next, we examined the physiological effects of M1R blockade with the 
selective antagonist, pirenzepine. M1R blockade also led to overall suppression 
of the neuronal population tested (n = 47; Figure 3.3A, top panel), just reaching 
significance (p = 0.047). Pirenzepine application significantly suppressed half of 
the tested DLPFC neurons (Figure 3.3A, bottom; n = 47, p < 0.05, rank-sum test 
on each neuron). Suppression of DLPFC activity by M1R blockade was only 
significant at higher dose ranges (21–100 nA; Figure 3.3B, right panel) and not 
for lower doses (0–20 nA; left panel). The proportion of significantly inhibited 
neurons was not different for pirenzepine application at low and high dose ranges 
(Figure 3.3B, pie charts; p = 1; Fisher exact test, low versus high dose; low dose, 
55%; high dose, 54% suppressed). Neurons tested for recovery from drug effects 
(n = 22) showed no significant restoration of activity after pirenzepine-induced 
suppression (Figure 3.3C). However, when we examined the final 200 s of the 
drug and recovery conditions, population average activity was significantly 
different (control versus final 200 s pirenzepine application, p = 0.002; final 200 s 
pirenzepine versus final 200 s recovery, p = 0.002; sign-rank test), suggesting 
that recovery was prolonged. Thus, M1R blockade also suppressed DLPFC 
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activity, and while neuronal suppression was stronger at higher doses, there was 
a ceiling on the proportion of inhibited neurons due to M1R blockade. 
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Figure 3.3 
M1R Blockade Dose-Dependently Suppresses Population Activity of PFC 
Neurons 
All colours, conventions, and statistical testing identical to Figure 3.2. 
(A) Effects of M1R antagonist on population average activity and proportion of 
neurons by drug effect (pie chart; bottom) are shown. 
(B) Effects of M1R blockade at low doses (0–20 nA; left) and high doses (21–100 
nA; right) on PFC population activity. Pie charts below show proportions of 
neurons by drug effect at low and high doses. 
(C) Average population activity of PFC neurons tested with drug and post-drug 
recovery shown for control (black), M1R antagonist (gray), and recovery (brown) 
conditions. Significance testing with sign-rank test and Holm-Bonferroni 
correction for multiple comparisons. 
Error bars: ± SEM. 
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 We also classified recorded PFC neurons on the basis of waveform width 
into narrow-spiking (NS) and broad-spiking (BS) waveforms (Figures 3.4A and 
3.4B). M1R stimulation significantly inhibited most tested NS neurons 
(Figure 3.4C; 7/8 significantly inhibited) and 22/39 BS neurons (11/36 excited). 
M1R blockade significantly inhibited 8/12 NS neurons (Figure 3.4D; 3/12 excited) 
and 16/35 BS neurons (9/35 excited). 
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Figure 3.4 
Classification of DLPFC Neurons Based on Waveform Shape 
(A) Shown are the normalized waveforms of 94 DLPFC neurons that were tested 
with VU0357017 and pirenzepine. Narrow-spiking (NS) neurons are shown in 
black and broad-spiking (BS) neurons in red. 
(B) Spike trough-peak duration histogram (25 µs bins) for the neuronal population 
(n = 94). 
(C) Trough-peak duration for each neuron (n = 47; blue diamonds) plotted against 
changes in normalized activity due to M1R agonist application. Dashed line 
shows cutoff for NS and BS neuron classification. M1R agonist suppressed most 
NS neurons. 
(D) Trough-peak duration for each neuron (n = 47; red circles) plotted against 
changes in normalized activity due to M1R antagonist application. 
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  Next, we examined the effects of M1R modulation on DLPFC activity in 
specific task epochs (Methods): 0.6 s after rule cue onset (early-rule epoch), 
0.6 s prior to stimulus onset (late-rule), and a 0.6 s period encompassing stimulus 
onset, saccade, and reward (post-stimulus epoch). A two-way ANOVA of 
neuronal activity with factors drug condition and epoch for M1R stimulation 
resulted in significant effect of drug (F1,276 = 9.92; p = 0.0018), but no significant 
effect of the trial epoch or the interaction (drug × epoch). M1R stimulation 
significantly decreased DLPFC activity in all epochs (Figure 3.S3A; sign-rank test 
with Holm-Bonferroni correction). With M1R blockade at all doses, there were no 
significant effects of drug, epoch, or the interaction (drug × epoch). M1R blockade 
overall only significantly suppressed activity in the post-stimulus epoch 
(Figure 3.S3B; sign-rank test with Holm-Bonferroni correction). However, at high 
doses of the M1R antagonist, the effect of the drug was significant (two-way 
ANOVA, F1,228 = 8.05; p = 0.005), while the main effects of epoch and the 
interaction were not. 
 
3.3.2 Effects of M1R Agents on Task Selectivity of DLPFC Neuronal Activity 
  We categorized DLPFC neurons using ANOVAs (Methods) of trial activity 
for each neuron during the memory (delay) epoch to delineate neurons with rule-
selective WM activity and during the stimulus and post-saccade epochs 
to identify neurons with saccade direction selectivity and stimulus location 
selectivity. The numbers of neurons in each defined population for both drugs 
tested are shown in Table 3.1. Neuronal populations selective for task attributes 
were not defined to be mutually exclusive, and many neurons displayed multiple 
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forms of task selectivity. We then examined drug effects on trial rule, saccade 
direction, and stimulus location selectivity in these respective populations by 
analyzing the area under the receiver operating characteristic curve (AUROC; 
Green and Swets, 1966). 
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Table 3.1 
Statistics of Task-Selective Neurons Identified by ANOVA 
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3.3.3 Trial Rule Selectivity 
 Figures 3.5A and 3.5B show two example DLPFC neurons possessing 
rule selectivity in the memory epoch that were challenged with M1R stimulation. 
The neuron in Figure 3.5A exhibited greater control period activity prior to 
stimulus onset during prosaccades than antisaccade trials (top panel;  
 Activitycontrol= 5.94 Hz; AUROCcontrol = 0.74). M1R stimulation significantly 
suppressed neuronal activity (bottom panel; Activitydrug= 4 Hz, p < 0.0001) and 
deteriorated the difference in prestimulus activity between prosaccade and 
antisaccade trials, thus reducing rule selectivity in WM (AUROCdrug = 0.69). 
Another neuron (Figure 3.5B) had greater delay epoch activity for antisaccade 
rule trials immediately prior to stimulus onset (top panel; Activitycontrol = 2.16 Hz; 
AUROC = 0.64). This neuron was tested with successive doses of VU0357017 
(20 and 40 nA, second and third panels, respectively). Increasing doses of M1R 
stimulation progressively decreased neuronal activity (Activitylow-dose= 1.75 Hz, 
pcontrol–low = 0.0001; Activityhigh-dose= 0.18 Hz, plow-high < 0.0001). Subsequently, the 
neuron’s activity was restored during the recovery condition (Activityrecovery= 
2.37 Hz; pcontrol–recovery = 0.09). Concomitant with changes in neuronal excitability, 
trial rule selectivity diminished with increasing doses, especially for the high dose 
(AUROCcontrol = 0.64; AUROClow = 0.62; AUROChigh = 0.52) and was restored 
during recovery compared to the high dose agonist application (AUROCrecovery = 
0.59). In some neurons, M1R stimulation increased activity and increased rule 
selectivity. Figure 3.S4A shows a DLPFC neuron with prestimulus preference for 
the antisaccade rule (top panel; Activitycontrol = 5.37 Hz; AUROCcontrol = 0.66). 
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M1R stimulation increased neuronal activity (bottom; Activitydrug = 8.68 Hz) and 
increased neuronal antisaccade selectivity (AUROCdrug = 0.73). The M1R-
preferring agonist McN-A-343 also suppressed DLPFC neuronal rule selectivity 
(Figure 3.S2B). Pneumatic pressure ejection of the M1R agonist also reduced 
activity of a DLPFC rule-selective neuron (Figure 3.S4B) and reduced trial rule 
selectivity, which recovered after cessation of the drug. 
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Figure 3.5 
Both M1R Stimulation and Blockade Inhibit Activity and Disrupt Rule Selectivity of 
Individual PFC Neurons 
(A) Trial rasters (blue lines, individual spikes on prosaccade trials; red lines, 
individual spikes on antisaccade trials) and average spike density functions (blue 
trace, prosaccades; red trace, antisaccades; line indicates average; shaded area 
indicates SEM) aligned on peripheral stimulus onset are shown for a DLPFC 
neuron that had selectivity for the prosaccade rule before stimulus onset. Top 
panel, control; bottom panel, M1R stimulation; dashed line, stimulus onset; green 
dots, rule cue onset in each trial. 
(B) Conventions identical to (A). Rasters and spike density functions for PFC 
antisaccade-preferring neuron are shown: control (top panel) for successive 
stimulation of M1R at a low dose (second panel), high dose (third panel), and 
subsequent recovery after drug application cessation (bottom panel). 
(C) Conventions identical to (A). Rasters and spike density functions are shown 
for a PFC neuron with selectivity for prosaccades during control (top panel) and 
application of M1R antagonist pirenzepine (bottom panel). 
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 Next, we examined the effects of M1R blockade on DLPFC neuronal rule 
selectivity. Figure 3.5C shows a DLPFC neuron with prestimulus preference for 
prosaccade trials (top panel; Activitycontrol =  10.46 Hz; AUROCcontrol = 0.82). 
Pirenzepine application suppressed the activity of this neuron (bottom panel; Activitydrug = 4.80Hz; pcontrol-drug < 0.0001) and diminished rule selectivity 
(AUROCdrug = 0.70). 
 To ascertain the overall effects of M1R stimulation and blockade on trial 
rule selectivity in our population of neurons, we analyzed all rule-selective 
neurons tested with either drug. M1R stimulation marginally reduced population 
rule selectivity (n = 18 rule-selective neurons), but this effect did not reach 
significance (AUROCcontrol =  0.61 ± 0.01; AUROCdrug = 0.59 ± 0.02; p = 0.17, sign-
rank test). It is possible that M1R stimulation initially augments rule selectivity, but 
this degrades as drug application proceeds. However, we found that rule 
AUROCs in the 200 s immediately after drug application initiation did not 
significantly change (n = 18; p = 0.2; sign-rank test). We then analyzed 
population effects of VU0357017 separately at low (0–20 nA) and high (21–100 
nA) doses. Population-normalized spike density functions (Figure 3.6A, top 
panel) for 13 neurons tested with low doses of VU0357017 show that the drug 
weakly suppressed population activity and had negligible effect on rule selectivity. 
This is further quantified by population AUROC values for rule activity for each 
neuron. (Figure 3.6B; control, abscissa; low-dose drug application, ordinate). 
Although individual neuronal AUROCs increased or decreased upon drug 
application, there was no significant shift in overall population AUROCs above or 
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below the equality line, indicating that low-dose drug application did not have 
systematic effects on rule selectivity (AUROCcontrol = 0.59 ± 0.01; AUROCdrug = 
0.59 ± 0.02; p = 0.95). Population-normalized spike density functions for 12 
neurons tested with high doses of VU0357017 (Figure 3.6C) demonstrate drug-
induced collapse of population activity for preferred and nonpreferred rules and 
accompanying reduction in rule selectivity. Population AUROCs plotted for 
control and high-dose drug application (Figure 3.6D) showed a shift of neuronal 
AUROCs below the equality line, indicating significant disruption of rule selectivity 
(AUROCcontrol = 0.62 ± 0.01; AUROCdrug = 0.55 ± 0.02; p = 0.021). Moreover, 
change in rule selectivity was not significantly correlated with activity suppression 
due to the M1R agonist at all doses (n = 18, Pearson’s correlation coefficient, R = 
0.4, p = 0.06) and at low doses (n = 13, R = 0.48, p = 0.09). However, for higher 
dose application of the M1R agonist, changes in the AUROC were significantly 
correlated with activity changes (n = 12, R = 0.58, p = 0.048), indicating that 
neuronal activity suppression led to reduction in population rule selectivity. 
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Figure 3.6 
M1R Stimulation Dose-Dependently Disrupts the Population Rule Selectivity of 
PFC Rule-Selective Neurons 
(A) Average normalized spike density functions aligned on stimulus onset (gray 
vertical line) for the preferred rule (blue) and nonpreferred rule (red) shown for 
the population of PFC rule-selective neurons during control (top) and low-dose 
(0–20 nA; bottom) stimulation of M1Rs. Thick lines indicate mean; shaded area 
indicates SEM. 
(B) Rule selectivity (quantified by AUROC) is plotted for each rule-selective 
neuron (n = 13; blue dots, prosaccade-preferring; red dots, antisaccade-
preferring) during control (abscissa) and low-dose M1R stimulation (ordinate). 
Green line indicates equality. 
(C) All conventions same as (A). Average normalized spike density functions for 
a population of PFC neurons tested with high doses of M1R stimulation (21–100 
nA). 
(D) All conventions same as (B). AUROC values for each neuron tested with 
high-dose M1R stimulation shown for control and drug. 
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 An analysis of the effects of M1R blockade with pirenzepine on population 
rule selectivity in 26 rule-selective neurons revealed no significant changes due 
to M1R blockade (AUROCcontrol = 0.617 ± 0.01; AUROCdrug = 0.595 ± 0.01; p = 0.12, 
sign-rank test). We then analyzed population selectivity for low (0–20 nA) and 
high (21–100 nA) dose ranges of pirenzepine application. Population-normalized 
spike density functions for 13 neurons tested at low doses (Figure 3.7A) and for 
21 neurons at high doses (Figure 3.7C) show that pirenzepine application did not 
appreciably change activity differences between preferred and nonpreferred rule 
trials. AUROCs demonstrated no significant overall effect of M1R blockade at 
both dose ranges on population rule selectivity (low doses, Figure 3.7B, p = 
0.147; high doses, Figure 3.7D, p = 0.455). Thus, M1R blockade, while 
influencing trial rule-related activity of individual PFC neurons, did not have a 
significant overall effect on rule selectivity of the neuronal population. 
	  	  
172 
 
Figure 3.7 
M1R Blockade Has No Effect on the Population Rule Selectivity of PFC Rule-
Selective Neurons 
All colours, conventions, and statistical tests in panels are identical to equivalent 
panels in Figure 3.6. 
(A) Average normalized spike density functions are shown for control period and 
low-dose (0–20 nA) M1R blockade for preferred and nonpreferred rules. Shaded 
area indicates SEM. 
(B) AUROCs for each neuron tested with low-dose M1R blockade shown for 
control and drug. 
(C) Average normalized spike density functions are shown for control and high-
dose (21–100 nA) M1R blockade for preferred and nonpreferred rules. 
(D) AUROCs for each neuron tested with high-dose M1R blockade shown for 
control and drug. 
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3.3.4 Saccade Direction Selectivity 
  We performed a similar analysis of M1R modulation for DLPFC neurons 
displaying selectivity for the direction of the saccade executed (contralateral or 
ipsilateral to the recording hemisphere). Figure 3.S6A shows activity of a DLPFC 
neuron preferring contralateral saccades. During the control period, this neuron 
was activated at saccade onset and had differential postsaccadic activity for 
contra- and ipsilateral saccades (top panel; saccade direction AUROCcontrol = 
0.79). M1R blockade suppressed neuronal activity and reduced postsaccadic 
directional selectivity therein (AUROCdrug = 0.63). Figure 3.S6B shows the activity 
of another DLPFC neuron with preference for the contralateral saccade that was 
tested with successive doses of pirenzepine, (top panel; AUROCcontrol = 0.59). 
Low-dose (15 nA) pirenzepine application did not affect overall neuronal activity 
(pcontrol-low = 0.09). However, the activity decrease was more pronounced for 
ipsilateral saccades (Δcontralateral = 1.23 Hz; Δipsilateral = 2.3 Hz; p < 0.0001), thereby 
increasing postsaccade direction selectivity (AUROClow-dose = 0.65). Subsequent 
higher dose M1R blockade suppressed overall activity (pcontrol-high < 0.0001) and 
decreased postsaccade direction selectivity (AUROChigh = 0.56). Saccade-
direction AUROCs were significantly reduced by M1R blockade in the saccade-
selective neuronal population (n = 31; p = 0.007(AUROCcontrol = 0.65 ± 0.01 
(AUROCdrug = 0.61 ± 0.01). In 20 neurons selective for contralateral saccades, 
pirenzepine reduced overall population AUROCs (Figure 3.S6C; p = 0.0001, sign-
rank test). This selectivity disruption was due to a greater decrease in activity for 
contralateral than ipsilateral saccades (Figure 3.S6D; p = 0.001). In 11 ipsilateral 
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saccade-selective neurons, pirenzepine had no effect on saccade selectivity (p = 
0.91). In contrast, M1R stimulation with VU0357017 had no significant effect on 
population saccade selectivity of contralateral saccade-selective neurons (n = 18; 
p = 0.472, sign-rank test on AUROC, drug versus control). Thus, moderate levels 
of M1R stimulation appear to be necessary for the maintenance of saccade-
related activity in PFC neurons, while overstimulation beyond endogenous 
cholinergic stimulation does not disrupt this activity. 
 We also analyzed the effects of M1R stimulation and blockade on neurons 
possessing selectivity for the peripheral stimulus direction. We found that neither 
M1R stimulation (n = 11, p = 0.10; sign-rank test) nor blockade (n = 16, p = 0.35) 
affected population stimulus direction selectivity measured by AUROCs. 
In summary, the major consequence of local stimulation of M1Rs was 
suppression of DLPFC neuronal activity, with disruption of trial rule selectivity at 
higher doses. M1R blockade also suppressed DLPFC activity overall, albeit to a 
lesser extent, and had no systematic effects on trial rule selectivity, but affected 
the selectivity of postsaccadic activity. 
 
3.4 Discussion 
 We found that local stimulation of M1Rs suppressed PFC neuronal activity 
in macaques and overstimulation at higher doses was detrimental to trial rule 
representation. Increasing doses of M1R stimulation progressively increased the 
proportion of inhibited PFC neurons, while individual exemplars of increased 
excitability proportionally decreased. M1R blockade also marginally suppressed 
PFC activity, but the proportion of PFC neurons suppressed or excited by M1R 
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antagonism did not show dose dependence. Moreover, M1R blockade spared 
rule WM and stimulus direction representations in PFC, but disrupted selectivity 
in neuronal postsaccadic activity for contralateral saccades. Since we have 
previously shown that general muscarinic blockade diminishes all aspects of task 
selectivity in PFC (Major et al., 2015), our results here showing only modest 
effects of M1R blockade on task selectivity suggest that another muscarinic 
receptor subtype, such as the M2R, may be responsible for disruptive effects of 
general muscarinic blockade on WM activity. These findings proffer a cautionary 
note to strategies for pharmacological treatment of cognitive dysfunction based 
on M1R stimulation (Conn et al., 2009). 
 
3.4.1 M1R Modulation of Neuronal Excitability in DLPFC 
 Several studies imputing an excitatory role for M1Rs in modulating cortical 
activity informed our prior hypotheses that M1R stimulation would increase PFC 
activity, and conversely, that M1R blockade would reduce PFC excitability, thus 
resembling the effects of general muscarinic blockade in PFC (Major et al., 2015, 
Zhou et al., 2011). Muscarinic stimulation of neurons in rodent cortical slices 
induces transient inhibition followed by prolonged excitation of cortical neurons 
(Gulledge et al., 2009, McCormick and Prince, 1985). Pirenzepine counteracts 
the slow excitation, but not the inhibitory component (McCormick and Prince, 
1985), and blocks ACh-induced excitation of rat parietal cortical neurons 
(Bradshaw et al., 1987). Pirenzepine also blocks persistent discharges induced 
by stimulation in the presence of cholinergic agonist carbachol in rodent 
entorhinal cortical slices, indicating that M1R is the conduit of this effect (Egorov 
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et al., 2002). Muscarinic stimulation induces a slow afterdepolarization in rodent 
medial PFC that is mediated by nonselective cationic conductances (Haj-
Dahmane and Andrade, 1996, Haj-Dahmane and Andrade, 1998) and inhibits 
KCNQ channels that carry the M-current (Brown and Adams, 1980). Moreover, 
blockade of the M-current reduces spatial WM activity in macaque PFC (Wang 
et al., 2011). Thus, there are many identified mechanisms by which muscarinic 
stimulation would be expected to increase cortical excitability. 
 However, M1R mechanisms have also been implicated in the transient 
inhibitory responses of cortical neurons to ACh application. Hyperpolarizing 
responses to ACh application have been attributed to GABAergic mechanisms, 
through direct excitation of inhibitory interneurons (McCormick and Prince, 1985, 
McCormick and Prince, 1986). Other studies reveal that brief muscarinic 
stimulation results in IP3 receptor-mediated Ca2+ release, which subsequently 
activates SK potassium channels, resulting in neuronal inhibition (Gulledge and 
Stuart, 2005). We found that, in awake, task-engaged monkeys, 81% of PFC 
neurons at higher doses of M1R stimulation were inhibited (62% at all doses), 
while the proportion of excited neurons dose-dependently reduced. This argues 
that, in primates with engaged arousal systems and normal cholinergic tone, M1R 
stimulation predominantly engages the inhibitory mechanisms summarized 
above. We also found that M1R blockade suppressed overall PFC activity. 
However, the proportions of pirenzepine-inhibited neurons remained 
approximately half of the neurons tested regardless of the dose. Inhibition due to 
both blockade and stimulation of M1R suggests that, in awake, behaving 
primates, there are some M1R-mediated excitatory mechanisms, including 
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activation of nonselective cation channels and inhibition of the M-current, that 
may, however, be near-maximally engaged by endogenous tonic ACh levels. At 
higher levels of cholinergic stimulation of M1Rs, as engendered by agonist 
application, cortical excitability is reduced, either through mechanisms dependent 
on GABAergic feedforward inhibition (McCormick and Prince, 1985), or by 
activation of SK potassium channels through IP3/Ca2+. 
 Here, analysis of excitability of neurons classified by waveform shape 
suggested that M1R stimulation did not lead to increased excitability of 
parvalbumin-positive (PV+) interneurons, which typically possess NS waveform 
properties (Kawaguchi and Kubota, 1993). On the contrary, our data suggest that 
NS interneurons were more strongly inhibited by M1R stimulation than BS 
neurons (88% inhibited versus 59% for BS neurons). Thus, feedforward inhibition 
due to increased excitability of PV+ interneurons may not explain the inhibitory 
effects of M1R stimulation here. However, we cannot rule out cholinergic 
mechanisms involving other interneuron types possessing BS-like waveforms in 
explaining our results (Kawaguchi and Kubota, 1993). Moreover, atypical 
excitatory neurons, like the thin-spiking pyramidal tract neurons found in 
macaque motor areas (Vigneswaran et al., 2011), may confound interpretation of 
these results. 
 Yi et al. (2014) found that muscarinic agonist muscarine potentiated 
current-induced activity in PV+ interneurons in both hippocampus and PFC slices 
in mice. Knocking out M1Rs in PV+ interneurons eliminated this effect in 
hippocampal interneurons. However, the authors did not investigate the 
consequences of M1R genetic deletion on muscarinic activation of PV+ 
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interneurons in PFC, so it is unclear if M1Rs were also responsible for 
muscarine’s actions on PFC PV+ interneurons. 
 We propose that our findings with M1R stimulation are instead explained 
by Gq-transduced activation of the IP3 receptor pathway leading to an increase in 
SK channel conductance as described above. Notably, Gq-coupled α1-adrenergic 
receptor stimulation reduces the excitability of macaque DLPFC WM neurons 
through actions on protein kinase C (Birnbaum et al., 2004), while focal activation 
of Gq-coupled metabotropic glutamate receptor type I triggers dendrosomatic 
Ca2+ waves in rat PFC neurons, which induce transient inhibition/prolonged 
excitation similar to muscarinic activation (Hagenston et al., 2008). Consistently, 
blockade of IP3 receptors or SK channel blockade in rat medial PFC improves 
WM performance (Brennan et al., 2008). 
 One confound of this proposed mechanism is that inhibitory SK channel 
inhibitory responses in rodent cortical slices decline over time, due to Ca2+ 
depletion after repeated cholinergic stimulation at resting membrane potentials. 
However, this decline does not occur at membrane potentials closer to threshold, 
when Ca2+ stores are rapidly replenished (Dasari et al., 2017). Since in awake, 
behaving primates, the cortical neuronal membrane potential is close to the spike 
threshold (Tan et al., 2014), SK channel responses may remain potent with 
prolonged M1R stimulation, and continue unabated, unlike cortical slices. 
 Another confound of this mechanistic hypothesis is that M1R-mediated 
inhibition in slices is transient and followed by prolonged increase in excitability. 
Gulledge et al. (2009) found that both inhibitory and excitatory responses to 
cholinergic stimulation with carbachol were diminished in PFC slices from M1R 
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knockout mice. Our results suggest that tonic M1R stimulation with iontophoresis 
or pulsed stimulation with pressure ejection results in inhibition of a majority of 
PFC neurons in behaving monkeys. It is possible we did not observe the 
excitatory phase of tonic M1R-dependent cholinergic stimulation in our 
experiments because of species differences or differences between cholinergic 
responses in cortical slices and intact cortical circuitry in awake, behaving 
animals, where cholinergic stimulation may already be substantial due to 
endogenous cholinergic tone. Alternatively, excitatory actions of M1R may 
manifest only in some cortical layers and not others (Gulledge et al., 2009). 
Nevertheless, the PFC neuronal inhibition by M1R agonist application we 
observe with both methodologies (but not by saline) indicates that, in behaving 
primates, overstimulation of M1Rs directly suppresses PFC neuronal activity 
through proximal signal transduction mechanisms, and that normal cortical 
cholinergic tone reflects an optimal balance between inhibitory and excitatory 
muscarinic modulation of frontal cortex through M1Rs. 
 
3.4.2 M1R Modulation of Behavioural Task Representation in PFC Activity 
 Trial activity of DLPFC neurons encodes selectivity for many task 
attributes in the pro- and antisaccade task, including maintenance of the task set 
in WM (rule representation), post-stimulus activity encoding stimulus location, 
and perisaccadic representation of the saccade direction (Everling and DeSouza, 
2005). Previously, we demonstrated that general muscarinic blockade with 
scopolamine suppressed PFC neuronal rule, stimulus location, and saccade 
direction selectivity (Major et al., 2015). Systemic scopolamine injections also 
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reduce PFC WM activity during memory-guided saccades, and disrupt 
behavioural performance (Zhou et al., 2011). We hypothesized that the disruptive 
effects of muscarinic blockade on PFC task selectivity are mediated by M1Rs 
because they are the most abundant muscarinic subtype in cortex (Flynn et al., 
1995) and they are localized at asymmetric synapses in spines and dendrites, 
poised to regulate glutamatergic transmission (Mrzljak et al., 1993). 
 Here we found, using an identical experimental paradigm as Major et al. 
(2015), that unlike general muscarinic blockade, M1R blockade had no consistent 
effects on population rule selectivity, even though rule representation in WM in 
individual PFC neurons was affected. Moreover, this was the case at both lower 
and higher doses, notwithstanding suppression of memory period activity at 
higher doses (Figure 3.3). Thus, our results suggest that the previously reported 
strong suppression of rule selectivity in WM by scopolamine (Major et al., 2015) 
is not mediated by M1Rs. Consistent with this, intraventricular injections of 
pirenzepine in rats had subtler effects on delayed match to position performance 
compared to scopolamine (Andrews et al., 1994). Intriguingly, mice lacking M1Rs 
have selective deficits only in certain kinds of delayed-response performance, 
which may need cortico-hippocampal connectivity (Anagnostaras et al., 2003). 
We have recently reported that general cholinergic stimulation with iontophoresis 
of carbachol excited a greater proportion of DLPFC neurons (49%) than our 
results with M1R stimulation here, also reducing neuronal rule selectivity (Major 
et al., 2018). Since ACh actions in cortex are thought to be primarily mediated by 
muscarinic receptors (Cox et al., 1994), our previous results with carbachol 
considered with our results with M1R here suggest that other muscarinic receptor 
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subtypes may have a more defining role in activity for rules and task set. M2Rs 
are also expressed in DLPFC and, in addition to presynaptic expression 
suggesting a role in modulating neurotransmitter release, are expressed in 
pyramidal neurons mostly in spines of apical dendrites apposed to glutamatergic 
synapses (Mrzljak et al., 1993, Mrzljak et al., 1998). M2Rs are Gi/o-coupled 
(Hulme et al., 1990) and their activation would be expected to decrease cAMP 
signaling. ACh application in mouse visual cortical slices at low and high doses 
enhanced and suppressed evoked neuronal responses, respectively, and the 
excitatory effect is blocked in M2R/M4R knockout mice (Kuczewski et al., 2005). 
Previous iontophoretic studies have shown that increased cAMP signaling 
through dopamine D1 receptors (Gs-coupled) suppresses macaque PFC 
neuronal activity (Vijayraghavan et al., 2007), while decrease in cAMP signaling, 
e.g., through Gi/o-coupled α2A receptor stimulation, increases DLPFC spatial WM 
activity (Wang et al., 2007). Thus, postsynaptic M2R activation in pyramidal 
neurons would be expected to increase PFC persistent activity, and may be the 
main effector of muscarinic modulation of rule representations in PFC. Future 
experiments examining this hypothesis are of paramount interest. 
 M1R stimulation at lower doses also did not affect rule selectivity in WM, 
but M1R overstimulation at higher doses disrupted trial rule selectivity. This 
suggests that M1R may have an equivocal role in maintenance of rules in WM at 
low (as mimicked by M1R blockade) to moderate levels of engagement, while 
excessive M1R stimulation disrupts cognitive representations, due to substantial 
general suppression of cortical activity. The reason for this discrepancy may be 
the engagement of different downstream signaling mechanisms by these M1R 
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agents. Future experiments manipulating the pharmacology of individual 
signaling components downstream of M1R may shed light on this. This is 
intriguing because systemic M1R stimulation can be beneficial in some cognitive 
tasks in monkeys (Shirey et al., 2009, Uslaner et al., 2013). However, it is difficult 
to compare systemic injections with the local PFC manipulations here. Our 
finding that prolonged overstimulation of M1R degrades rule WM is interesting 
given a recent study that found intermittent stimulation of the cholinergic nucleus 
basalis was beneficial to WM performance, while continuous stimulation had 
adverse effects (Liu et al., 2017). 
 We also found that M1R blockade, while sparing rule maintenance in WM, 
attenuated saccade direction selectivity of PFC neurons in the postsaccadic 
epoch, while M1R stimulation did not affect this activity. This may be another 
indicator that different signaling mechanisms downstream of M1R differentially 
modulate cognitive representations. Previously, dopamine D2 receptors were 
shown to modulate perisaccadic activity during memory-guided saccades (Wang 
et al., 2004) and in the antisaccade task (Vijayraghavan et al., 2016), but did not 
have consistent effects on WM for spatial stimuli and rules, respectively. This 
resembles our findings here with M1R blockade. Location-selective perisaccadic 
activity in PFC has been hypothesized to carry feedback signals from the 
superior colliculus updating the FEF about an executed eye movement (Sommer 
and Wurtz, 2006). However, its role in periprincipal PFC is not entirely clear 
(Vijayraghavan et al., 2017). Interestingly, most macaque nucleus basalis 
cholinergic neurons are active during the response/reward epoch, and not the 
delay epoch of a delayed response task, with most activity predicting rewarding 
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or aversive stimuli (Richardson and DeLong, 1986). This suggests that phasic 
ACh release coincident with the motor response may strengthen information 
about rewarded actions after a trial. Our results suggest that endogenous M1R 
engagement may have a role in modulating this function. 
 M1R stimulation has been viewed with promise in the development of new 
cognitive enhancers (Melancon et al., 2013). Conventional cholinergic 
enhancement using cholinesterase inhibitors has dubious efficacy in the 
treatment of dementia in Alzheimer’s disease (Fisher, 2008). Since this disease is 
characterized by degeneration of the cholinergic system, directly targeting 
downstream receptors may be more effective. Indeed, M1R allosteric modulators 
have shown some promise in enhancing cognitive performance in animal models 
(Shirey et al., 2009, Uslaner et al., 2013), with fewer side effects than 
cholinesterase inhibitors (Vardigan et al., 2015). However, our results with M1R 
modulation of DLPFC cognitive physiology suggest that, in primates, M1R 
overstimulation in the PFC may be detrimental to cognitive performance. These 
results will inform treatment strategies based on M1Rs for use in neuropsychiatric 
disorders. Our results also broach the hypothesis that excitatory mechanisms 
modulating cognitive representations in PFC are mediated by other muscarinic 
receptor subtypes that may be potential targets for the synthesis next-generation 
cognitive enhancers for use in health and disease. 
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3.5 Supplemental Results 
 
  
Table 3.S1: Trial count statistics and individual statistics of neuronal 
recovery from drug effects  
(A) Table enumerates means, medians, and standard deviation of trial counts for 
the control conditions, various drug conditions, and recovery conditions analyzed 
in this study. 
(B) Statistics for neurons tested with recovery from M1R agonist and antagonist 
application are shown. Trial activity from each neuron was analyzed for 
significant effects (rank sum test, p < 0.05).   
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Figure 3.S1 
Inhibition of PFC neurons by pneumatic pressure ejection of M1R agonist 
VU0357017 
(A) Sliding average activity (60 s window, running average) of a PFC neuron that 
was tested with several pneumatic pressure pulse ejections of VU0357017 (10 
mM in saline) and saline is shown. Blue shaded areas indicate time of pressure 
ejections of the M1R agonist at 30 psi using a 75 ms ON/500 ms OFF cycle. Light 
green shaded area indicates time of pressure ejection of saline at 30 psi (75 ms 
ON/500 ms OFF). Dark green shaded area indicates time of saline ejection at 
twice the time per cycle (30 psi; 150 ms ON/500 ms OFF). Red arrowheads point 
to complete suppression of neuronal activity after VU0357017 application. The 
first application of M1R agonist lasted only 15 s, and the suppression was 
observed after some delay. The subsequent applications were longer (57 s, 60 s, 
60 s, 60 s), and turned off soon after neuronal suppression was underway. Unlike 
VU0357017 ejection, activity after saline ejection at a comparable rate and at 
twice the rate did not result in any suppression of neuronal activity. 
(B) Sliding average activity (60 s window, running average) of another PFC 
neuron which was tested with a pneumatic pressure ejection of M1R agonist, 
VU0357017 is shown (10 mM in saline; blue shaded rectangle indicates the onset 
and duration of application). The M1R agonist ejected at 60 psi using a 125 ms 
ON/500 ms OFF cycle. Agonist application lasted for 35 s and resulted in 
immediate suppression of the neuron followed by a prolonged and gradual 
recovery of neuronal activity 
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Figure 3.S2 
Effects of M1R-preferring agonist McN-A-343 on PFC neurons 
(A) Shown in the left panel is the mean trial activity of 18 neurons during control 
(black) and after M1R stimulation with McN-A-343 (grey). Drug application 
significantly reduced the population activity of PFC neurons. Pie chart to the right 
shows proportions of neurons that were significantly inhibited (blue; rank sum 
test, p < 0.05), excited (pink), and not affected (yellow). Most neurons were 
inhibited by the drug (11/18). 
(B) Rasters and spike density functions aligned to stimulus onset (dashed line) 
for a DLPFC neuron with selectivity for the antisaccade rule (red) compared with 
the prosaccade rule (blue) are shown. McN-A-343 application at 50 nA 
suppressed the activity of the neuron (Activitycontrol = 4.5 Hz;  Activitydrug = 1.35 
Hz) and reduced rule selectivity (AUROCcontrol = 0.64; AUROCdrug = 0.61). Green 
dots indicate rule cue onset. 
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Figure 3.S3 
Effects of M1R agonist VU0357017 and M1R antagonist pirenzepine application 
over the course of the trial 
(A) Effects of M1R agonist at all doses on average trial activity are shown for the 
early rule epoch (left), late rule epoch (middle), and stimulus response epoch 
(right) during control (black) and drug (grey) conditions. M1R agonist application 
significantly suppressed population activity in all trial epochs. ANOVA with factors 
drug and epoch show no significant effect of trial epoch or the interaction (drug X 
epoch), showing that M1R agonist stimulation had uniform effects on behavioural 
trial activity. Statistical testing with paired sign rank test with corrections for 
multiple comparisons with the Holm-Bonferroni corrections. 
(B) Effects of M1R antagonist at all doses on average trial activity are shown for 
the early rule epoch (left), late rule epoch (middle), and stimulus response epoch 
(right) during control (black) and drug (grey). After correction for multiple 
comparisons, M1R antagonist application significantly reduced population activity 
only in the post-stimulus epoch epoch (sign rank test with Holm-Bonferroni 
correction for multiple comparisons). ANOVA with factors drug and epoch show 
no significant effect of drug, epoch, or the interaction. 
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Figure 3.S4 
Examples of excitation of DLPFC rule selective neuron and enhancement of 
DLPFC neuronal rule selectivity by iontophoretic M1R stimulation and reduction 
in rule selectivity due to M1R agonist pressure ejection. 
(A) Rasters and spike density functions aligned to stimulus onset (dashed line) 
are shown for prosaccade trials (blue) and antisaccade trials (red) during control 
(top panel) and during M1R stimulation (bottom panel). M1R stimulation 
increased the activity of this neuron and enhanced rule selectivity. Green dots 
indicate rule onset.  
(B) Example of effects on activity and rule selectivity of PFC rule-selective neuron 
by pressure ejection of M1R agonist. Rasters and spike density functions aligned 
to stimulus onset (dashed line) are shown for prosaccade trials (blue) and 
antisaccade trials (red) during control (top panel) and during M1R stimulation with 
pressure ejection of VU0357017 (60 psi air pressure; 50 ms ON/ 500 ms OFF; 
middle panel). M1R stimulation suppressed the neuron (Activitycontrol = 4.34 
Hz;  Activitydrug = 3.12 Hz) and disrupted prosaccade rule selectivity (AUROCcontrol 
= 0.64; AUROCdrug = 0.61). Subsequent recovery from drug application restored 
trial activity (Activityrecovery = 5.08 Hz) and rule selectivity (AUROCrecovery = 0.68). 
Green dots indicate rule onset. 
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Figure 3.S5 
M1R blockade disrupts population postsaccadic selectivity for the contralateral 
saccade PFC saccade-selective neurons 
(A) Rasters and spike density functions aligned on saccade onset are shown for 
a PFC saccade-selective neuron during the control period (top) and after M1R 
blockade (bottom). Purple raster lines: individual spikes on contralateral saccade 
trials; green raster lines: individual spikes on ipsilateral saccade trials. Purple 
spike density functions: contralateral saccades; green spike density functions: 
ipsilateral saccades. Dashed vertical line: saccade onset. Black dots: peripheral 
stimulus onset on each trial. 
(B) Conventions and colours same as (A). Rasters and spike density functions for 
another PFC neuron with perisaccadic selectivity are shown during control (top 
panel) and for successive doses of M1R antagonist (low dose: 2nd panel; high 
dose: 3rd panel). 
(C) Saccade direction selectivity (quantified by AUROC) for each PFC 
contralateral-saccade-selective neuron (purple dots) is shown during control 
(abscissa) and drug application (ordinate).   
(D) M1R blockade-induced reduction in normalized activity was significantly 
greater for contralateral than ipsilateral saccades. 
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CHAPTER 4 – CHOLINERGIC RECEPTORS IN MACAQUE PREFRONTAL 
CORTEX INFLUENCE CORTICAL OSCILLATIONS IN A RULE-BASED 
SACCADE TASK 
 
4.1 Introduction 
 Executive functions such as working memory maintenance and the use of 
rules are deficient in disorders of cognition and rely on intact prefrontal cortex 
(PFC; Miller and Cohen, 2001; Perlstein et al., 2001; Bussiere et al., 2003; 
Schroeter et al., 2012). Oscillations in the local field potential (LFP) are thought to 
flexibly coordinate neuronal activity, allowing cortex to respond to a variety of 
complex behaviours (Sejnowski and Paulsen, 2006; Womelsdorf et al., 2007; 
Akam and Kullmann, 2010). Cognitive processing can be represented in the LFP 
of nonhuman primate PFC, which can show tuning in a variety of cognitive tasks, 
including memory-guided saccades (Pesaran et al., 2002; Womelsdorf et al., 
2007; Babapoor-Farrokhran et al., 2017) and pro- and antisaccades (Ma et al., 
2018). During macaque performance in visual working memory tasks, bursts of 
gamma power are observed in PFC during cue and stimuli presentations and 
increased beta power is found during delay periods that require working memory 
maintenance (Wimmer et al., 2016; Lundqvist et al., 2018). LFPs can also 
influence interregional communication, acting as a gating mechanism to enhance 
or stifle incoming information (Busch et al., 2009; Babapoor-Farrokhran et al., 
2017; Fiebelkorn et al., 2018). For example, Liebe et al. (2012) reported theta 
coupling between macaque V4 and PFC can predict performance in a mnemonic 
task. 
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 Cholinergic innervation of the PFC is essential for optimal executive 
behaviour. Disruption of the cholinergic system, via cholinergic-specific lesion 
(Aigner et al., 1991; Croxson et al., 2011) or pharmacological blockade 
(Klinkenberg and Blokland, 2010), can elicit strong deficits in cognitive tasks such 
as working memory maintenance. In Alzheimer’s disease and schizophrenia, in 
which the cholinergic system is perturbed (Whitehouse et al., 1982; Mesulam, 
2013; Carruthers et al., 2015), both cognitive performance and cortical LFP 
oscillations are abnormal (Jeong, 2004; Uhlhaas and Singer, 2010). Therefore, 
investigating the impacts of cholinergic compounds on LFP may reveal important 
insights into how altered cholinergic function may influence cognition in these 
neuropsychiatric conditions. 
 Systemic blockade of muscarinic receptors in healthy human participants 
generally results in increased theta LFP power, as recorded by EEG, and 
decreased alpha power (Sloan et al., 1992; Sannita et al., 1993; Neufeld et al., 
1994; Kikuchi et al., 1999). Systemic stimulation of cholinergic receptors, albeit 
less thoroughly explored, may induce opposing effects on LFP power (Saletu et 
al., 1989; Knott et al., 1998). For example, Fisher et al. (2012) found nicotine gum 
increased alpha power in the frontal cortex of nonsmokers. 
 Although studies involving systemic administration of drugs are useful, 
resulting neurophysiological effects may be influenced by extraneous factors 
other than local receptor perturbation, such as afferent influences from distant 
connected regions. This is especially relevant in the case of studying LFP, as 
frequency band synchrony is thought to affect communication between brain 
regions (Fries, 2015). Further, cholinergic receptors have long been proposed to 
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modulate incoming information (Gil et al., 1997; Medalla and Barbas, 2012). 
Local ejection of cholinergic compounds may provide more accurate insights into 
how cholinergic receptor stimulation or blockade affects LFP in the local area 
surrounding drug ejection. Aptly, several investigators have explored the LFP 
effects of local ejection of these compounds in rats (Rowntree and Bland, 1986; 
Howe et al., 2017), cats (Biedenbach, 1966), and macaque inferior temporal 
cortex (Kuravi and Vogels, 2018). 
 However, the effects of local ejection of cholinergic compounds on LFP in 
nonhuman primate PFC remain poorly characterized. The study of nonhuman 
primate neurophysiology is especially important for research related to 
neuropsychiatric conditions because nonhuman primates have a granular PFC, a 
cytoarchitectural feature shared with human PFC (Petrides and Pandya, 1999) 
that is thought to be important for higher order cognitive functions.  
 In this study, the muscarinic antagonist scopolamine and cholinergic 
agonist carbachol were iontophoretically ejected in rhesus dorsolateral PFC 
during performance of a rule-based saccade task that required monkeys to 
maintain the task rule in working memory. Changes in LFP power and rule tuning 
of power were quantified. Based on previous reports involving human 
electrophysiology and systemic injection of cholinergic compounds, scopolamine 
was expected to increase theta power and decrease alpha power. Carbachol was 
expected to increase alpha power. This investigation may provide insights into 
the mechanisms behind altered LFP power spectra in conditions with disrupted 
cholinergic systems, such as Alzheimer’s disease and schizophrenia (Jeong, 
2004; Schnitzler and Gross, 2005; Uhlhaas and Singer, 2010).  
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4.2 Materials and Methods 
4.2.1 Animals 
  Experimental procedures were performed on two male rhesus macaques 
(Macaca mulatta; age 8–11 years, weight 9–12 kg) in accordance with the 
Canadian Council of Animal Care policy and a protocol approved by the Animal 
Care Committee of the University of Western Ontario Council on Animal Care. 
This paper analyzes the LFPs from previously published datasets (Major et al., 
2015). These monkeys were previously subjects in pharmacological studies using 
iontophoretic drug ejection (Major et al., 2015; Vijayraghavan et al., 2016; Major 
et al., 2018; Vijayraghavan et al., 2018) and a multielectrode array recording 
during systemic administration of ketamine (Skoblenick and Everling, 2012, 
Skoblenick and Everling, 2014; Ma et al., 2015; Skoblenick et al., 2016). Both 
animals had a head restraint and plastic recording chambers implanted above 
their right lateral PFC as described previously (Skoblenick and Everling, 2012). 
 
4.2.2 Behavioural Task 
 Behavioural task was identical to those described in previous reports 
(Major et al., 2015; Major et al., 2018). Briefly, animals performed a rule-based 
working memory task known as the pro- and antisaccade task (Fig. 4.1A; 
Everling and Fischer, 1998). After fixation on a central white dot (0.5°, 300 ms, 
fixation window 4° x 4°), a central coloured cue was flashed (red or green, 100 
ms), before reverting to white for another 800–1300 ms. Colours represented the 
current trial, pro- or antisaccade, and were counterbalanced between monkeys. 
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The fixation spot then disappeared during a brief gap period (150–300 ms). A 
peripheral stimulus was pseudorandomly presented to the left or right (0.5° 
dot,17° eccentricity). To receive liquid reward, subjects were required to make the 
appropriate saccade towards (prosaccade) or away from (antisaccade) the 
stimulus within 500 ms. Thus subjects had to maintain the task rule in working 
memory. Trials were separated by a 1700–2200 ms intertrial interval. Horizontal 
and vertical eye movements were recorded at 1 kHz with an EyeLink 1000 
infrared eye tracker and software package (SR Research). Task and reward 
delivery were controlled using CORTEX (National Institutes of Mental Health). 
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Figure 4.1 
Experimental paradigm and recording with concurrent iontophoresis. 
A, After central fixation (300 ms), a green or red cue was flashed (100 ms), 
indicating a pro- or antisaccade trial. This task rule was maintained over an 800–
1300 ms delay and a short gap (150–300 ms). Subjects then performed a 
saccade towards (prosaccade) or away from (antisaccade) the peripheral 
stimulus to receive liquid reward. Dashed circles represent gaze of the animal 
and white arrows represent saccade direction. ITI, intertrial interval. B, 
Extracellular recordings were performed in the right dorsolateral prefrontal 
cortices of two rhesus macaques. Custom-made glass iontophoretic electrodes 
were used to eject general muscarinic antagonist scopolamine and general 
cholinergic agonist carbachol onto neurons and the local extracellular space. 
Beige area represents recording locus. AC, arcuate sulcus; PS, principal sulcus. 
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Delay 800–1300 ms
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Fixation 300 ms
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A
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saccade
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4.2.3 Recording and drug administration 
 Electrophysiological recordings were performed using custom seven-
barreled glass iontophoretic electrodes as reported previously (Major et al., 2015; 
modified from the design of Millar and Williams, 1989). Briefly, seven-barreled 
glass pipettes (Friedrich and Dimmock) were pulled over 50 µm diameter 
tungsten wire (Midwest Tungsten Service) using a PMP107L-e Multipipette Puller 
(MicroData Instrument). Typical impedances of the tungsten recording electrode 
ranged from 0.5 to 1 MΩ (measured at 1 kHz). General muscarinic antagonist 
scopolamine (scopolamine hydrobromide; 100 mM) and general cholinergic 
agonist carbachol (carbamoylcholine chloride; 100 mM) were dissolved in pH 3 
deionized water and pushed to the tip of peripheral barrels in the glass electrode 
(Tocris Bioscience). Drugs were ejected using a Neuro Phore BH-2 iontophoretic 
ejection system (Harvard Apparatus; ejection currents of 5–100 nA with no 
current balancing, -8 nA retention current). There is no effect of pH of drug 
solution on neuronal discharge rate (Disney et al., 2007; Vijayraghavan et al., 
2007). The electrode was mounted on a hydraulic micromanipulator (MO-95, 
Narishige Group) and lowered into dorsolateral PFC (Fig. 4.1B) through a 23-
gauge dura-penetrating stainless steel guide tube. 
 
4.2.4 Data Analysis 
 At least one recorded neuron was present in all analyzed channels. 
Neuronal signals were amplified, digitized, and filtered (0.5–200 Hz, four-pole 
Bessel) with an OmniPlex Neural Data Acquisition System (Plexon). LFP data 
was analyzed offline (MATLAB, MathWorks) using the FieldTrip toolbox (Donders 
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Institute for Brain, Cognition and Behaviour; Oostenveld et al., 2011).  
 Artifacts in the continuously recorded LFP were removed using z-score 
thresholding. Due to variability in noise levels across different recording sessions, 
z-score threshold was set manually for each recording. All sessions were visually 
inspected for artifacts based on variance, absolute values, and physiological 
shape of power spectrum. Additionally, only channels with at least 10 prosaccade 
trials and 10 antisaccade trials during both control and drug conditions were 
included in the analysis.  
Data was low-pass filtered at 150 Hz (six-pole Butterworth) and line noise 
was removed at 60 and 120 Hz with discrete Fourier transform. To determine 
time-frequency representations of trial-aligned LFP power, fast Fourier 
transformation was performed using a Hanning window (7 cycles for each 
frequency) every 50 ms across the entire frequency range (1–60 Hz). 
Changes in LFP power were examined in two task trial periods: baseline 
epoch (intertrial interval; last 600 ms before start of trial) and delay epoch 
(prosaccade and antisaccade trials; 200 ms to 800 ms after rule cue, first 200 ms 
of delay were omitted to avoid visual representation of cue and focus on 
mnemonic period). In order to reliably compare power between different 
recording sessions, different animals, and to avoid any possible noise related to 
iontophoretic drug ejection, decibel normalization was used. To observe effects of 
drugs on individual epochs, drug condition was normalized to control condition 
(Fig. 4.2B and 4.2D): 
Pnorm  =  10  x  log10(Pdrug/Pcontrol) 
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To observe delay-related effects in the delay epoch, delay epoch was 
normalized to baseline epoch (Fig. 4.3): 
Pnorm  =  10  x  log10(Pdelay/Pbaseline) 
To quantify rule preference of LFP power, d’ was calculated to contrast 
power between pro- and antisaccade rules in the delay epoch: 
d’  =   x̄anti  -­‐  x̄pro!!(s!"#$! + s!"#! )  
where x̄ is mean (of antisaccade and prosaccade trials) and s is standard 
deviation of a channel’s trial-wise power. Preference for pro- and antisaccades 
varied significantly depending on the recording (e.g., some recordings have 
greater beta power during antisaccades, some have greater beta power during 
prosaccades). Therefore, we analyzed power preference using absolute d’, to 
show overall ability of frequency bands to represent power regardless of binary 
trial preference. 
 To determine significant changes in normalized power and changes in d’, 
we first performed Wilcoxon signed rank tests on the classically defined 
frequency bands: theta (3–7 Hz), alpha (8–13 Hz), beta (14–35 Hz), and low 
gamma (36–60 Hz). However, drug-induced effects don’t necessarily operate 
within these precise predefined frequency bands. Therefore, we also used a 
nonparametric cluster-based method to identify significantly changed frequency 
bands without a priori band definitions (Maris and Oostenveld, 2007). Specifically, 
Wilcoxon signed rank tests were performed on power data, resulting in z statistics 
at each frequency. Frequencies with z statistic values within the 10th and 90th 
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quantiles were removed, and the remaining values were sorted into clusters 
based on frequency adjacency. Each cluster’s z statistics were summed. 
Significance of clusters was determined by comparing cluster z statistic sums to a 
distribution of maximum z statistic sums from 1000 iterations of randomly 
permuted data. Clusters with z statistic sums greater than 99.5% of shuffled z 
statistic maximum sums were considered significantly different between 
conditions. 
 
4.3 Results 
 Two rhesus macaques were trained on the “memory gap” variant of the 
antisaccade task (Fig. 4.1A), which requires both rule association with a coloured 
cue and maintenance of that cue in working memory. This type of task is known 
to recruit dorsolateral PFC (Fig. 4.1B; Funahashi et al., 1993b) and likely recruits 
cholinergic input due to its attentional requirement (Kozak et al., 2006). We 
sought to characterize the local role of cholinergic receptors in macaque 
dorsolateral PFC during performance of this rule-based working memory task. 
Concurrent with extracellular recordings, general muscarinic antagonist 
scopolamine and general cholinergic agonist carbachol were applied via 
iontophoresis. These drugs’ effects on neuronal spiking activity in macaque PFC 
have been previously characterized (Major et al., 2015, Major et al., 2018). This 
report now explores the effect of local cholinergic receptor perturbation on LFP 
power during working memory performance. A total of 30 recording sessions 
were included in the analysis of scopolamine application (Monkey T: n = 13, 
Monkey O: n =17) and 30 sessions in the analysis of carbachol application 
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(Monkey T: n = 16, Monkey O: n = 14). Each trial’s delay period was analyzed 
from 200 ms to 800 ms after cue onset, as the subjects fixated and maintained 
rule information in working memory (Fig. 4.1A). The 600 ms intertrial interval 
before fixation was used as baseline. Drug application was always preceded by a 
control condition, each typically lasting a minimum of 10 min. Absence of drug 
effects on behavioural metrics has been described previously (Major et al., 2015, 
Major et al., 2018).  
 
4.3.1 Effect of cholinergic receptor perturbation on LFP power 
 Mean LFP power during baseline and delay epochs, before and after drug 
applications, are shown in Figure 4.2A. Figure 4.2B illustrates the change in 
power after scopolamine on individual epochs as drug condition power decibel 
normalized to control condition power for each frequency (±SEM). Using 
classically defined frequency bands (theta: 3–7 Hz, alpha: 8–13 Hz, beta: 14–35 
Hz, and low gamma: 36–60 Hz), no significant changes in power were observed 
in the baseline or delay epochs (p > 0.05, Wilcoxon signed rank test of 
normalized power vs. zero). However, drug-induced changes to cortical 
oscillations would not necessarily follow these predetermined frequency ranges. 
We therefore performed a nonparametric cluster-based method across all 
frequencies from 1 to 60 Hz (Oostenveld et al., 2011; clustering of Wilcoxon 
signed rank test z statistics, see Materials and Methods). During the baseline 
epoch, the cluster-based method identified that low beta power (17–21 Hz) during 
scopolamine condition was significantly decreased compared to the control 
condition (p < 0.005, normalized power vs. zero; shown as a horizontal bar below 
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curve in Fig. 4.2B, left panel). During the delay epoch, alpha/low beta normalized 
power was increased during prosaccades (12–14 Hz, p < 0.005; Fig. 4.2B, middle 
panel), and high beta normalized power was increased during both prosaccades 
(26–31 Hz; p < 0.005) and antisaccades (30–35 Hz; p < 0.005; Fig. 4.2B, right 
panel). Overall, scopolamine decreased low beta power during the baseline 
epoch and increased high beta power during the delay epoch. 
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Figure 4.2 
Effect of local muscarinic blockade and cholinergic stimulation on raw local field 
potential (LFP) power. 
A, Mean LFP power during the baseline (black) and delay (green) epochs during 
control (solid line) and scopolamine (dashed lines) conditions are shown on a 
logarithmic scale for 30 sessions. B, Mean normalized power (±SEM; 
scopolamine condition power normalized to control condition power) is shown for 
the baseline epoch (left panel), delay epoch during prosaccade trials (middle 
panel), and delay epoch during antisaccade trials (right panel). These values 
signify the change in power at different frequencies between control and 
scopolamine conditions for each epoch. Thick solid lines denote frequencies that 
were significantly different between control and drug conditions (see Results). C, 
Mean LFP power before and after carbachol application for 30 sessions. 
Conventions are the same as in A. D, Mean normalized power (±SEM; carbachol 
condition power normalized to control condition power). These values signify the 
change in power at different frequencies between control and carbachol 
conditions for each epoch. Conventions are the same as in B. 
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 Mean LFP power before and after cholinergic agonist carbachol 
application are shown in Figure 4.2C. Relative to scopolamine, carbachol 
generally had a more enhancing effect on LFP power. Using a nonparametric 
cluster-based method, change in normalized high beta power (26–31 Hz) was 
significantly greater than zero in the baseline epoch. During the delay period of 
both pro- and antisaccade trials, change in normalized theta power (3–6 Hz) was 
significantly greater than zero. In contrast to scopolamine, which had effects 
limited to the beta band, carbachol significantly increased both beta and theta 
power in the baseline and delay epochs, respectively. 
 
4.3.2 Cholinergics receptors modulate delay-related beta power 
 Next, we searched for delay-epoch-specific effects of cholinergic drug 
ejection to gain further insights into working memory maintenance in this rule-
based task. To reliably compare delay-related power between different recording 
sessions, delay epoch power was decibel normalized to baseline epoch. 
Normalized power data in the delay epoch before and after drug applications are 
shown in Figures 4.3A and 4.3D. These figures illustrate that compared to the 
baseline epoch, delay power was generally decreased at most frequency bands 
(shown as blue in Fig. 4.3A and 4.3D) except in the alpha and beta frequency 
bands, which were enhanced (shown as red).  
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Figure 4.3 
Delay-related effects of scopolamine and carbachol on delay period LFP power. 
A, Delay period LFP power, decibel normalized to baseline epoch, during control 
(left panels) and scopolamine conditions (right panels), split into prosaccade (top 
panels) and antisaccade trials (bottom panels). Data are aligned to 200 ms after 
cue onset at start of delay epoch. B, Mean change in normalized power (±SEM; 
delay epoch normalized to baseline epoch; scopolamine condition normalized 
power minus control condition normalized power) for prosaccade trials (top panel) 
and antisaccade trials (bottom panel). Thick solid lines denote frequencies that 
were significantly different between control and drug conditions (see Results). C, 
Scopolamine-induced change in normalized power, split into separate subjects: 
Monkey T (left panels) and Monkey O (right panels). D, Delay period normalized 
LFP power before and after carbachol application. Conventions are the same as 
in A. E, Mean change in normalized power between control and carbachol 
conditions, for both prosaccade trials (top panel) and antisaccade trials (bottom 
panel). Conventions are the same as in B. F, Carbachol-induced change in 
normalized power, split by separate monkeys. G,  
Difference between scopolamine-induced change and carbachol-induced 
change. Change in normalized power due to carbachol is subtracted from change 
in normalized power due to scopolamine (±SEM) for prosaccade trials (left panel) 
and antisaccade trials (right panel). Positive values signify delay-related power at 
that frequency was augmented more by scopolamine than by carbachol. For 
example, during the delay epoch of prosaccade trials, normalized beta power 
was increased more by scopolamine application (see B, top panel) than by 
carbachol application (see E, top panel), resulting in negative t statistics and thus 
denoted in blue in G (right panel). Thick solid lines denote frequencies that were 
significantly different between control and drug conditions. 
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 Mean scopolamine-induced change in normalized power (±SEM) is shown 
for each frequency in Figure 4.3B. To examine drug-induced changes in delay-
related LFP power, we first examined the classically defined frequency bands 
using Wilcoxon signed rank test. In these bands, neither scopolamine nor 
carbachol revealed any significant effects (p > 0.05, Wilcoxon signed rank test). 
Nonparametric permutation test was performed to evaluate changes in delay-
related power during prosaccade and antisaccade trials of the delay epoch (e.g., 
top panel of Fig. 4.3B is the result of a direct comparison between the upper 
panels in Fig. 4.3A). Permutation test revealed that scopolamine application 
significantly increased delay-related power in a select frequency range of the high 
beta band during both prosaccades (27–32 Hz; p < 0.005, normalized control 
power vs. normalized drug power; Fig. 4.3B, top panel) and antisaccades (31–35 
Hz; p < 0.005; Fig. 4.3B, bottom panel). It is important to note that this change in 
delay-related power is the result of high beta power increasing more in the delay 
epoch (Fig. 4.2B, middle and right panels) than in the baseline epoch (Fig. 4.2B, 
left panel). Similar patterns were observed when data were separated by subject 
(Fig. 4.3C), however we did not explore single subject significance due to low 
number of individual monkey sessions (Monkey T, n = 13; Monkey O, n = 17).  
 Delay-related power before and after iontophoretic carbachol application 
are shown in Figure 4.3D. In the delay epoch of prosaccades, normalized power 
after carbachol application was significantly decreased in the low beta range (14–
17 Hz; p < 0.005; Fig. 4.3E, top panel; this is a direct comparison between the 
upper panels in Fig. 4.3D). This change in 14–17 Hz low beta is due to low beta 
increasing more in the baseline epoch (Fig. 4.2D, left panel) than in the delay 
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epoch of prosaccade trials (Fig. 4.2D, middle panel). In contrast to the delay-
related effect of scopolamine, this carbachol-induced decrease in low beta may 
not be specifically related to mnemonic processing. Individual subject change in 
normalized power is shown in Figure 4.3F (Monkey T, n = 16; Monkey O, n = 14). 
During antisaccade trials, no changes in delay-related power were observed.  
 Next, we directly compared the effects of scopolamine and carbachol on 
the delay-related power in prosaccade trials (Fig. 4.3B, upper panel vs. Fig. 4.3E, 
upper panel), which is visualized in Figure 4.3G (left panel). We also compared 
the effects during antisaccade trials (Fig. 4.3B, lower panel vs. Fig. 4.3E, lower 
panel), shown in Figure 4.3G (right panel). Using classical frequency bands, no 
significant differences were observed between scopolamine-induced changes 
and carbachol-induced changes in normalized power (p > 0.05, Wilcoxon rank 
sum test). Next we performed cluster-based permutation test and found that 
scopolamine enhanced high beta activity more than carbachol, during both 
prosaccades (26–30 Hz; p < 0.005, clustering of Wilcoxon rank sum test z 
statistics) and antisaccades (31–35 Hz; p < 0.005). These effects are likely driven 
by the scopolamine-induced increase in high beta compared to the lack of effect 
of carbachol on high beta (i.e., compare Fig. 4.3B and 4.3E). 
 In summary, scopolamine increased delay-related high beta power in the 
delay period of both trial types, while carbachol decreased delay-related low beta 
power during prosaccade trials only. When compared directly, scopolamine 
increased high beta power more than carbachol. 
 
4.3.3 Effect of cholinergic receptor perturbation on rule preference of LFP power 
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 Prosaccade or antisaccade preference of normalized LFP power was 
determined using d’, an index accounting for both differences in mean and 
variance in power within each rule (see Materials and Methods; e.g., greater d’ 
values signify greater normalized power differences between prosaccade and 
antisaccade trials). We were interested in overall ability for LFP power to 
represent rule preference, rather than prosaccade- or antisaccade-specific 
preference (which varied between recording locations as one would expect from 
a region that represents both rules). Therefore, to explore drug-induced 
enhancement or suppression in rule preference of power, we compared absolute 
d’ before and after drug application at all frequencies. Figure 4.4A (left panel) 
displays mean absolute d’ rule preferences (±SEM) for each frequency during 
control condition (blue) and scopolamine condition (red). Permutation test 
revealed absolute d’ was significantly reduced in a narrow frequency range of 
gamma (57–60 Hz). As an exploratory measure, we further investigated changes 
in the binned classical frequency bands using Wilcoxon signed rank test. 
Scopolamine decreased absolute rule d’ in beta (14–35 Hz, p = 0.0034; Fig. 4.4B, 
top panel) and low gamma (36–60 Hz, p = 0.0023; Fig. 4.4B, bottom panel) 
frequency bands. Rule preference was not significantly affected in the theta (3–7 
Hz; p = 0.1779) or alpha frequency bands (8–13 Hz; p = 0.2802).  
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Figure 4.4 
Rule preference of normalized LFP power before and after drug application. 
A, Mean rule preference, as measured by absolute d’, of control (blue) and 
scopolamine (red) conditions for all frequencies. Shaded error bars denote SEM. 
Thick solid lines denote frequency bands with significantly different absolute d’ 
between control and scopolamine conditions. B, Scatter plots are shown for beta 
and low gamma frequency band as an exploratory analysis, with individual 
sessions’ absolute d’ during control (abscissa) and scopolamine (ordinate) 
conditions. For example, sessions with greater rule preference during the control 
condition compared to the drug condition are shown below the equality line. p 
value from Wilcoxon signed rank test is shown for each frequency band. C, Rule 
preference before and after carbachol application. Conventions are the same as 
in A.  
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  The effect of local carbachol application on rule preference of power was 
not as strong as scopolamine. Permutation test only revealed a carbachol-
induced decrease in a small frequency range of high beta power (27–29 Hz). 
There were no significant effects in the binned frequency bands (theta: p = 
0.1846, alpha: p = 0.9754, beta: p = 1779, low gamma: p = 0.2289; Fig. 4.4B, 
right panels). Overall, muscarinic blockade attenuated rule preference in beta and 
low gamma frequency bands, whereas cholinergic receptor stimulation by 
carbachol only affected rule preference of LFP power in a narrow beta frequency 
range. 
 
4.4 Discussion 
  The cholinergic system innervates PFC and is crucial for effective 
cognitive processing (Ballinger et al., 2016). LFPs show task-related tuning 
during cognitive tasks and mediate communication between brain areas (Fries, 
2015). Neuronal activity in a given region tends to oscillate, with excited phases 
followed by suppressed phases. If two connected regions are coherent (i.e., 
excited phases occurring simultaneously or with minimal lag), action potentials 
delivered from one area to the other are more likely to result in a post-synaptic 
action potential, compared to an action potential arriving at a suppressed phase 
(Fries, 2015). LFPs can be affected by cholinergic influence and the current study 
aims to characterize the effect of cholinergic receptors on LFP during rule-based 
working memory. Our findings show that local application of cholinergic 
compounds affect PFC oscillations and alter delay-related mnemonic LFPs. The 
muscarinic antagonist scopolamine primarily affected beta activity: it decreased 
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low beta power during baseline and delay epochs in prosaccade trials; and 
increased high beta power in the delay epoch under both rules. This heightened 
high beta during the mnemonic period led to increased delay-related high beta 
power for both rules. However, these effects were not beneficial to rule 
preference of LFP power, which was decreased in both beta and low gamma 
frequency bands. The cholinergic agonist carbachol enhanced beta power during 
the baseline epoch and increased theta power in the delay epoch. Carbachol only 
affected delay-related power in the low beta band, which was decreased during 
prosaccade trials. Carbachol decreased rule preference of power in a small 
frequency band of beta. Below, we will discuss the effects of the cholinergic 
compounds on LFP power, on delay-related oscillations, and the effect of 
scopolamine on LFP power rule preference. 
 
4.4.1 Beta power was enhanced by both scopolamine and carbachol 
 Similar to theta, beta oscillations may couple information between distant 
cortical regions (Kay and Beshel, 2010; Parnaudeau et al., 2013; Babapoor-
Farrokhran et al., 2017). Beta oscillations have been thoroughly explored in 
motor networks, wherein rhythmicity increases after cue presentation that directs 
a movement, and diminishes upon movement onset (Sanes and Donoghue, 
1993; Baker et al., 1997). Beta activity may play a similar role during cognitive 
tasks, to maintain a cognitive set over delay periods (Siegel et al., 2009; Engel 
and Fries, 2010; Salazar et al., 2012) via top-down coordination from higher-
order cortices such as lateral PFC (Buschman and Miller, 2007; Bastos et al., 
2015; Mejias et al., 2016). In the present study, we observed an enhancement of 
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beta oscillations after cue presentation, during the mnemonic delay period, in 
both control and drug conditions (Fig. 4.3A and 4.3D). This appears to be 
consistent with reports that beta is involved in maintenance of cognitive set, or 
“status quo”, prior to an informed response (Spitzer and Haegens, 2017). 
 After cholinergic drug application, we found beta oscillations were the most 
frequently affected frequency band. However, the low and high beta frequency 
ranges experienced different effects. Both scopolamine and carbachol could 
enhance LFP power, especially in the higher beta frequency range (Fig. 4.2). 
Muscarinic blockade suppressed low beta power in the baseline epoch and delay 
epoch during prosaccades, yet increased high beta power during the delay period 
of both rules (Fig. 4.2B and 4.3B). Previous reports suggest that cholinergic 
stimulation can increase beta activity, while muscarinic blockade has been 
speculated to decrease beta activity (Lee et al., 2013). Therefore, our 
scopolamine-induced increase in beta power was unexpected. Yet increased 
beta power may follow the antimuscarinic pattern of disrupting working memory 
functions: beta oscillations are proposed to be inhibitory to feedforward working 
memory signals in superficial layers of PFC (Miller et al., 2018). Thus, increasing 
local beta activity could decrease working memory capacity of the local 
microcircuit. Without further experiments, we can only speculate on potential 
mechanisms of how scopolamine increased beta activity. 
 There are multiple proposed generators of beta rhythms, including either 
local or distal pacemakers (Whittington et al., 2000). For example, loops between 
basal ganglia and cortex have been shown to propagate beta, and are overactive 
in Parkinson’s disease (Holgado et al., 2010; Leventhal et al., 2012). Medial 
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dorsal nucleus of the thalamus (MD) has been proposed to drive cortical beta 
activity (Ketz et al., 2015) and MD-PFC beta synchrony may correlate with spatial 
working memory performance (Parnaudeau et al., 2013). The connection 
between MD and PFC is well established in macaques (Giguere and Goldman-
Rakic, 1988). Our drug application may have influenced these thalamocortical 
connections. Thalamocortical terminals express muscarinic and nicotinic 
receptors in rodents (Gioanni et al., 1999; Lambe et al., 2003; Broicher et al., 
2008; Bista et al., 2012), but have not been established in primates. 
  Using Granger causality, Babapoor-Farrokhran et al. (2017) found beta 
activity in ACC may drive frontal eye field beta activity. Muscarinic receptors have 
been proposed to gate such corticocortical afferents (Gil et al., 1997). 
Connections between frontal areas (ACC and area 46 to area 9) express 
muscarinic M2 receptors (Medalla and Barbas, 2012), which are typically 
considered inhibitory. Therefore, it’s possible scopolamine disinhibited incoming 
corticocortical afferents via muscarinic M2 receptor blockade, enhancing 
propagation of beta activity. 
 Alternatively, previous models and in vitro experiments have shown that 
reciprocally connected pyramidal and inhibitory neuron networks can produce 
beta rhythms locally, without input from distant regions. Of particular relevance, 
this proposed intrinsic beta rhythm relies on the M current in pyramidal neurons, 
the very current blocked by muscarinic receptor activation (Jensen et al., 2005; 
Roopun et al., 2006; Kramer et al., 2008). Models have suggested it is cholinergic 
stimulation, not muscarinic blockade, that would enhance beta activity (Sherman 
et al., 2016). Cholinergic stimulation has indeed been shown to induce beta 
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oscillations in both hippocampal and cortical slices (Arai and Natsume, 2006; van 
Aerde et al., 2009; Lee et al., 2013; Hashimoto et al., 2017). Here, carbachol 
increased beta oscillations in the baseline epoch (Fig. 4.2D, left panel). It is 
curious that both muscarinic blockade with scopolamine and cholinergic 
stimulation with carbachol elicited increased beta activity, and suggests these 
effects occurred via different mechanisms. As previously mentioned, nicotinic 
receptors have been proposed to presynaptically gate cortical afferents from 
thalamus (Gil et al., 1997; Gioanni et al., 1999; Lambe et al., 2003), a potential 
generator of beta rhythms (Ketz et al., 2015). Further experiments are required to 
disambiguate the mechanisms by which these compounds enhanced high beta 
activity. 
  In the low beta range, carbachol increased baseline power more than 
prosaccade delay power, resulting in decreased delay-related low beta power 
during prosaccades (Fig. 4.3E, top panel). Although this was a delay-related 
change, this nonspecific increase is reminiscent to overstimulation of cholinergic 
receptors (opposed to an effect on working-memory-related circuitry), as seen 
during spiking activity (Sato et al., 1987; Zinke et al., 2006; Herrero et al., 2008; 
Major et al., 2018). 
 
4.4.2 Cholinergic stimulation enhanced theta power 
 Theta activity is associated with entrainment of distant cortical areas, such 
as during mnemonic processing (Fell and Axmacher, 2011; Colgin, 2013). Theta 
phase can predict attentional performance in both macaques (Fiebelkorn et al., 
2018) and humans (Fiebelkorn et al., 2013) and is enhanced during increased 
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task difficulty or working memory load (Sauseng et al., 2005; Payne and Kounios, 
2009). 
 Acetylcholine release is coincident with visual cue presentations 
(Richardson and DeLong, 1986; Parikh et al., 2007) and elicits cortical 
desynchronization (Metherate et al., 1992; Harris and Thiele, 2011), which is 
thought to enhance processing of sensory information (Goard and Dan, 2009). 
Cholinergic drive may influence theta propagation. Cape and Jones (2000) found 
NMDA microinjection to rat basal forebrain (a source of cortical acetylcholine) 
increased neocortical theta activity. Some neurons of the nucleus basalis may 
discharge rhythmically in the theta range (Buzsaki et al., 1988; Khateb et al., 
1992; Lee et al., 2005), but cholinergic neurons of medial septum, another 
possible source of theta oscillations (Vertes and Kocsis, 1997; Colgin, 2013), do 
not fire rhythmically with theta (Simon et al., 2006). 
Here, cholinergic stimulation enhanced theta power in the delay epoch 
(Fig. 4.2D, middle and right panels). Although we may have expected carbachol 
application to mimic the aforementioned endogenous cholinergic 
desynchronization (i.e., a decrease in low frequency power), previous in vitro 
research has reported carbachol can induce theta oscillations in hippocampal 
slices (Bland and Colom, 1993; Levesque and Avoli, 2018), anesthetized rats 
(Rowntree and Bland, 1986), and human temporal cortex slices (Florez et al., 
2015). Notably, Yener et al. (2007) found untreated Alzheimer’s disease patients 
(with a deficient cholinergic system) had disrupted frontal theta oscillations, but 
theta activity of healthy participants and acetylcholinesterase-treated patients 
was normal. 
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 In contrast to our predictions, our findings were not consistent with some 
reports of systemic drug administration to humans and concurrent EEG 
recordings. For example, cholinergic receptor stimulation was expected to 
increase alpha power (Saletu et al., 1989; Knott et al., 1998; Fisher et al., 2012), 
but we found alpha oscillations were not affected in any metric and may be more 
resilient to local drug ejection. This discrepancy may be related to differences 
between systemic and local drug application, or state differences between EEG 
recordings during rest and LFP recordings during task performance. Local drug 
ejection is an important tool to examine how different neurotransmitters influence 
LFP, and may bridge our knowledge between systemic injections and slice 
physiology. 
 Curiously, our findings appear more consistent with in vitro results, which 
have shown carbachol can induce theta, beta, and low gamma oscillations in rat 
hippocampal and medial PFC slices (Fellous and Sejnowski, 2000; Arai and 
Natsume, 2006; van Aerde et al., 2009; Hashimoto et al., 2017). Florez et al. 
(2015) investigated LFP activity in human temporal neocortical slices from 
epileptics. They found these slices were able to produce theta and gamma 
oscillatory activity when both glutamatergic and cholinergic receptors were 
stimulated (via kainate and carbachol). Further, they found it was specifically the 
muscarinic variety of cholinergic receptors that were required for this activity. 
Florez et al. (2015) also reported phase coherence between IPSCs in pyramidal 
cells and theta oscillations, suggesting this neocortical theta likely requires both 
pyramidal and inhibitory neurons. In opposition of the view that cortical theta 
rhythms originate from distant generators such as hippocampus (Buzsaki, 2002), 
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Florez et al (2015) and others (Raghavachari et al., 2006) have shown that with 
the help of glutamatergic and muscarinic receptors, theta rhythms can be 
generated locally in small volumes of neocortex. It is possible that the carbachol-
induced enhancement of theta power observed here (Fig. 4.2D), similar to 
proposed intrinsic mechanisms of beta generation (Roopun et al., 2006), was 
triggered by local muscarinic-receptor-mediated mechanisms.  
 Certain cell types differentially influence generation of cortical LFP 
oscillations (Takada et al., 2014; Voloh and Womelsdorf, 2018). Our observed 
effects may be mediated by cholinergic receptors expressed on GABAergic 
interneurons (Mrzljak et al., 1993; Kawaguchi, 1997; Mrzljak et al., 1998; Porter 
et al., 1999; Disney et al., 2007; Gulledge et al., 2007; Disney and Aoki, 2008; 
Medalla and Barbas, 2012). Future work is required to explore the effects of 
different cholinergic receptor subtypes on different interneuron populations. 
Cholinergic receptors are well positioned to influence communication between 
brain regions and have been shown experimentally to modulate LFP oscillations. 
 
4.4.3 Muscarinic antagonism disrupted task rule preference of cortical 
oscillations 
 Several investigators have shown that prefrontal field oscillations can be 
tuned to represent different task aspects, such as cue location during memory-
guided saccades (Pesaran et al., 2002; Womelsdorf et al., 2007; Babapoor-
Farrokhran et al., 2017) and pro- vs. antisaccades (Ma et al., 2018). Using multi-
electrode recording, Buschman and Miller (2007) found that task rules during a 
saccadic task were represented in the LFP of macaque dorsolateral PFC in the 
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alpha and beta frequencies. From this, we expected disruption of normal 
cholinergic signaling to disturb attention-related beta signaling. 
 We used absolute d’ to measure magnitude of rule representation in delay-
related LFP power. Scopolamine attenuated rule preference in beta and low 
gamma frequency bands, but not rule preference in theta or alpha bands (Fig. 
4.4A). These effects of scopolamine are reminiscent of previous spiking data, 
which showed strong attenuation of task selectivity for several task aspects 
(Major et al., 2015). 
 The effects of carbachol on LFP rule preference were not as strong as 
scopolamine. The relatively weak effect of carbachol on power rule preference is 
surprising considering it disrupted selectivity of neuronal spiking (Major et al., 
2018) and suggests that LFP representation of task-relevant information may be 
more resilient to change than single unit activity. 
 The present results illuminate potential mechanisms by which endogenous 
acetylcholine affects cortical oscillations. Acetylcholine is released during 
heightened attention, and influences cortical oscillations through muscarinic and 
nicotinic receptors. We observed the most robust effects in the beta frequency 
band, which is associated with motor preparation and maintenance of task set. 
As investigators unravel laminar differences in cortical oscillations (Bastos et al., 
2018, Johnston et al., 2019), future work should examine differential cholinergic 
influence on these layers. The use of receptor-subtype-selective compounds will 
yield important implications for disorders of cognition, as cholinergic receptor 
expression is affected in both Alzheimer’s disease (Flynn et al., 1995; Rodriguez-
Puertas et al., 1997) and schizophrenia (Dean et al., 2002; Leonard et al., 2002).  
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CHAPTER 5 – GENERAL DISCUSSION 
 
5.1  Summary of Main Findings 
Disorders of cognition such as AD and SZ are burdened with impaired 
cognitive functions that is associated with abnormal prefrontal and cholinergic 
functioning. The objective of this research project was to examine the ability of 
different cholinergic receptors to influence prefrontal neuronal activity, such that 
we may gain insights into altered cognitive function in conditions of impaired 
cognition. In general, we found that application of cholinergic compounds 
influenced discharge rates and was often maladaptive to task-related activity, 
such as delay period rule preference. Local cortical oscillatory power was also 
affected, especially in the beta frequency band. Receptor subtype-specific 
compounds now allow characterization of specific muscarinic receptors through 
allosteric binding sites and future work is required to continue exploration of 
different muscarinic receptors subtypes’ functions. 
 
5.1.1 Local cholinergic stimulation had mixed effects on prefrontal activity and 
decreased task-related rule preference 
 Previously, we have reported local antagonism of muscarinic receptors 
suppressed prefrontal neuronal discharge rate and task-related selectivity during 
macaque performance of the memory antisaccade task (Major et al., 2015). 
These findings coincide with the abundant literature that shows muscarinic 
blockade is disruptive to performance in multiple cognitive domains (Klinkenberg 
and Blokland, 2010). Next, we sought to emulate the effects of acetylcholine 
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using the general cholinergic agonist carbachol. Carbachol yielded mixed effects 
on discharge rate: some neurons were excited and others were suppressed. 
However, putative pyramidal neurons more often increased discharge rate. 
  The mechanisms behind this pyramidal-neuron-specific effect remain 
speculative. Mixed effects of local cholinergic receptor stimulation have been 
found in other cortical recordings (Inoue et al., 1983; Aou et al., 1983; Nelson et 
al., 1973; Matsumura et al., 1990; Soma et al., 2012), including data on 
interneurons (Pafundo et al., 2013). Sawaguchi and Matsumura (1985) 
suggested different cortical layers respond differently to exogenous transmitter 
application, e.g., with ACh having the most excitatory effect in supra- and 
infragranular layers. The rise of linear electrode arrays with combined 
pharmacology will allow for more precise exploration of cholinergic receptors in 
different cortical layers. 
 Upon examination of rule neurons (i.e., neurons that preferentially fire for 
one task rule over the other), we found carbachol attenuated the ability of 
prefrontal neurons to discriminate between rules. Two different clusters of 
neurons were identified within this group of decreased rule tuning. Some neurons 
were excited, with activity increasing more for nonpreferred rules than preferred 
rules. Other neurons were inhibited, with activity decreasing more for preferred 
rules than nonpreferred. We can only speculate, but this finding aligns with 
previous suggestions that for effective cognitive circuitry, there is an optimal 
range of cholinergic stimulation, in which too little or too much stimulation is 
disruptive (i.e., inverted-U curve). For example, Herrero et al. (2008) found that 
ACh can enhance attentional modulation of macaque V1 neurons, but higher 
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doses of ACh offered no advantage or decreased attentional modulation. 
Carbachol also attenuated putative pyramidal neurons’ ability to preferentially 
discharge for one saccadic direction over the other (e.g., left- or rightward 
saccades). 
 Our results suggest that similar to muscarinic blockade, overstimulation of 
cholinergic receptors can be maladaptive to normal prefrontal circuitry during 
rule-based WM behaviour. The mechanisms behind the observed decrease in 
task-related activity can be explored with the use of cholinergic receptor subtype-
specific compounds. 
 
5.1.2 Stimulation of muscarinic M1 receptors was inhibitory to prefrontal 
discharge rate and attenuated rule preference 
 The exploration of muscarinic receptor subtype was historically impeded 
by a lack of subtype-selective ligands. More recently, molecules have been 
designed to allosterically bind muscarinic receptor subtypes, such as VU0357017 
that selectively binds M1Rs. M1Rs are the most prevalent muscarinic receptor in 
cortex, are prominently found postsynaptically on dendritic spines of pyramidal 
neurons, and are typically considered excitatory (i.e., depolarizing to neuronal 
membrane potential). M1R agonists are an interesting pharmacological target 
because they have shown cognitive-enhancing abilities in macaques (Uslaner et 
al., 2013), people with AD (Bodick et al., 1997), and people with SZ (Shekhar et 
al., 2008). After characterizing the effects of muscarinic blockade and general 
cholinergic stimulation, we sought to detail the effects of receptor subtypes. 
Based on past in vitro electrophysiology, we predicted M1R stimulation would 
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excite prefrontal neurons. Using similar methodology, we iontophoretically 
applied M1R-selective agonist VU0357017 and M1R-preferring antagonist 
pirenzepine to prefrontal neurons during rhesus performance of antisaccades. 
 Unexpectedly, both stimulation and blockade of M1Rs suppressed 
discharge rates of prefrontal neurons. Although unexpected, inhibition after M1R 
stimulation is not unique. McCormick and Prince (1985) were among the first to 
show ACh application elicit two effects: brief inhibition followed by prolonged 
stimulation. Muscarinic receptors signal many complex second messenger 
pathways, which likely vary by cell type and receptor localization on neurons. For 
example, M1Rs can activate SK channels, which hyperpolarize neurons by 
allowing K+ entry (Gulledge and Stuart, 2005). M1R stimulation with VU0357017 
also decreased rule selectivity of prefrontal neurons at high doses. This effect is 
reminiscent of the carbachol-induced decrease in rule preference detailed in 
Chapter 2. However, most cases of decreased rule tuning were due to a greater 
magnitude of decreased preferred rule activity compared to nonpreferred rule 
activity. This finding highlights to importance of carefully selecting doses during 
pharmacological intervention of cognitive disorders. 
  When we found strong suppression of prefrontal activity after muscarinic 
blockade, we suggested this was prominently due to inhibition of excitatory drive 
from M1Rs. We tested this suspicion using local application of pirenzepine, an 
M1R-preferring antagonist. Although pirenzepine was indeed suppressive to 
neuronal activity, only around half of neurons were significantly inhibited, and this 
effect was only significant at the population level at high doses. We must be 
careful with our interpretations since pirenzepine also has binding affinity for 
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other muscarinic receptors, but these findings suggest other muscarinic receptors 
were also responsible for the strong inhibition observed after scopolamine 
administration. 
 
5.1.3 Cholinergic receptor perturbation primarily affects oscillatory power in the 
beta frequency band 
 Cortical oscillations are emerging as important aspect of cognitive circuitry 
during working memory behaviour (Fiebelkorn et al., 2013; Fries, 2015; Miller et 
al., 2018). For example, beta oscillations are thought to represent maintenance of 
task sets during delay periods of working memory tasks (Engel and Fries, 2010; 
Siegel et al., 2009; Salazar et al., 2012). This beta activity is thought to be a top-
down feedback signal from higher order cortices such as lateral PFC (Bastos et 
al., 2015; Mejias et al., 2016; Buschman and Miller, 2007). EEG activity (a 
noninvasive proxy for cortical voltage fluctuations) is disrupted in conditions of 
altered cognition such as AD and SZ (Jeong, 2004; Uhlhaas and Singer, 2010) 
and may represent the underlying aberrant circuitry. EEG abnormalities in AD 
correlate with cognitive impairment (reviewed in Jeong, 2004). Studies of both 
systemic and in vitro administration of drugs show that cholinergic receptors can 
influence cortical oscillations (Sloan et al., 1992; Arai and Natsume, 2006). There 
is discussion about the presence of both local and distant generators of 
oscillatory rhythms such as beta activity (Raghavachari et al., 2006), and we 
explored the effect of local cholinergic receptor manipulation on prefrontal LFP 
power during macaque performance of antisaccades.  
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 Local muscarinic blockade predominantly enhanced power in the high beta 
frequency band, especially during the delay period of pro- and antisaccades. The 
mechanisms of this task-related increase in beta activity remain unknown. Beta 
activity is associated with maintenance of task set during WM delays (Miller et al., 
2018), it is therefore unexpected that a drug with suppressive and anti-cognitive 
effects boosts delay-related beta activity. Other rhesus cortical regions densely 
express muscarinic receptors on PV interneurons (Disney and Aoki, 2008; Disney 
et al., 2014), which are known to facilitate widespread lateral inhibition (Wang et 
al., 2004). One may speculate that our observed enhancement of beta activity 
could be related to the removal of PV interneuron inhibition. However, more 
detailed investigations of interneurons are required. 
 Carbachol was found to enhance LFP power in the theta and beta 
frequency ranges. Carbachol’s effect on task-related changes during the delay 
epoch were not as pronounced as scopolamine. Similar to scopolamine 
application, the effects of carbachol did not match expectations based on past 
EEG recordings and systemic administration of cholinergic compounds (Sloan et 
al., 1992; Arai and Natsume, 2006). In fact, the multiband enhancement of 
oscillations seen with carbachol more closely resembled cholinergic stimulation in 
vitro (Florez et al., 2015). Since our results are similar to slice 
electrophysiological results, this suggests our carbachol-induced power 
enhancement may be via locally-generated theta and beta generators 
(Raghavachari et al., 2006). However, it is possible cholinergic stimulation is 
augmenting incoming theta and beta oscillations from distant regions (Buzsaki, 
2002; Roopun et al., 2006; Ketz et al., 2015). For example, cholinergic receptors 
	  	  
240 
are proposed to gate corticocortical and thalamocortical afferents (Gil et al., 1997; 
Gioanni et al., 1999; Lambe et al., 2003). 
 The effect of cholinergic compounds on local oscillations provides insight 
on conditions with altered cholinergic functioning. For example, cholinergic 
receptor expression is altered in AD and SZ (Flynn et al., 1995; Rodriguez-
Puertas et al., 1997; Dean et al., 2002; Leonard et al., 2002). Future 
examinations of the role of specific receptor subtypes on different neuronal 
classes will help unravel the role of the cholinergic system and oscillations in WM 
circuitry. 
 
5.2 Caveats and Limitations 
  Although we can argue the NHP model in neuroscience has many 
advantages over rodents — especially in the study of prefrontal cognitive circuitry 
— there are many differences between NHPs and humans. Firstly, humans can 
simply be instructed of the task rules and can be expected to learn new 
paradigms such as the antisaccade task almost immediately. In contrast, 
macaques must progressively learn oculomotor tasks over the course of many 
weeks through operant conditioning techniques. Training is thus long term and 
possibly involves different forms of memory compared to when a human is 
quickly taught the antisaccade task. Whereas a naïve human participant is relying 
solely on new instructions in WM, over-trained monkeys may be invoking 
procedural or conditioned responses in addition to WM. In addition, humans are 
known to often rely on verbal strategies during WM behaviour. Finally, as 
discussed at length in Chapter 1 (also see Coppola and Disney, 2018), there are 
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several between-species differences in the cholinergic system. Patterns of 
cholinergic innervation and distribution of cholinergic receptors vary between 
brain regions, cortical layers, and cell types. Despite these above disparities, 
NHPs remain one of the best models for studying prefrontal cognitive circuitry 
and have neuromodulatory systems that are much more similar to humans than 
rodent models. 
  Another potential caveat regarding the interpretation of these experiments 
is related to the time course of drug application. Our typical drug regimen is 
relatively long related to endogenous ACh dynamics. We would typically collect 
approx. 15–20 min of baseline activity as control, then a drug condition of similar 
length, and sometimes followed by a recovery condition. During the drug 
condition, the iontophoretic drug ejection from the electrode’s drug barrel into the 
extracellular space is continuous. This is our routine for a practical reason: we 
need to acquire enough behavioural trials to achieve statistically informative 
results. Some in vitro electrophysiology and combined pharmacology 
experiments examine cholinergic receptor function in a much more transient 
timeline. For example, applying drugs for seconds or a few minutes then 
observing resulting changes in discharge rate or conductance (Valentino and 
Raymond, 1981; Wang et al., 2003; Moore et al., 2011; Engle et al., 2012). 
 As discussed in Chapter 1, endogenous ACh is released and metabolized 
on the order of seconds. Thus, continuous ejection of a cholinergic compound 
such as carbachol is quite different from natural cholinergic receptor stimulation. 
It is possible, and perhaps likely, that our drug ejection stimulated cholinergic 
receptors much more than what is normal. As discussed in Chapter 2, we 
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suspect this overstimulation may be why task-related selectivity of neurons was 
decreased by carbachol. Although we did not observe this, it’s possible that very 
lower doses of carbachol could increased task-related activity, as others have 
found with low doses of ACh (i.e., in rhesus V1 during an attention-demanding 
task; Herrero et al., 2008). Further, carbachol is not broken down by 
cholinesterases as quickly as ACh, and therefore may have prompted a stronger 
effect. 
 Another issue is the availability of receptors after several minutes of 
receptor stimulation. Tonic exposure of exogenous cholinergic compounds over 
the course of an experiment likely leads to desensitization, internalization, and 
downregulation of receptors (Siman and Klein, 1979). Continuous application of 
general cholinergic agonist carbachol has been shown to reduce surface 
expression of muscarinic receptors within 30 minutes, especially for muscarinic 
M2 receptors and muscarinic M4 receptors (Thangaraju and Sawyer, 2012). 
Continuous application of muscarinic receptor antagonists such as scopolamine 
can actually lead to increased surface expression of muscarinic receptors (Wall 
et al., 1992; Witt-Enderby et al., 1995). Further, stimulation of muscarinic 
autoreceptors are known to decrease endogenous acetylcholine release from 
cholinergic terminals (Yonehara et al., 1980; Smiley et al., 1999; Zhang et al., 
1998). Originally, this was thought to be the primary function of M2Rs in cortex. 
Unfortunately, we do not know the state of cholinergic receptor expression over 
the time course of our experiments and must keep this in mind when drawing 
interpretations. 
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5.3 Future Directions 
 Future experiments should take a comprehensive approach to the design 
of local drug application timeline. For the reasons discussed above, it is important 
to supplement tonic drug ejection with transient drug ejection. For example, in a 
separate recording session, applying carbachol for 10 s and observing the short-
term effects on neuronal discharge rate and LFP power. This would be useful to 
complement the results on discharge rate from continuous drug ejection, 
although analysis of task-related neuronal activity would not be practical for this 
design. Also, future experimenters must remember the importance of using 
multiple drugs for each pharmacological target of interest. For example, the use 
of both VU0357017 and McN-A-343 to probe the role of M1R provided added 
certainty to the results. As discussed in Chapter 1, this is also important because 
different drugs can often display functional selectivity of second messenger 
pathways (Urban et al., 2007; Thomas et al., 2008; Digby et al., 2012). Using 
multiple drugs can be especially important for newly developed compounds for 
which functional details are not complete, e.g., if binding affinities for different 
receptors have not been fully explored. VU0357017 was originally thought to only 
stimulate M1Rs via allosteric mechanisms, but a more recent study reports this 
molecule can also bind M1Rs orthosterically, making it a bitopic ligand (Digby et 
al., 2012). 
 The study of neuromodulatory receptors should also take advantage of the 
emergence of linear multielectrode arrays, which allow recording of neuronal 
activity and LFP across all layers of cortex. Further, some linear probes are now 
available that can pressure eject fluid into specific cortical layers. Several labs 
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have reported the effects of local drug ejection using such probes and resultant 
effects on different cortical layers in NHPs (Self et al., 2012; van Kerkoerle et al., 
2014; Liu and Pack, 2017; Liu et al., 2018). An exciting prospective experiment 
would be to dissociate the actions of NMDA receptor (or cholinergic receptor) 
stimulation in superficial layer III and infragranular layer V. One potential 
drawback of this technique would be if ejected fluid leaked vertically along the 
shaft of the probe. An experimenter would have to observe the laminar spread of 
drug over time (e.g., by observing changes in discharge rates or gamma power of 
adjacent recording channels) and only use timepoints when drug effected the 
layer of interest. Despite several technical difficulties, such experiments could 
accurately reveal the role of different neurotransmitters in different cortical layers, 
which are known to vary in neurotransmitter innervation and receptor expression. 
 In addition to local drug ejections, future researchers exploring the role of 
cholinergic receptors should also focus on what is occurring naturally: 
endogenous release of ACh. New techniques now allow for quantification of 
different neurochemicals on a second-to-second timescale. This is important data 
that can be compared with neuronal and network activity, LFP and 
communication between brain regions, and of course behaviour of animals. For 
example, Quanteon LLC develops probes that can detect various endogenous 
neurotransmitters such as acetylcholine, glutamate, and dopamine at the 
resolution of seconds. 
  Finally, an enormous niche that remains to be filled is microanatomy of 
cholinergic receptors in cortex. Despite many histochemical examinations, a clear 
picture of muscarinic receptor expression in different prefrontal areas, layers, and 
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cell types remains intangible. Researchers are often left speculating on how 
cholinergic perturbation affects WM circuitry and downstream effectors, and more 
detailed anatomy would be extremely beneficial. For example, knowing the 
expression of cholinergic receptors (and other neuromodulatory receptors) on the 
different classes of interneurons would provide helpful direction to 
pharmacological targets to influence WM circuitry. 
 
5.4 Concluding Remarks 
 Many conditions are afflicted with disrupted cholinergic functioning and 
impaired executive function. Investigations of the cholinergic system using rodent 
models have provided a wealth of information, but inferences to human clinical 
outcomes are difficult due to between-species differences. The NHP model of 
cognitive behaviour offers a bridge between rodent literature on cholinergic 
functioning and human neuropsychiatric conditions that rely on pharmacological 
intervention. The granular PFC and cholinergic system of rhesus macaques are 
more similar to that of humans, and in vivo electrophysiology allows online 
observation of prefrontal neurons that are involved in cognitive circuitry. 
Concurrent local pharmacological manipulation with iontophoresis allowed us to 
characterize the impacts of direct cholinergic receptor stimulation. 
 Over the course of this project, the effects of stimulation and blockade of 
different receptors were described in putative pyramidal and nonpyramidal 
neurons of macaque prefrontal cortex, during performance of an oculomotor rule-
based WM task. The effects of M1R-specific compounds came as a surprise and 
are a reminder of the differences between pharmacology in slice 
	  	  
246 
electrophysiology and in an awake, behaving NHPs. Local ejections were also 
found to manipulate cortical oscillatory power, particularly the beta frequency 
band. Future studies will continue to illuminate the role of muscarinic receptors in 
prefrontal LFP and cognitive circuitry. My hope is this work will inform the ongoing 
progression of neuroscience research, such that the sciences can alleviate the 
symptoms and development of neuropsychiatric conditions that affect millions 
worldwide. 
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